Cell-based gene therapy for mending infarcted hearts by Poudel, Bhawana & Poudel, Bhawana
  1 
 
 
 
 
 
CELL-BASED GENE THERAPY FOR MENDING 
INFARCTED HEARTS 
 
 
By 
Bhawana Poudel 
 
 
A Dissertation Submitted for the Examination 
for the Transfer of Status to the Degree of  
Doctor of Philosophy 
 
 
 
Supervisors 
Professor Nadia Rosenthal 
Dr. Maria Paola Santini 
 
 
 
Harefield Heart Science Centre 
National Heart and Lung Institute 
Imperial College London 
2011 
 
  2 
ABSTRACT 
 
The goal of this study was to analyse the efficiency of a combinatorial cell/growth factor 
therapy to improve function of infarcted murine hearts. The Insulin-like Growth Factor-1 
(IGF-1) isoform, IGF-1Ea, has been shown to reduce scar formation and decrease cell 
death after MI. The present study utilized P19Cl6-derived, IGF-1Ea over-expressing 
cardiomyocytes to achieve its goal. 
 
The P19Cl6 cells were stably transduced with IGF-1Ea using a lentiviral vector and 
investigated first in vitro for their feasibility for in vivo cell therapy. The engineered 
pluripotent cells over-expressing IGF-1Ea survived better to hypoxia-induced injury than 
the control cells. The cells maintained their pluripotency and efficient differentiation 
capacity towards ventricular cardiomyocyte lineage, generating large quantities of 
cardiomyocytes optimal for the transplantation study. The generated cardiomyocytes were 
functionally active and exhibited a mature phenotype.  
 
Transplantation of the cardiomyocytes into allogeneic wild type murine infarcted hearts 
conferred a tendency for maintenance of function at short-term time point. At long-term 
however, this effect was lost, returning to the level of the control infarcted hearts. Cell 
tracing assessment revealed engraftment of both IGF-1Ea- and empty-cells, although the 
cells failed to couple with the recipient tissue. Scar size and capillary density analyses 
revealed no significant difference between the cells transplanted compared to the saline 
treated hearts, corroborating with the long-term functional data. Interestingly, the IGF-
1Ea-cell transplanted hearts expressed significantly higher amount of VEGFa compared to 
the controls, albeit no change in capillary density. Further investigation revealed that the 
enhanced VEGFa expression in IGF-1Ea-cells transplanted hearts was associated with 
reduced hypertrophy, marked by reduced cell cross-sectional area at the border-zone, aSK 
and bMHC expression compared to the control hearts. Nonetheless, modulation of 
hypertrophic response and transplantation of IGF-1Ea-cells were not able to confer lasting 
functional preservation, possibly due to lack of sufficient engraftment and coupling of the 
transplanted cells.   
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Bcl-2 B-cell lymphoma 2 
VEGF Vascular Endothelial Growth Factor 
IGF-1 Insulin-like Growth Factor-1 
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MLC-2v Myosin Light Chain-2 ventricular 
MLC-1 Myosin Light Chain-1 
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EB Embroid Body 
MEF2c Myocyte Enhancer Factor 2c 
BMP Bone Morphogenic Protein 
αMHC alpha Myosin Heavy Chain 
βMHC beta Myosin Heavy Chain 
IGF-1Ea Insulin-like Growth Factor-1 Ea isoform 
IGF-2 Insulin-like Growth Factor-2 
IGF-1R Insulin-like Growth Factor-1 Receptor 
IGF-2R Insulin-like Growth Factor-2 Receptor 
IGFBP Insulin-like Growth Factor Binding Protein 
DNA  Deoxyribonucleic Acid 
RNA Ribonucleic Acid 
mRNA messenger RNA 
MGF   Mechano Growth Factor 
Gata2   Gata-binding protein-2 
S-Phase  Synthesis Phase 
PI-3 kinase  Phosphoinositide-3 kinase 
DHP   Dihydropyridine 
MAP kinase  Mitogen Activated Protein kinase 
IRS   Insulin Receptor Substrate 
SHC   Src-homology containing protein 
Grb2   Growth factor receptor-bound protein 2 
SOS   Sons of Sevenless 
ERK   Extracellular Regulated Kinase 
Rb   Retinoblastoma protein 
MEF   Myocyte Enhancer Factor 
PDK-1   Phosphoinositide-dependent protein kinase-1 
NF-ATc  Nuclear Factor of Activated T cells 
Tet   Tetracycline 
TetR   Tet Repressor 
TetO2   Tetracycline Operator 
qRT-PCR  quantitative Real Time-Polymerase Chain Reaction 
αSK   alpha Skeletal actin 
HT1080  Human connective tissue fibrosarcoma cell line 
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HEK(293)  human embryonic kidney cell line 
EMEM  Eagle’s Minimum Essential Medium 
FBS   Fetal Bovine Serum 
DMEM  Dulbecco’s Modified Eagle Medium 
NEAA   Non-Essential Amino Acids 
LDH   Lactate Dehydrogenase 
INT   2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium chloride 
FACS   Fluorescence Activated Cell Sorting 
PI   Propidium Iodide 
EF   Ejection Fraction 
FAC   Fractional Area Change 
FS   Fractional Shortening 
PFA   Paraformaldehyde 
WGA   Wheat Germ Agglutinin 
LCA/LAD ligation Left-anterior Descending Coronary Artery ligation 
SEM   Standard Error of the Mean 
SD   Standard Deviation 
ROS   Reactive Oxygen Species 
CICR   Calcium Induced Calcium Release  
NCX   Na+/Ca2+ exchanger 
SERCA  Sarco(endo)plasmic Ca2+-ATPase 
Rhod   Rhodamine based 
WT   Wild Type 
ECG   Echocardiogram 
VEGFR  Vascular Endothelial Growth Factor Receptor 
BM-MNC  Bone Marrow-Mononuclear Cells 
LVAD   Left Ventricular Assist Device 
 
 
 
    
 
 
 
  7 
TABLE OF CONTENTS 
 
TITLE.............................................................................................................................................................. 1 
ABSTRACT .................................................................................................................................................... 2 
ACKNOWLEDGEMENT ............................................................................................................................. 3 
ABBREVIATIONS......................................................................................................................................... 4 
TABLE OF CONTENTS ............................................................................................................................... 7 
TABLE OF TABLES ................................................................................................................................... 10 
TABLE OF FIGURES ................................................................................................................................. 11 
CHAPTER 1.................................................................................................................................................. 13 
1.1 SECTION I: GENERAL INTRODUCTION ................................................................................... 14 
1.1.1 Cardiovascular diseases .............................................................................................................. 14 
1.1.2 Inflammatory cell infiltration, phagocytosis and fibrosis following ischemic injury ............... 15 
1.1.3 Current available treatments for ischemic injury....................................................................... 16 
1.1.4 Regeneration of mammalian hearts ........................................................................................... 17 
1.1.5 Strategies to support regeneration and functional restoration .................................................. 17 
1.1.6 Improvement of active function .................................................................................................. 20 
1.1.6.1 Cell therapy ..........................................................................................................................................20 
1.1.6.2 Endogenous cell sources for regeneration..........................................................................................21 
1.1.6.3 Exogenous cell sources for regeneration ............................................................................................23 
1.1.6.4 Delivery of exogenous cells ..................................................................................................................25 
1.1.7 Improvement of passive function ................................................................................................ 26 
1.1.7.1 Gene therapy ........................................................................................................................................26 
1.1.7.2 Ways to deliver genes...........................................................................................................................27 
1.1.7.3 Candidate genes for therapy ...............................................................................................................27 
1.1.8 Animal models of myocardial infarction .................................................................................... 27 
1.1.9 Table 1: Overview of recent cell transplantation studies in animal models of MI.................... 29 
1.2 SECTION II: THE CELL AND THE GENE OF CHOICE ............................................................ 32 
1.2.1 The Cell: P19Cl6 ......................................................................................................................... 32 
1.2.1.1 P19 Embryonal Carcinoma-derived stem cells (P19EC) ..................................................................32 
1.2.1.2 Derivation and characteristics of P19Cl6 cells ..................................................................................32 
1.2.1.3 Differentiation mechanism of P19EC/P19Cl6 cells ...........................................................................33 
1.2.1.4 Mesodermal differentiation characteristics of P19EC/Cl6 cells.......................................................34 
1.2.1.5 Characteristics of P19 cell derived cardiac myocytes .......................................................................34 
1.2.2 The Gene: Insulin-like Growth Factor-1 (IGF-1) ..................................................................... 35 
1.2.2.1 Insulin-like Growth Factor (IGF) system ..........................................................................................35 
1.2.2.2 Insulin-Like Growth Factor-1 isoforms .............................................................................................36 
1.2.2.3 IGF-1 Function.....................................................................................................................................38 
1.2.2.4 IGF-1 signaling.....................................................................................................................................41 
1.2.3 Tetracycline regulated expression of IGF-1Ea .......................................................................... 45 
1.2.4 Objectives of this study ................................................................................................................ 46 
1.2.5 Aims of this study ........................................................................................................................ 47 
CHAPTER 2.................................................................................................................................................. 50 
2.1 MATERIALS AND METHODS ....................................................................................................... 51 
2.1.1 DNA preparation and quantification.......................................................................................... 51 
2.1.2 RNA isolation and quantification ............................................................................................... 51 
2.1.2.1 Tissue Samples.......................................................................................................................................51 
2.1.2.2 Cultured cells.........................................................................................................................................52 
2.1.3 mRNA quantification by Real-Time Polymerase Chain Reaction (qRT-PCR) ......................... 52 
2.1.4 cDNA synthesis............................................................................................................................ 53 
2.1.5 Quantitative Real Time PCR (qRT-PCR) ................................................................................... 53 
2.1.6 Cloning of IGF-1Ea cDNA into lentiviral backbone ................................................................. 55 
2.1.7 Sequencing of IGF-1Ea .............................................................................................................. 56 
2.1.8 Virus production.......................................................................................................................... 57 
2.1.9 Determining antibiotic sensitivity ............................................................................................... 58 
  8 
2.1.10 Lentiviral stock tittering ............................................................................................................ 58 
2.1.11 Transduction of viral vectors .................................................................................................... 59 
2.1.12 Tetracycline regulated gene expression.................................................................................... 59 
2.1.13 Cell culture ................................................................................................................................ 60 
2.1.13.1 HT1080 ................................................................................................................................................60 
2.1.13.2 293T .....................................................................................................................................................60 
2.1.13.3 P19Cl6-MLC2v-GFP-IGF-1Ea Culture and Differentiation ...............................................................60 
2.1.13.4 Neonatal Rat Cardiomyocytes Isolation and Culture ..........................................................................61 
2.1.14 Immunofluorescence................................................................................................................. 62 
2.1.15 Hypoxia and normoxia induction ............................................................................................. 62 
2.1.15.1 LDH assay ...........................................................................................................................................62 
2.1.15.2 Hypoxia or normoxia treatment of neonatal rat cardiomyocytes with/without IGF-1Ea conditioned 
media .................................................................................................................................................................64 
2.1.16 Protein extraction ...................................................................................................................... 64 
2.1.17 Western Blot analysis ................................................................................................................ 65 
2.1.18 Confocal Calcium transient analysis ........................................................................................ 65 
2.1.19 FACS Analysis........................................................................................................................... 65 
2.1.20 PI Staining for DNA analysis using FACS .............................................................................. 66 
2.1.21 General animal husbandry ....................................................................................................... 67 
2.1.22 LCA ligation and cell injection ................................................................................................. 67 
2.1.22.1 Left-anterior Descending Coronary Artery (LCA) ligation..................................................................67 
2.1.22.2 Cell Injection .......................................................................................................................................68 
2.1.23 Functional analysis by Echocardiography ............................................................................... 68 
2.1.24 Histological analyses ................................................................................................................. 69 
2.1.24.1 Masson’s Tri-chrome Staining.............................................................................................................69 
2.1.24.2 Anti-GFP Staining ...............................................................................................................................70 
2.1.24.3  Isolectin-B4 Immunohistological Labelling for Capillary Density Quantification .............................71 
2.1.24.4 Wheat Germ Agglutinin (WGA) Staining for Assessing Cell Cross-sectional Area .............................72 
2.1.25 Statistical analysis: .................................................................................................................... 72 
CHAPTER 3.................................................................................................................................................. 74 
3.1 SECTION I: CREATING TOOLS FOR STABLE TRANSDUCTION OF IGF-1EA INTO 
PLURIPOTENT P19CL6 CELLS AND TETRACYCLINE REGULATED EXPRESSION OF THE 
GENE ........................................................................................................................................................ 75 
3.1.1 INTRODUCTION ....................................................................................................................... 75 
3.1.2 RESULTS .................................................................................................................................... 76 
3.1.2.1 Cloning and Sequencing of IGF-1Ea .....................................................................................................76 
3.1.2.2 Determining Antibiotic Sensitivity .........................................................................................................76 
3.1.2.3 Viral Titre Determination ......................................................................................................................77 
3.1.2.4 Tetracycline Regulated Expression of IGF-1Ea ....................................................................................78 
3.1.3 DISCUSSION.............................................................................................................................. 80 
3.2 SECTION II: EFFECTS OF IGF-1EA TRANSDUCTION AND CONSTITUTIVE 
EXPRESSION ON PROPERTIES OF P19CL6 CELLS BEFORE AND AFTER 
DIFFERENTIATION.............................................................................................................................. 82 
3.2.1 INTRODUCTION ....................................................................................................................... 82 
3.2.2 RESULTS .................................................................................................................................... 84 
3.2.2.1 Staining for Pluripotency Marker Oct3-4 ..............................................................................................84 
3.2.2.2 Cell cycle analysis by Propidium Iodide (PI) Staining ..........................................................................85 
3.2.2.3 Differentiation of P19Cl6 Cells into Cardiomyocytes............................................................................86 
3.2.2.4 FACS Analysis to Quantify GFP Positive Ventricular Cardiomyocytes ................................................88 
3.2.2.5 Sarcomeric alpha-actinin Staining ........................................................................................................90 
3.2.2.6 IGF-1Ea Expression Following Differentiation.....................................................................................92 
3.2.3 DISCUSSION.............................................................................................................................. 93 
3.3 SECTION III: TESTING FEASIBILITY OF THE IGF-1EA TRANSDUCED CELLS IN VITRO 
FOR IN VIVO CELL THERAPY ........................................................................................................... 96 
3.3.1 INTRODUCTION ....................................................................................................................... 96 
3.3.2 RESULTS .................................................................................................................................... 98 
3.3.2.1 Confocal [Ca2+] Transient Analysis ......................................................................................................98 
3.3.2.2 Cytotoxicity Assessment .......................................................................................................................100 
3.3.2.3 Effect of IGF-1Ea over-expression on cell survival .............................................................................101 
3.3.2.4 Effect of IGF-1Ea conditioned media on cardiomyocyte survival .......................................................102 
3.3.3 DISCUSSION............................................................................................................................ 103 
CHAPTER 4................................................................................................................................................ 106 
  9 
4.1 TO TEST IF FUNCTION OF IMPAIRED HEARTS COULD BE IMPROVED BY 
TRANSPLANTATION OF THE IGF-1EA TRANSDUCED P19CL6 CELLS ................................. 107 
4.1.1 INTRODUCTION ..................................................................................................................... 107 
4.1.2 RESULTS .................................................................................................................................. 109 
4.1.2.1 Survival Analysis of Surgical Animals .................................................................................................109 
4.1.2.2 Functional Analyses.............................................................................................................................109 
4.1.2.3 Molecular Analyses of Short-term Samples .........................................................................................117 
4.1.2.4 Histological Analyses of Long-term Samples.......................................................................................119 
4.1.2.5 Molecular Analyses of Long-term Samples..........................................................................................126 
4.1.2.6 Molecular and Histological Analysis of the Recipient Tissue for Hypertrophic Response ..................128 
4.1.3 DISCUSSION............................................................................................................................ 130 
CHAPTER 5................................................................................................................................................ 136 
5.1 GENERAL DISCUSSION............................................................................................................... 137 
5.2 LIMITATIONS AND FUTURE DIRECTION .............................................................................. 144 
5.3 CONCLUDING REMARKS ........................................................................................................... 147 
REFERENCES ........................................................................................................................................... 149 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  10 
TABLE OF TABLES 
 
Table 1. Overview of recent cell transplantation studies in animal models of MI……………………………..29 
Table 2. cDNA Synthesis…………………………………………………………………........................................53 
Table 3. Recipe for Real Time PCR………………………………………………………………………………….54 
Table 4. Taqman off-the shelf assays for Real Time PCR analysis………………………................................54 
Table 5. IGF-1Ea Sequencing Primers……………………………………………………………………………...56 
Table 6. Enzyme Digestion and Cell Collection…………………………………………....................................61 
Table 7. Functional Analysis of Infarcted Cell/Saline Injected Hearts…………………...............................113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  11 
 
TABLE OF FIGURES 
 
 
Figure 1. Regenerating Mechanical Function of Injured Hearts.. ................................................................. 19 
Figure 2. Structure of the Rat Insulin-like Growth Factor-1 Gene and Protein............................................. 37 
Figure 3. Overview of IGF-1/IGF1R Signaling Pathway............................................................................... 42 
Figure 4. Mechanism of Tetracycline Regulated Expression of IGF-1Ea Gene............................................. 46 
Figure 5. Outline of Experimental Plan...........................................................................................................49 
Figure 6. Maps of Lentiviral Constructs......................................................................................................... 56 
Figure 7. Antibiotic Assessment of HT1080 Cells treated with Zeocin. ......................................................... 77 
Figure 8. Antibiotic Sensitivity Assessment of HT1080 cells Treated with Blasticidin................................... 77 
Figure 9. Determining Viral Titre. ................................................................................................................. 78 
Figure 10. Tetracycline regulated IGF-1Ea expression on HT1080 cells...................................................... 78 
Figure 11. Loss of tetracycline regulated expression of IGF-1Ea in transduced P19Cl6 cells...................... 79 
Figure 12. Constitutive IGF-1Ea expression.................................................................................................. 80 
Figure 13. Staining for Pluripotency Marker Oct3-4.. ................................................................................... 85 
Figure 14. Cell Cycle analysis by Propidium Iodide Staining........................................................................ 86 
Figure 15. Representative Confocal Images of Differentiated P19Cl6-MLC2v-GFP Cells.. ......................... 87 
Figure 16. A quantitative Real Time PCR analysis for cardiac specific marker expression by IGF-1Ea 
untransduced and IGF-1Ea transduced P19Cl6 cells with or without differentiation. .................................. 88 
Figure 17. Quantification of GFP Positive Ventricular Myocytes by FACS Analysis.................................... 90 
Figure 18. Sarcomeric alpha-Actinin Staining. .............................................................................................. 92 
Figure 19. IGF-1Ea Transcript Expression in Differentiated Cells with/without IGF-1Ea Transduction..... 93 
Figure 20. Confocal Ca2+ Transient Analysis............................................................................................... 99 
Figure 21. Determining Cytotoxicity following Normoxia or Hypoxia Treatment. ...................................... 101 
Figure 22. Effect of IGF-1Ea Over-expression on Cell Survival in vitro.. .................................................. .102  
Figure 23. Effects of IGF-1Ea Conditioned Media on Cardiomyocyte Survival.. ........................................ 103 
Figure 24. Echocardiographic Images of M-Mode and B-Mode.................................................................. 110 
Figure 25. Ejection Fraction (EF) Analyses upon Myocardial Infarction Induction and Cell 
Transplantation.. .......................................................................................................................................... 112 
Figure 26. Fractional Shortening (FS) Analyses upon Myocardial Infarction Induction and Cell 
Transplantation.. .......................................................................................................................................... 114 
Figure 27. Fractional Area Change (FAC) Analysis upon Induction of Myocardial Infarction and Cell 
Transplantation. ........................................................................................................................................... 116 
Figure 28. Mean Relative Paracrine Factor Expression.............................................................................. 118 
Figure 29. Scar Size Analysis by Trichrome Staining. ................................................................................. 120 
Figure 30. Cell Engraftment Assessment by anti-GFP Staining using Immunofluorescence Technique. .... 121 
Figure 31. Cell Engraftment Assessment by anti-GFP Staining using Immunohistochemical Technique.. . 123 
Figure 32. Capillary Density Assessment.. ................................................................................................... 125 
Figure 33. Mean Relative Paracrine Factors Expression with 2-month Samples.. ...................................... 127 
  12 
Figure 34. Molecular and Histological Analyses for Hypertrophic Response. ............................................ 129 
Figure 35. Mechanism of P19Cl6 cells and IGF-1Ea mediated Amelioration of Injured 
Tissue…………………………………………………………………………………………………………………….135  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13 
CHAPTER 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 14 
1.1 SECTION I: GENERAL INTRODUCTION 
 
1.1.1 Cardiovascular diseases 
Cardiovascular diseases (CVDs) are among the top killers in the western world and the 
majority of people who suffer from cardiac diseases is exposed to several risk factors [1]. 
CVDs are disorders of the blood vessels and the heart. In 2004 alone CVDs claimed 17.1 
million lives worldwide, representing 29% of all global deaths. Among these deaths, 7.2 
million were caused by coronary heart disease and 5.7 million by stroke [2]. CVDs are 
either innate or acquired defects of the heart. Congenital heart defect, which is one of the 
CVDs, is a result of malformation of the heart or blood vessels near the heart during 
development of the organ. The causes of congenital heart defects are not completely 
known. However, environmental factors such as exposure to toxic substances [3] or 
viruses like measles during pregnancies have been implicated in causing congenital heart 
defects [4]. Progress has been made on understanding the underlying mechanisms and 
pathways of the congenital heart defects. Research has shown the involvement of a 
number of transcription factors such as TBX5 [5], Nkx2-5 [6], Gata4 [7] among others in 
causing different kinds of defects. With a better understanding of the underlying molecular 
pathways and improved surgical interventions, many of the existing defects can be 
corrected today. However, these interventions generally only repair the symptoms rather 
than the cause. Therefore, patients who suffer from congenital heart defects may develop 
other problems during their adult lives.  
 
During adulthood, people may develop other CVDs such as the valvular heart diseases, 
inflammatory heart diseases, hypertensive heart diseases and atherosclerosis. The valvular 
heart diseases affect one or several of the heart valves. Some examples of valvular heart 
disease are aortic valve stenosis, mitral valve prolapse and valvular cardiomyopathy [8, 9].  
The inflammatory heart disease as the name implies, is caused by inflammation of the 
heart muscle or other tissue within the organ. Some examples of such diseases are 
endocarditis, inflammatory cardiomegaly and myocarditis [10, 11]. The hypertensive heart 
disease is one of the largest groups among the acquired CVDs. It is caused by high blood 
pressure and includes left ventricular hypertrophy, coronary heart disease, congestive heart 
failure, hypertensive cardiomyopathy and cardiac arrythmias [12]. Another common 
cardiovascular disease is atherosclerosis. Atherosclerosis is marked by the thickening of 
the blood vessels through deposition of lipid plaques, extreme form of which restricts 
  15 
blood supply to certain parts of the heart causing ischemic injury. Ischemic injury can also 
result from blockade of blood vessels by blood clots. Prolonged ischemia then causes 
myocardial infarction (MI). MI, which is marked by necrotic death of cardiomyocytes, 
consequently leads to heart failure, ‘the inability of heart to pump blood efficiently’. MI 
causes inflammatory cell infiltration and remodelling of the affected region, which often 
results in cardiac arrest and death of the patient [13]. Being one of the most common types 
of CVDs, the focus of this study is ischemic injury leading to myocardial infarction.     
 
1.1.2 Inflammatory cell infiltration, phagocytosis and fibrosis following ischemic 
injury 
A myocardial injury is rapidly accompanied by an inflammatory reaction. Inflammatory 
reaction involves complement cascade and tissue resident mast and/or macrophage cells 
activation, infiltration of circulating leukocytes in the affected tissue, which mediate 
cellular destruction and phagocytosis of degenerating cardiomyocytes. Mast cells reside in 
essentially all tissue types throughout the body (reviewed in [14]). Upon activation by 
injury or infection, they release cytokines and molecules such as TNFα, IL-6, IL-1, 
histamine, serotonin and newly synthesized platelet-activating factor (PAF), leukotrienes. 
The mediators affect either the vasculature to either express endothelial adhesion 
molecules for inducing rolling and infiltration of the leukocytes, activate leukocytes 
directly and/or affect both events (reviewed in [14]). The activation of mast cells upon 
injury or infection is driven by various factors such as bradykinins, complement system, 
bacterial toxins etc (reviewed in [14]). Hill and Ward [15] were the first to report that the 
myocardial ischemic injury activated the complement cascade, which are capable of 
activating mast cells or have a direct impact on neutrophil infiltration via chemotaxis. 
Upon infiltration into injured tissue, neutrophils conduct cellular destruction of damaged 
or infected cells. They can however, exacerbate muscle injury by damaging uninjured 
myocytes via generation of proteolytic enzymes and reactive oxygen species or by directly 
binding to  cardiomyocytes, which is dependant on the Mac-1-ICAM-1 (Macrophage-1 
antigen, Inter-Cellular Adhesion Molecule 1) interaction [16, 17]. The myocytes have to 
be stimulated by cytokines such as IL-1 (Interleukin-1), TNFα (Tumor Necrosis Factor 
alpha) and IL-6 (Interleukin-6) to induce ICAM-1  expression and neutrophils stimulated 
by IL8 or PAF to show Mac-1 [16]. The infiltrated neutrophils, the macrophages together 
with the resident mast cells mediate inflammation, cellular destruction and phagocytosis 
of the injured tissue.  
  16 
The inflammatory response in the myocardial injury eventually leads to the initiation of 
repair and healing processes, which in the heart result in formation of a scar. The 
infiltrated inflammatory cells attract fibroblast to the injury site to remodel the damaged 
tissue by recruiting a combination of cytokines that are secreted by the inflammatory cells 
themselves. During the healing process, mast cells together with macrophages provide 
cytokines and growth factors necessary to support fibroblast proliferation and new vessel 
formation [16]. Fibroblasts secrete high amounts of transforming growth factor-ß (TGF-
ß), collagen and glycoproteins, which take part in forming the scar tissue (reviewed in [16, 
18]).  
 
Scar formation is crucial for rapidly resolving damage by secluding the lesion from the 
undamaged area and preventing uncontrolled damaging events [19]. Although scar 
formation represents a vital evolutionary adaptation of higher vertebrates to injury, it leads 
to restriction of regeneration. In addition, scar tissue does not possess biochemical, 
physical and functional properties of the original healthy tissue leading to adverse effects 
on overall function of the heart. Therefore, to restore cardiac function after an infarct, 
attenuation of scar size and replacement of contractile cardiac tissue is necessary.  
 
1.1.3 Current available treatments for ischemic injury 
Current interventions for ischemic injury are targeted at physical removal of the 
obstructions or reperfusion of the heart to restore blood flow to ischemic tissue. Physical 
removal of the obstruction re-establishes the blood flow. However, this intervention only 
transiently eliminates the symptom especially if the obstructions are lipid plaques, rather 
than permanently curing the problem. Reperfusion has the potential to rescue at-risk 
myocardium very quickly. If blood flow is restored rapidly, the loss of a few myocytes 
unlikely affects the overall function of the heart. However, for the myocardium that is 
unable to survive the injury, reperfusion is of little help. In fact reperfusion of the tissue 
leads to increased radical oxygen species production, which potentially causes adverse 
effects on the surviving myocardium [20]. There are other interventions that are targeted at 
improving mechanical function of an injured heart such as balloon pumps and left 
ventricular assist devices [21, 22], which however offer only temporary solutions. 
Currently the ultimate intervention to a failing heart is organ transplantation. The shortage 
of donors and the bigger challenge that is faced by organ transplantation, immune 
rejection, make organ transplantation unrealistic for a majority of patients. Moreover, 
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these solutions are mainly short-term solutions. Long-term solution must be focused at 
improving function via restoration of mechanical function of the injured heart itself.  
 
1.1.4 Regeneration of mammalian hearts 
Regeneration is a biological process that refers to replacement of body parts lost due to 
injury [23]. Invertebrates of the Planariidae family and Hydra genus have the potential to 
regenerate their whole bodies from small body parts or pieces, indicating their immortal 
existence [24-26]. In mammals however, regeneration of organs such as the cardiac 
muscle, appendages and spinal cord is very limited (reviewed in [23]). As the capacity for 
renewal of cardiac myocytes following injury is limited, mammalian hearts following 
myocardial infarction suffer from impairment of function due to permanent loss of 
contractile cell mass. Over the past decades, treatment for myocardial ischemia has made 
significant progress, however curing myocardial infarction remains still a challenge as the 
existing treatments for infarction fail to address the problem of contractile-cell loss.   
 
The mechanical function of the heart can be separated into active (contractile) and passive 
(non-contractile) components, both of which should be targets for regenerative therapy 
[27, 28]. The active function is a result of contraction of individual myocytes and the 
passive component results from the cell-cell and cell to extracellular matrix interaction, 
which provides a compliant environment for contraction and relaxation. During 
myocardial infarction and heart failure both of these components are affected. The passive 
component is affected by formation of new non-contractile fibrotic tissue that replaces the 
contractile cells and extracellular matrix leading to a noncompliant stiff scar. Due to the 
introduction of stiff scar, the systolic contraction is decreased. In addition, the diastolic 
function is also affected as the heart is not able to relax completely. Both of these 
components should be addressed to improve mechanical properties of infarcted hearts.  
 
1.1.5 Strategies to support regeneration and functional restoration 
There are several strategies that can be exploited in mammals to potentially support 
regeneration of an injured heart. For improving the passive function, the lack of flexibility 
resulting from the scar tissue could be considered. Scar tissue is mainly composed of 
collagen and fibroblasts. Addition or inducing expression of elastin, an extracellular 
matrix protein, in the stiff scar tissue might improve flexibility of the stiff myocardium. 
Mizuno et al. showed that over-expression of elastin by endothelial cells preserved cardiac 
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function and decreased scar size compared with non-expressing control cells suggesting 
that elastin might replace the collagen or signal for decreasing collagen synthesis in the 
infarct region [29]. Matsubayashi et al. used a biopolymer scaffold seeded with vascular 
smooth muscle cells to replace scar tissue in the myocardium in a rat model [30]. Eight 
weeks post implantation of the scaffold they found increased extracellular elastin and 
fractional area shortening, without observing any mechanical activity in the patch region. 
This suggested that the functional improvement observed was due to compliance achieved 
through the implantation rather than restoration of contraction in the patch region.  
Similarly, Fujimoto et al. implanted a biodegradable polymer called the polyester urethane 
urea (PEUU) cardiac patch on the epicardial surface of sub-acutely infarcted rat LV wall, 
which resulted in increased number of smooth muscle cells, fractional area shortening and 
tissue compliance in the infarct region [31]. Injection of mesenchymal stem cells (MSC) 
has also been shown to improve compliance by decreasing stiffness and fibrosis without 
transdifferentiating into cardiomyocytes [32]. All of these studies demonstrated that 
implantation of compliant material or cells in a scar region could potentially improve 
passive mechanical function by decreasing stiffness.  
 
While improving the passive function of the infarcted heart possibly leads to overall 
improvement of heart function, it is vital to regenerate the stiff scar tissue with new 
contractile tissue to achieve an improvement of the active function of the infarcted region 
[28]. Mammalian tissue regeneration and active function are mainly impaired by failure of 
the damaged tissue to support survival, proliferation and/or differentiation of homing stem 
or progenitor cells. The hostile toxic microenvironment created by reactive oxygen species 
resulting from inflammation does not provide the cells with a favourable environment to 
home and reconstitute the lost contractile tissue. This significantly reduces the opportunity 
for the homing stem cells to regenerate the injured tissue and maintain mechanical 
function of the organ. There are several strategies that could be applied to counter this 
problem. A combinatorial cell and growth/survival factor therapy could be one of the 
approaches to utilize. This strategy could potentially (i) help reconstitute the lost tissue 
with the donor cells, (ii) with the growth/survival factor component, confer better survival 
of the transplanted cells and (iii) upon the release of the growth factor, create a favourable 
environment for engraftment of transplanted cells. In addition, with the release of the 
growth/survival factors, this approach could confer protection to the native cells; hence 
protect the at-risk cells from death. By creating a favourable microenvironment, the 
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combinatorial therapy might also enhance engraftment of endogenous stem cells that 
home into the injured organ. Alternatively, the regeneration of overall function could be 
obtained by non-combinatorial approach, which is independent of exogenous cell 
transplantation. This could be performed by supplementing the injured organ with factors, 
which could increase engraftment, survival, proliferation and differentiation of the 
endogenous progenitor cells to reconstitute the injured tissue. Although both of the 
combinatorial and non-combinatorial approaches will serve to improve overall function of 
the injured organ, a combinatorial approach might be more beneficial to patients who are 
elderly and have reduced levels of endogenous progenitor cells, for instance cardiac 
progenitor cells (CPCs) that have been reported to decline with age (reviewed in [33]).  
 
The following figure outlines strategies that could be employed to regenerate mechanical 
function of the hearts following injury (Figure 1).  
 
 
Figure 1. Regenerating Mechanical Function of Injured Hearts. Figure outlines various strategies for 
regenerating both the active and passive functions of injured hearts to obtain regeneration of the 
overall mechanical function. Figure adapted from Gaudette, G.R., Cardiac Regeneration: Materials 
Can Improve the Passive Properties of Myocardium, but Cell Therapy Must Do More, Circulation, 
Volume 114, Issue Number 24, Copyright (2006), with permission from Wolters Kluwer Health 
provided by Copyright Clearance Centre.  
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1.1.6 Improvement of active function 
Improvement of active function of injured hearts can be achieved by (i) transplantation of 
cells that have the ability to contract and integrate with the recipient tissue, (ii) 
proliferation of adult cardiomyocytes or (iii) differentiation of endogenous progenitor cells 
into contractile cells.  The following paragraphs will discuss in detail the different cell 
types that could be utilized for improving cardiac active function. 
 
1.1.6.1 Cell therapy 
1.1.6.1.1 An Ideal Cell for Therapy 
For a successful regenerative strategy, the donor cells must possess a number of qualities. 
They should exhibit electrophysiological and contractile properties of cardiomyocytes and 
when delivered they should be able to integrate both physically and functionally within the 
host tissue. In order to engraft and synchronously beat with the host myocardium, they 
must possess adhesion and gap junction proteins such as N-cadherin and Connexin-43 
respectively. Similarly, the implanted cells must possess all the cardiomyocyte specific 
proteins that are necessary for their mechanical (e.g. sarcomeric alpha-actinin, ventricular 
myosin heavy chain) and electrical functions (e.g. ion channel proteins). The proteins must 
also be functional. The cells should exhibit a calcium-induced calcium-release 
mechanism, which is ion channel dependent and is essential for excitation-contraction 
coupling. Both the calcium-induced calcium-release and excitation-contraction coupling 
are properties of functional cardiac myocytes. Upon delivery to the infarcted hearts, an 
ideal cell for regenerative therapy must improve overall heart functions. The functional 
improvement should ideally correlate with the regenerated muscle mass to demonstrate 
that the functional improvement is a direct effect of cell implantation. In addition, the 
donor cells must contract in synchrony with the native cells to circumvent arrhythmias.   
 
All the methods for regeneration of muscle mass to improve active function of the heart 
must include addition of cell mass. This can be achieved through two different cell 
sources, namely the endogenous and the exogenous cells.   
 
1.1.6.1.2 Cell Sources for Transplantation 
An ideal cell for transplantation must have a high proliferative and differentiation 
capacity, an autologous origin and be readily available in large quantities for cell-based 
therapy. To date, five different cell types have been analysed and used in animal models. 
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These include Skeletal Myoblasts (SM), Mesenchymal Stem Cells (MSC) from bone 
marrow and adipose tissues, Cardiac Stem Cells (CSC), Embryonic Stem Cells (ESC) and 
induced Pluripotent Stem cells (iPS). Native adult cardiomyocytes could be induced to 
proliferate endogenously to regenerate the injured tissue. CSC and MSC are endogenous 
cell sources that could be recruited to the injury site to replenish the lost myocyte mass. 
ESC, SM and iPS cells are exogenous sources which have to be maintained and expanded 
in culture, and then delivered to the injured heart.    
 
1.1.6.2 Endogenous cell sources for regeneration 
1.1.6.2.1 Native adult Cardiomyocytes 
In zebra fish and amphibians adult cardiomyocyte proliferation is a known phenomenon 
where amputation of their hearts leads to induction of mitotic cell division of native 
cardiomyocytes which then regenerates the entire heart [34, 35].  Studying further the cell 
cycle progression and regeneration mechanisms in lower vertebrates and invertebrates and 
applying these mechanisms in mammals could potentially help regenerate mammalian 
hearts after injury. However, unlike in the lower organisms, in higher vertebrates, scar 
formation seems to be favoured over cardiomyocyte proliferation, the reasons for which 
are not completely understood. Previously, there was a common understanding that 
cardiomyocytes were terminally differentiated cells that lacked the ability to proliferate. 
However, in 2001 Anversa et al. reported evidence on human cardiomyocytes at the 
border zone of an injured region dividing after myocardial infarction, suggesting that 
cardiomyocytes might re-enter cell cycle following injury. Their data showed 
approximately 4% of cardiomyocytes at the border zone positive for the proliferative cell 
marker Ki-67 [36]. Recently, Bergmann et al. became the first to produce evidence on 
renewal of cardiomyocytes in humans [37]. They took advantage of the carbon-14 
integration into the DNA to establish the age of cardiomyocytes in humans. The carbon 14 
level in the atmosphere increased after the Cold War due to bomb testings. They 
demonstrated that the DNA from cardiomyocytes from individuals born before the Cold 
War during which the atmospheric carbon-14 concentration was lower than after the Cold 
War, consisted of comparable level of carbon-14 to the after- Cold War subjects.  This 
finding was the first to suggest in human, the renewal of cardiomyocytes. Considering the 
findings of these studies, the native cardiomyocytes appear to have the ability to replace 
lost tissues after injury. However, to develop a strategy for complete regeneration based 
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on stimulating this innate ability for proliferation, a better understanding of cell cycle and 
injury repair processes in mammals versus lower organisms is necessary.  
 
1.1.6.2.2 Native Stem Cells 
Native stem cells from the bone marrow, adipose tissue or the heart have a huge advantage 
over exogenous cell transplantation due to the circumvention of immune rejection. 
Potapova et al. showed that mesenchymal stem cells from the bone marrow have the 
ability to form cardiac myocytes when induced with 5-azacytidine, a DNA methylation 
agent. The resulting cardiac cells expressed cardiac specific proteins and formed 
sarcomeres [38]. Similarly, evidence suggests that cells from adipose tissue and heart 
differentiate into cardiomyocytes [39, 40]. The property of all these cells to differentiate 
into myocytes provides the possibility to develop a therapy to increase their homing to the 
injured region. Factors such as monocyte chemotactic protein-3 (MCP-3) [41] and 
stromal-derived factor-1 (SDF-1) [42] have been identified as homing molecules which 
could potentially be utilized to induce increased homing of the stem cell population to the 
injured site.  
 
Transplantation of bone marrow cells improved cardiac function of infarcted hearts, 
indicated by increased left ventricular ejection fraction (LVEF) [43-48].  Meta-analyses on 
clinical studies on transplantation of bone marrow stem cells into patients reported a slight 
improvement in function, indicated by  3-4% mean absolute increase in left ventricular 
ejection fraction (LVEF) [49]. Reports from two groups show that the functional results 
are better in patients with low LVEF, or if cell infusion is delayed until at least 5 days post 
myocardial infarction. They observed an absolute increase in EF by 5.1% versus no 
increase if the infusion was done after 5 days or in the first 4 days after injury respectively 
[50] and [51]. However, another report by Bone Marrow Transfer to Enhance ST-
Elevation Infarct Regeneration (BOOST) has reported that bone marrow cell 
transplantation had no long-term clinical benefit as the improved cardiac function declined 
at 18 months [46]. A nonrandomized trial with a 5-year follow-up time reported an 
improvement of global cardiac function, which was persistent with decreased mortality 
and infarct size and increased myocardial perfusion [52]. The functional improvement 
observed in these studies however has not been linked directly to the transplanted cells. 
Paracrine effects therefore have been suggested as a possible explanation for the 
improvement [48].  
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Cardiac stem cells are the next native stem cell type that has potential for cell-based 
cardiac repair. CSCs have innate capacity to differentiate into both cardiac and vascular 
lineages [53]. Human CSCs was obtained from myocardial biopsies and expanded in vitro. 
Upon expansion, the cells were transplanted into immunodeficient rat infracted hearts 
where they resulted in a chimera with human cardiomyocytes, coronary resistance 
arterioles and capillaries, showing clearly their cardiac and vascular lineage differentiation 
[53]. Therefore increasing their proliferation and differentiation into cardiomyocytes and 
vascular cells following injury would be a potential endogenous way to improve 
regeneration. However, the number of CSC declines with age, making it difficult to 
proliferate and differentiate them in large numbers in elderly patients [33]. Moreover, a 
better understanding and characterization of CSC is still lacking, which is vital to increase 
their efficiency of differentiation into cardiomyocytes for a cell therapy approach. 
 
Promoting regeneration using endogenous cell populations seems promising due to their 
qualities to differentiate into cardiomyocytes and to avoid immune rejection. However, the 
biggest challenge in using them as a therapy is their low efficiency of differentiation into 
cardiomyocytes and/or the large number that needs to home into the injured site in order to 
regenerate the entire injured region.  Due to these problems, alternative exogenous 
regeneration has received considerable attention in recent years. Exogenous regeneration 
aims at differentiating a stem cell population into cardiomyocytes in high quantities and 
delivering them into an injured site. To do so, the stem cells are expanded and driven 
towards cardiac lineage in vitro prior to their delivery.   
 
1.1.6.3 Exogenous cell sources for regeneration 
1.1.6.3.1 Skeletal Myoblast 
Skeletal myoblasts are precursor cells for skeletal myocyte regeneration [54]. There are 
several features that make skeletal myoblasts an attractive cell type for cardiac cell 
transplantation. Skeletal myoblasts have an autologous origin, they more readily survive in 
the hostile post-infarct environment [55] and they have the capacity to regenerate. Due to 
their autologous origin, they are faced with no ethical problems. In addition they are 
available in abundance and they circumvent immune rejection that other cell types are 
faced with. Skeletal myoblasts differentiate into striated muscles, sharing similarity with 
cardiomyocytes, which are also striated. Due to their similarities, these cells were chosen 
to be the first cell type for cell therapy in myocardial infarction. The major limitation for 
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using skeletal myoblast for cell therapy however, is the lack of evidence of 
electromechanical coupling between the grafted cells and the native cardiomyocytes. In 
vivo: skeletal myoblasts lose their capability to express major adhesion and gap junction 
proteins like N-cadherin and Connexin-43 respectively when the cells differentiate into 
myotubes [56]. Connexin-43 and N-Cadherin are essential for electromechanical coupling 
of cardiomyocytes [56, 57], therefore transplantation of skeletal myoblasts and their 
differentiation into myocytes might not be ideal for coupling with native cardiomyocytes. 
Also, myoblasts have not been shown to transdifferentiate into cardiomyocytes in vivo 
therefore they cannot substitute lost host tissue completely. In clinical trial, transplantation 
of autologous skeletal myoblasts into infracted scars during bypass surgery into patients 
with severe post infarction LV dysfunction resulted in ventricular arrhythmia [58], and 
this study was confirmed in another nonrandomized study [59].  
 
1.1.6.3.2 Induced Pluripotent Stem Cells 
Until recently, reprogramming of differentiated cells into a pluripotent state was beyond 
imagination. Takahashi et al. however have remarkably realized this concept. They were 
able to successfully induce formation of ESC-like pluripotent cells from adult human 
fibroblasts by defined factors [60]. The group transfected human fibroblast cells with 
Oct3/4, Klf4, Sox2 and c-Myc containing viral vectors, which resulted in derivation of 
fibroblast cells into ESC-like cells that were named induced pluripotent cells (iPS cells) 
[60]. Following this work, two other groups were able to differentiate these iPS cells into 
cardiomyocytes [61, 62]. These were major advances in stem cell research, as they now 
allow researchers to derive and obtain pluripotent stem cells from somatic cells. iPS cells 
are important in research and potentially have therapeutic uses, bypassing the use of 
embryos, which is still ethically controversial. Because the iPS cells are derived from a 
patient’s own somatic cells, they may be less prone to immune rejection than ESC.  
However, the transfection of the genes in these studies was conducted via retroviruses, 
which raised yet another important issue on safety of these cells for clinic as virus can 
cause cancers. In 2008, Okita et al. and Stadtfeld et al. individually demonstrated the 
generation of murine iPS cells without viral integration by using adenoviral vectors [63, 
64]. The efficiency of reprogramming using this method however was very low. Similarly, 
Woltjen et al. utilized yet another method for obtaining iPS cells without viral integration 
called piggyBac transposition, which utilized the transposon/transposase system. This 
system was also successful in obtaining iPS cells, but with low efficiency similar to 
  25 
previous findings [65].  While the efficiency of reprogramming somatic cells into iPS is 
making progress, the efficiency of differentiation of iPS cells into cardiac myocytes for 
therapeutic use is still inadequate. In addition, iPS cells still require improved methods of 
directed differentiation for generating homogenous populations, to be useful for cell 
therapy. Intramyocardial transplantation of iPS cells in the infarcted murine hearts 
attenuated ventricular remodelling and improved function compared to control cells 
injected hearts [66]. Although iPS cell transplantation has shown potential to improve 
function after transplantation, cells developed from the current methods have been shown 
to induce teratoma formation.   
 
1.1.6.3.3 Embryonic Stem Cells 
Embryonic stem cells represent a clear advantage for cell-based therapy. These cells have 
the capacity to create all body tissues and to differentiate efficiently into cardiomyocytes 
both in vitro and in vivo. Kolossov et al. transplanted undifferentiated ESC into mouse 
hearts and were able to find ESC-derived striated cardiac myocytes [67]. Several studies 
have shown that transplantation of embryonic stem cell-derived cardiomyocytes into 
rodent [68, 69], sheep [70] and pig [71] improved ventricular function and created new 
myocardial tissue after cardiac infarction. Moreover, human ESC-derived cardiomyocytes 
integrated functionally and structurally into the host myocardium, and survived following 
transplantation [71] and (reviewed in [72]). A factor limiting the use of ESCs is their 
inherent capacity to form teratomas when transplanted as undifferentiated cells. Therefore, 
in cell-based therapy, transplantation of a differentiated cell population is necessary. Even 
though it is very clear that ESC have great potential to regenerate and improve function of 
injured hearts, information is still lacking to correlate the number of engrafted cells with 
functional improvement observed in all these studies. Also, a complete regeneration and 
functional recovery is still not achieved. In addition, use of embryos for isolating ESC is 
still a matter of controversy and huge debate that scientist have to overcome.   
 
1.1.6.4 Delivery of exogenous cells  
Improving quantities and qualities of exogenous cells for transplantation is as important as 
improving methods of cell delivery into infarcted organs. Currently there are three routes 
that are being utilized for cell delivery, the intravascular, intracoronary and 
intramyocardial routes. Intravascular delivery is the least invasive route of delivery. 
However, the drawback with this route is its very low efficiency of cell delivery into the 
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heart due to entrapment of donor cells in the lungs [73]. The intracoronary delivery is 
efficient for direct delivery into the myocardium during angioplasty. However, following 
angioplasty when the blood flow is restored, the transplanted cells get washed away by the 
flow of blood, therefore intracoronary delivery of cells is also not a perfect way to deliver 
cells [74]. Although intramyocardial route shows discrepancies on cell engraftment [75] 
and it is a very invasive route, it is still more efficient to deliver cells than the 
intravascular and intracoronary routes. Hou et al. showed an 11% engraftment of delivered 
cells following this route [74]. Therefore, intramyocardial route was chosen as the method 
of delivery of P19Cl6-derived cardiac myocytes in this study.  
 
1.1.7 Improvement of passive function 
Passive function can be improved by (i) transplantation of cells that release paracrine 
factors that enhance function by increasing vessel density, reducing scar size and 
inflammation or enhancing engraftment of endogenous progenitor cells and (ii) direct 
supplementation of survival/ growth factors, angiogenic or anti-inflammatory and anti-
fibrotic molecules by gene or pharmacotherapy.  
 
1.1.7.1 Gene therapy 
Regeneration of lost muscle mass seems possible with a cell therapy approach. However, 
an injured heart does not have a favourable environment for endo/exogenous cells to home 
and engraft. Inflammation is necessary as a first measure of defence to an injury to resolve 
injury as fast as possible, but the inflammatory cells produce radical oxygen species which 
are toxic and cause adverse effects on uninjured tissue and resident and/or homing stem 
cells. Therefore, for a successful regeneration and restoration of normal function of an 
injured heart, it seems necessary to combine cell therapy with cyto-protective survival 
factors that provide protection to both the donor cells and the recipient tissue. The factors 
could be delivered via either gene or pharmacotherapy. Pharmacotherapy usually is 
unspecific resulting in ectopic action of the factors that could have adverse effects. Gene 
therapy on the other hand can be utilized to express certain factors in a less ectopic 
manner. Unlike pharmacotherapy, in a gene therapy approach, a gene could be expressed 
in a regulated manner at a desired amount and specific site.  
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1.1.7.2 Ways to deliver genes 
There are several ways to conduct gene therapy. The gene can be delivered as cDNA in a 
naked plasmid although this type of delivery is not efficient due to low transfection 
efficiency [76]. It can also be delivered via viral vectors. The issue with using virus would 
be the choice of virus. A virus for gene delivery must be safe and persistent. Adenoviruses 
are quite safe as they do not integrate into the genome of the cell when transduced into 
cells. However, because they are episomal they are also not very persistent. Lentiviruses 
and Adeno-associated Viruses are more persistent because of their integration into the 
genome of the cells. However, they are less safe compared to the Adeno virus as they 
permanently integrate into the genome of the recipient cells, possibly leading to adverse 
effects like mutations of DNA leading to generation of cancer cells. Nevertheless, for 
cardiac gene therapy, a viral vector must be able to integrate into non-dividing cells as 
cardiomyocytes are non-dividing cells and for this purpose, lentivirus and adeno-
associated viruses make the best candidates [76].  
 
1.1.7.3 Candidate genes for therapy 
For cardiac gene therapy, one can use a few kinds of viral vectors but numerous genes to 
counter the resulting effects of injury. In Chronic Heart Failure (CHF) due to Myocardial 
Infarction, there are three instances where gene therapy could be utilized. It could be used 
to reduce the scar size, to attenuate left ventricular dilation or to treat CHF.  Lowering scar 
size has to be performed immediately after occurrence of an infarct, therefore this could be 
a challenge for chronic myocardial infarction. However, left ventricular dilation and CHF 
proceed infarction hence these could be attenuated easily. The attenuation of LV dilation 
and treatment of CHF could be achieved by delivering transgenes that are anti-apoptotic 
(e.g Bcl-2), angiogenic (e.g. VEGF) or growth hormones such as Insulin-like Growth 
Factor-1 (IGF-1), which have multiple beneficial functions [77, 78]. Supplementation of 
these factors potentially protects at-risk myocardial cells from injury, inhibit expansion of 
scar, increase vessel formation and protect hearts from further functional impairment, 
preventing CHF.   
 
1.1.8 Animal models of myocardial infarction 
Due to the limited possibilities for controlled human studies, animal experimental models 
have become vital for studying myocardial infarction. The animal studies on myocardial 
infarction are targeted either at understanding the mechanisms underlying the injury or at 
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applying cell therapy approaches, testing pharmacological agents or devices for treating 
the injury. There are various ways to induce myocardial infarction in the animal hearts. 
Some of the commonly used techniques are: (i) occlusion of the left anterior descending 
coronary artery (LCA) either by physical ligation of the LCA [79] or by physical 
obstruction of the artery by placing a coil [80], (ii) chemical destruction of the tissue by 
injecting cardiotoxin [77], and (iii) physical destruction by cryo-injury i.e. applying metal 
probe chilled to -196°C locally to the LV wall [81]. Technique (i) involves ligation of the 
LCA that leads to the death of the cardiac tissue resulting from ischemia. Techniques (ii) 
and (iii) on the other hand do not involve occlusion of blood supply but direct death of the 
cardiac tissue by chemical and physical actions respectively. The advantages of using 
these latter models are that the injury obtained from them is localized, highly reproducible 
and the technique itself is comparatively less invasive than LCA ligation. However, 
cardiotoxin- and cryo-injuries do not occur naturally therefore, from clinical perspective 
these techniques are not the desired models for understanding human ischemia induced 
MI. Moreover, the LV remodelling events that occur after cryo-injury and injury induced 
by myocardial infarction and reperfusion are fairly different [82], suggesting that the 
outcomes of studies utilizing the cryo-injury model have to be carefully considered when 
the outcomes are to be translated into clinical studies. The LCA ligation model on the 
other hand involves occlusion of the coronary artery as it happens in humans, although the 
occlusion in humans occurs due to atherosclerotic plaques or blood clots in the arteries 
rather than physical ligation. The major disadvantage of using LCA ligation model is the 
massive variability on infarct size, which complicates comparison of animals within a 
group.  In general, the use of healthy and young animals for studies is also a limiting 
factor faced by all these animal models. Patients with myocardial ischemia usually 
demonstrate spontaneous ischemia leading to infarction and this is not the case with young 
healthy animals. Therefore, neither of the techniques mentioned above mimics completely 
myocardial infarction as it happens in human hearts, thus better animal models need to be 
developed in order to capture fully, the disease model in animals. Despite these 
drawbacks, the available animal models contribute significantly to our understanding of 
the disease. And from the available models, the LCA ligation model currently represents 
the clinical scenario more closely than the others, therefore this model was chosen for 
establishing the myocardial ischemia in this study.   
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The following table provides a general overview on cell transplantation studies conducted 
on animal models of MI. The present study utilized Insulin-like Growth Factor-1Ea-gene 
therapy approach through transplantation of P19Cl6 cells, for a proof of principle. The 
objective behind using cell-based gene therapy was to obtain more than a single beneficial 
long-term effect from transplantation of the cells. For instance transplantation of SK with 
VEGF was shown to improve not only function and cell engraftment but also blood flow 
through generation of new vessels [83]. This study was inspired by combinatorial cell 
therapy approaches such as the SK-VEGF study and some others mentioned below, in 
order to obtain a long-term beneficial effect. The reasons for using particularly IGF-1Ea 
and P19Cl6 cells are described in 1.2 Section II.  
 
1.1.9 Table 1: Overview of recent cell transplantation studies in animal models of MI 
Cell 
Type 
Number of 
cells 
administere
d per 
animal 
Recipient 
 
 
 
Setting 
 
Objectives Results Follow
-up 
Reference 
iPS cells 3*10^5 in 
10µl DMEM 
mice, female 
immunocom
petent  
acute MI by 
LCA 
ligation, 
intramyocard
ial 
transplantati
on 
-effect of SK-derived 
iPS cells on 
regeneration of 
infracted hearts 
-cells engrafted 
-teratoma 
observed in iPS 
cells injected but 
not in skeletal 
myoblast injected 
control 
 
4 
weeks 
[84] 
iPS cells 2*10^5 in 
10µl 
differentiatio
n media, 
injected in 4 
spots, 2.5 
µl/spot 
mice, male 
8-12 old, 
immunocom
petent as 
well as 
athymic 
nude mice 
acute MI by 
LCA 
ligation, 
intramyocard
ial 
transplantati
on 
-test potential of iPS 
cells for heart disease 
therapy 
-cells engrafted 
without detectable 
tumour 
-EF↑, FS↑, 
RSWT↑  
4 
weeks 
[66] 
CPCs 1*10^6 in 
1ml PBS  
rats, female 
3 months old  
1 month after 
MI by LCA 
ligation and 
reperfusion, 
intracoronary 
infusion  
-clinical perspective 
on CPC 
transplantation, using 
a chronic MI model 
and intracoronary 
transplantation of 
cells as these 
methods are more 
clinically relevant 
-cells engrafted   
-EF↑, LVEDP↓, 
dP/dt↑  
35 days [85] 
 
CPCs 
with 
IGF-1 
1*10^5 in 10 
µl saline 
rats, female 
3 months old  
acute MI by 
LCA 
ligation, 
intramyocard
ial 
transplantati
on 
-to test whether 
transplantation of 
CPCs together with 
nanofiber coupled 
growth factor IGF-1 
enhances repair after 
infarction 
-detected 
myocardial 
regeneration 
- dP/dt↑, EF↑ 
1 
month 
[86] 
 
 
 
 
 
CPC 
sheet  
2.0 ± 0.2 × 
10^6 per 
sheet  
mice, male 3 
months old  
acute MI by 
LCA 
ligation, 
intramyocard
ial 
transplantati
on 
-to understand the 
mechanism  of 
improvement in 
function after CPC 
cell transplantation 
-LVDd↓, LVDs↓, 
FS↑, LVEDP↓, 
+dP/dt↑ 
3, 4 
weeks  
[87] 
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SK 
expressin
g VEGF 
under 
hypoxia 
exposure
, VEGF 
delivered 
via 
nanoparti
cles 
 
 
1*10^7  
 
 
rabbit, 
female  
 
 
acute MI by 
LCA 
ligation, 
intramyocard
ial 
transplantati
on 
 
 
-to test a promoter 
controlled expression 
of VEGF through cell 
therapy 
 
 
-increased SK 
survival 
-increased blood 
vessels and blood 
flow 
- EF↑ 
 
 
 
max. 
14 
days, 
variabl
e time 
points 
 
 
[83] 
Repeated 
injection 
of SK  
average 
329*10^6  
pigs chronic MI 
by 
vasculoembo
lization coil 
insertion, 6 
weeks, 
intramyocard
ial 
transplantati
on 
-to test sequential 
transplantation of 
cells to improve 
engraftment 
- engraftment of 
cells                    -
↑dLVEF,             -
↑tissue 
vasculogenesis, -
↓fibrosis 
7 
months 
[80] 
transgeni
c MSCs 
expressin
g GSK-
3β 
1*10^5 in 30 
µl saline  
mice, male 3 
months old  
acute MI by 
LCA 
ligation, 
intramyocard
ial injection 
-to investigate the 
effect of GSK-3β on 
cardiac based cell 
therapy with MSC 
after MI 
-increased survival 
and cardiomyocyte 
differentiation of 
MSC 
-increased 
vascularisation 
- LVEDD, 
LVESD and   
LVEDP not 
elevated, FS↑  
-increased wall 
thickening 
12 
weeks 
[88] 
MSC 
with 
EPC 
1*10^6 MSC 
and 1*10^6 
EPC in 200 
µl medium 
rats isoproterenol 
induced 
myocardial 
injury, cells 
transplantati
on 4 weeks 
after injury 
induction 
-to test effects of 
transplantation of a 
cocktail of different 
cells on function 
improvement  
-cells detected 
-↑ angiogenic 
growth factor 
expression,  
-↓ collagen 
deposition,         - 
↑ regional blood 
flow 
12 
weeks 
[89] 
 
 
 
 
 
 
ESC-
derived 
CPCs 
0.5-1.0*10^6 
in saline in 
30 µl saline 
mice, female 
8-10 weeks 
old  
acute MI by 
LCA ligation 
-to test  if 
transplantation of 
ESC derived CPCs 
improve muscle 
generation and 
neovascularization 
-cells engrafted 
-↓LVID, ↑EF, 
↑FS, ↓ cardiac 
remodelling 
4 
weeks 
[90] 
human 
ESC-
derived 
CM 
1.5*10^6 in 
saline 
rat 7-10 days 
after 
infarction 
- to test ability of 
ESC-derived CM  to 
engraft and improve 
impaired function 
-FS↑, EDV↓ 4 
weeks 
[91] 
human 
ESC-
derived 
CM 
with pro-
survival 
factors 
1*10^7 in 
saline 
rat 4 days after 
MI by LCA 
ligation 
-to improve 
efficiency of 
differentiation of 
hESC into CM, 
improve their purity 
and survival 
-myocardial grafts 
observed 
-FS↑, EDV↓ 
-↑wall thickening 
4 
weeks 
[92] 
ESC-
derived 
CM and 
BM 
3*10^4-
1*10^5  
mice, male 
12 weeks old  
acute MI by 
LCA 
-which cell  is ideal 
for transplantation 
and understanding 
fate of ES-CM and 
BM cells upon 
transplantation 
-BM cells no 
positive effect, 
ES-CM ↑ function 
-cells engrafted 
-no teratoma 
observed 
-EF↑, EDV↓ 
 
4-5 
months 
for cell 
engraft
ment 
analysi
s 
3-4 
weeks 
functio
n 
analysi
s 
[67] 
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human 
ESC-
derived 
CM 
 
1*10^6 
 
mice, 11-12 
weeks old, 
immune 
compromise
d 
 
acute MI by 
LCA 
 
-long term analysis of 
hESC-derived CM 
transplantation 
 
-cells engrafted 
-EF↑ at 4 weeks 
which became 
comparable to 
control at 12 
weeks 
 
12 
weeks 
 
[93] 
mouse 
cardiac 
lineage 
committe
d ESC 
3*10^7 in 
medium 
sheep 14 days after 
myocardial 
injury caused 
by placing a 
coil 
-to test heterogenous 
transplantation of 
ESC with the view 
that ESCs are 
immune priviledged 
-cells engrafted 
-EF↑, variable 
1 
month 
[70] 
 
 
 
 
 
iPS: induced pluripotent cells, CPC: cardiac progenitor cells, SK: skeletal myoblasts, MSC: Mesenchymal Stem Cells, ESC: embryonic 
stem cells, CM: cardiomyocytes, EPC: endothelial progenitor cells, BM: bone marrow cells, VEGF: vascular endothelial growth factor, 
dP/dt: change in systolic pressure over time, LVEDP: left ventricular end diastolic pressure, LVESP: left ventricular end systolic 
pressure, LVEDD: left ventricular end diastolic diameter, LVESD: left ventricular end systolic diameter, EDV: end diastolic volume, 
LCA: left coronary artery, MI: myocardial infarction, EF: Ejection Fraction, FS: fractional shortening, ESV: end systolic volume, 
RSWT: regional septal wall thickness, LVDd: left ventricular diastolic diameter, LVDs: left ventricular systolic diameter, LVID: left 
ventricular internal diastolic diameter 
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1.2 SECTION II: THE CELL AND THE GENE OF CHOICE 
 
1.2.1 The Cell: P19Cl6 
 
1.2.1.1 P19 Embryonal Carcinoma-derived stem cells (P19EC)  
P19EC are pluripotent cells like the ESCs. They are derived from teratocarcinoma. When 
injected into blastocysts, they are able to form tissues of all three germ layers [94].  
Moreover, when treated with 1% DMSO they differentiate very efficiently into 
spontaneously beating cardiac myocytes. P19EC cells are very suitable for deriving clonal 
sub-lines [94-96]. P19Clone6 (P19Cl6) cells were made from P19EC cells with long-term 
culture of the cells under conditions promoting mesoderm differentiation [97]. P19Cl6 
have even higher efficiency of differentiation into cardiac myocytes than P19EC and they 
are easier to maintain and manipulate in culture than embryonic or other candidate cells as 
they grow without feeder layer. Therefore P19Cl6 cells were chosen as the model system 
for cell therapy in this study.  However, as these cells are derived from teratocarcinoma, 
this study only represents a proof of principle for cell therapy. To translate the outcome of 
this study to clinical applications, future investigations on safer model systems will be 
necessary.  
 
1.2.1.2 Derivation and characteristics of P19Cl6 cells 
P19Cl6 are a clonal derivative of pluripotent P19EC cells derived from teratocarcinoma. 
Teratocarcinomas are malignant tumors that arise from defective germ cells in the testis of 
mice and humans. They can also be derived artificially by transplanting early murine 
embryos from the uterus to ectopic sites [98, 99]. P19EC cells were isolated from 
teratocarcinoma formed after transplantation of a 7.5 day old embryo into murine testis 
[99]. The 7.5 day old embryo was derived from crossing C3H/He female mice with feral 
males carrying a number of variant alleles. The isolated undifferentiated P19EC cells had 
euploid male karyotype and the cells grew quickly in culture without feeder layer 
(reviewed in [98]). When these cells were injected into blastocysts of a different mouse 
strain, they formed tissues of all three germ layers in the resulting chimeric mice, proving 
their pluripotent potential [94]. P19EC cells are very suitable for deriving clonal sub-lines 
[94-96]. To select for ventricle specific cardiac myocytes, Moore et al. created a 
transgenic reporter cell line from P19Cl6, which expressed green fluorescent protein 
(GFP) under the transcriptional control of the rat myosin light chain-2v (MLC-2v) 
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promoter [100]. Myosin is a protein consisting of two heavy and two light chains, which 
are a major element of the contractile part of muscle cells [101]. The Myosin Light Chain 
(MLC) is of two types, MLC-1 and MLC-2. The MLC-2 is the regulatory chain [102] 
which is expressed in mouse and rat heart ventricles exclusively as MLC-2v [103]. To 
generate the MLC2v-GFP vector, Moore et al. cloned the 250bp rat MLC2v cDNA into a 
promoter free vector peGFP-N2 vector. This resulted in no detectable GFP expression in 
the P19Cl6 cells. Therefore they sub-cloned a ubiquitous CMV promoter in front of the 
MLC2v cassette, which then resulted in a higher expression of GFP in cardiomyocytes 
derived from P19Cl6 cells. This system provides an extra tool for positive selection of the 
ventricular cell population from a pool of differentiated cell lineages for various 
applications and studies [100].  The current study utilizes P19Cl6MLC2v-GFP cells 
generated by Moore et al. for transplantation.    
 
1.2.1.3 Differentiation mechanism of P19EC/P19Cl6 cells 
Both P19EC and P19Cl6 can be differentiated into different cell types using 
pharmacological agents such as Retinoic acid, DMSO or Oxytocin [100, 104, 105]. 
Initially P19EC cells were observed to efficiently differentiate into different cell types 
when cultured in non-adherent aggregates called Embryoid Bodies (EBs) [106, 107]. In 
addition, it was observed that adding retinoic acid on a teratocarcinoma stem cell-line 
called F9 cells in monolayer culture resulted into differentiation of these cells [108]. 
Taking together these findings, a combination of the EB formation and drug treatment was 
then used to induce P19EC cells to differentiate into different cell types. Treatment of the 
cells with retinoic acid led to formation of neuronal and glial tissue [104], whereas 
treatment with 0.5-1% DMSO differentiated these cells into both endo- and mesodermal 
cell lineages. Among the resulting mesodermal cell types, cardiac myocytes and skeletal 
muscles caught most attention from researchers [95, 109]. The mechanism by which 
DMSO induces differentiation of these cells is not fully uncovered. However, the 
induction of differentiation by DMSO seems not to be unique to P19EC cells. Other cell 
types such as Friend erythroleukemia (MEL) cells [110], lung cancer cells [111] and even 
mouse ES cells [112] have been reported to undergo differentiation by DMSO treatment. 
These findings suggest that the signaling pathway mediated by DMSO during 
differentiation could be a general one. It is known that the use of DMSO in P19 and 
various other cell types led to a transient increase in intracellular calcium due to their 
release from intracellular compartments. This release of calcium probably plays a vital 
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role in activating downstream signaling for inducing cardiac differentiation [113]. It has 
also been suggested that the DMSO differentiation pathway is linked to Oxytocin 
pathway. Interestingly, when P19EC were exposed to an inhibitor of Oxytocin, cell 
differentiation into cardiomyocytes was inhibited even in DMSO-treated cells, suggesting 
that DMSO acts by activation of the Oxytocin pathway [98]. However, a clear mechanism 
of DMSO action is still unclear.  
  
1.2.1.4 Mesodermal differentiation characteristics of P19EC/Cl6 cells 
The differentiation mechanism of P19EC cells is very similar to ES cell differentiation 
[99]. Compared to P19EC, P19Cl6 differentiate more efficiently into cardiac myocytes 
due to their long-term culture in mesoderm favouring media during their derivation 
(reviewed in [98]). Upon differentiation by DMSO, these cells express various mesoderm 
and muscle specific transcription factors. Mesoderm-specific Brachyury T is expressed on 
Day 2, followed by cardiac specific transcription factors Gata-4 on day 3. Expression of 
transcription factors Nkx2-5 and MEF2c followed Gata-4 expression on day 4 of 
differentiation [98, 114]. Several efforts have been made to understand the regulation of 
expression of the cardiac transcription factors mentioned above. Bone morphogenic 
proteins (BMPs) had been studied in chick embryo where the exposure of the embryo to 
BMP using soaked beads led to expression of Nkx2-5 and Gata-4 ectopically in the 
embryo [115]. From this observation, it was postulated that BMPs have a role in cardiac 
differentiation of P19 cells. However, studies showed that DMSO did not induce 
expression of BMP but DMSO-induced P19 cell differentiation into cardiomyocytes 
depended on BMP signalling [116]. Application of Noggin, a natural inhibitor of BMP, 
during induction of differentiation led to failure of P19 cells differentiation into cardiac 
myocytes [117].  
 
1.2.1.5 Characteristics of P19 cell derived cardiac myocytes 
Differentiation of P19 cells into cardiac myocytes leads to expression of many cardiac 
structural, contractile, ion channel and receptor proteins. An mRNA level analysis on day-
6 beating myocytes revealed expression of cardiac actin. The cardiac myocytes co-
expressed MLC1v, MLC2a, alpha-MHC and beta-MHC [118]. A contractile apparatus in 
P19 derived cardiomyocytes consists of both light and heavy chains, meaning components 
of both atria and ventricle. In addition they also expressed the skeletal form of actin, 
which showed another similarity with ESC derived cardiac myocytes [118]. In addition, 
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other cardiac structural proteins such as Cardiac Troponin C and Desmin have also been 
reported (reviewed in [98]). P19 derived cardiomyocytes demonstrate spontaneous 
beating, express calcium channels and limited amounts of sodium channels that are 
functional [119-121]. Their maximum diastolic potential is fairly low and the nature of 
their action potential resembles primary isolated embryonic cardiomyocytes (reviewed in 
[98]). Taken together, even though P19Cl6 are derived from teratocarcinoma, the 
cardiomycytes resulting from their differentiation resemble the myocytes derived from 
embryonic stem cells or embryonic cardiomyocytes, therefore appear to be a good 
candidate for a proof of principal for cell therapy.     
 
1.2.2 The Gene: Insulin-like Growth Factor-1 (IGF-1)  
A previous study from our laboratory suggested that one of the isoforms of IGF-1, IGF-
1Ea, induces cardiac recovery with decreased scar formation and lower inflammatory 
response after myocardial infarction [77]. Furthermore, IGF-1Ea induced a gene 
expression profile related to decreased oxidative stress and increased cardiac-specific 
protective molecules, such as Adiponectin [77]. Similarly, Musaro et al. reported that in 
dystrophic muscle that underwent repetitive rounds of muscle damage and repair resulting 
in exhaustion of muscle regeneration and scar formation, IGF-1Ea transgene was able to 
attenuate this condition by reducing the extent of fibrotic tissue formation [122, 123]. 
Results from both Musaro and Santini indicated that expression of IGF-1Ea in a tissue-
specific manner could be an effective and powerful approach to counter a number of life-
threatening muscle damages [77, 122]. Direct gene therapy would be a possibility to 
deliver IGF-1Ea to the injured area, however gene therapy is yet to provide satisfactory 
clinical solutions due to its relatively inefficient delivery and possibly harmful ectopic 
expression. Therefore, a cell-based approach was utilized to deliver IGF-1Ea into injured 
hearts to improve both the active and the passive functions.  
 
1.2.2.1 Insulin-like Growth Factor (IGF) system 
The Insulin-like growth factor (IGF) system consists of Insulin (I), Insulin-like Growth 
Factor-1 (IGF-1) and Insulin-like Growth Factor-2 (IGF-2), cell surface receptors (IR, 
IGF-1R and IGF-2R) and six IGF binding proteins (IGFBP-1 to 6). In circulation and in 
the extracellular environment, IGFs can exist either in an unbound form or in bound 
complexes with IGF binding proteins (IGFBP). The IGFBPs serve as carrier molecules for 
IGFs, extend their half-life and modulate their actions and availability [124, 125].  
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1.2.2.2 Insulin-Like Growth Factor-1 isoforms 
The rat Insulin-like Growth Factor-I gene used in this study spans more than 70kb of 
genomic DNA [126]. There are four different forms of IGF-1 that are synthesized from 
distinct mRNAs which are produced by alternative splicing, alternative promoter usage or 
post-translational modifications of the original IGF-1 transcript [18, 126, 127].  The IGF-1 
gene consists of 6 exons separated by 5 introns. Transcripts initiated at exon 1 are spliced 
to produce mRNAs that contain exon 1 but lack exon 2 (class 1 IGF-1), whereas  
transcripts initiated at exon 2 produce mRNAs that lack exon 1 but contain exon 2 (class 2 
IGF-1) [128, 129].  In addition, alternative splicing at the 3’-end of the IGF-1 gene adds 
further complexity to the IGF-1 transcripts and their resulting translated isoforms. When 
exon 4 is spliced to exon 6, 19 amino acids are added to the common 16 amino acids 
encoded by exon 4, thus generating a 35 amino acid long E-peptide, termed Ea-peptide. A 
second E-peptide, in rat known as the Eb-peptide, is translated when a 52 base fragment, 
derived from exon 5, is included and spliced to exon 6. This insertion encodes 17 codons 
and causes a frame shift in the reading frame, thereby introducing an earlier in-frame stop 
codon in the exon 6 sequence. The Eb-peptide contains 41 amino acids, with exon 4 
coding for 16 amino acids, exon 5 for 17 amino acids, and exon 6 for eight amino acids 
[130]. Figure 2 shows the structure of the rodent IGF-1 gene and the isoforms that result 
from the several splicing events described above. 
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Figure 2. Structure of the Rat Insulin-like Growth Factor-1 Gene and Protein. (a) Shows multiple 
start sites indicated by the horizontal arrows at Exon 1, 2 and 3. The translation start codon AUG are 
located at positions -48, -32 and -22 with respect to the mature IGF-1 coding region (70 amino acid) 
marked by red boxes in exons 1, 2 and 3 respectively. Figure (b) shows alternative splicing events that 
occur at the 5' and 3' ends of the IGF-1 transcripts. Figure (c) shows IGF-1 protein isoforms resulting 
from the different splicing events. (Reprinted from Growth Hormone & IGF Research, Shavlakadze 
et al. Reconciling data from transgenic mice that over-express IGF-I specifically in skeletal muscle, 
Copyright (2005), with permission from Elsevier) 
 
Different isoforms of IGF-1 exert different biological functions. IGF-1 is known to play 
an important role in growth, survival, differentiation and proliferation [18]. The rodent 
IGF-1 gene is very similar to human IGF-1 in its structure. Moreover, the nucleotide 
sequence and amino acids between the two species are highly conserved [126], therefore 
this study utilizes the rodent IGF-1 gene.   
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1.2.2.3 IGF-1 Function 
IGF-1 is a multi-functional protein that plays a role in survival, growth, proliferation, 
differentiation and hypertrophy of various cell types. IGF-1 can induce both proliferation 
and differentiation, demonstrated very clearly by Musaro et al. in skeletal muscles [122, 
131]. Studies on gene disruption of IGF-1 or IGF-2, as well as the receptors IGF-1R and 
IGF-2R have led to important information on functions of IGF-1. Mice lacking either 
IGF-1 or IGF-2 exhibited growth retardation with weights approximately 60% of that of 
wild-type littermates [132]. More severe was the phenotype of mice lacking a functional 
IGF-1R. These mice were born with only 45% of normal weight and died soon after birth 
from respiratory failure [132]. IGF-2R null mice on the contrary exhibited a completely 
opposite phenotype, characterised by fetal overgrowth syndrome (135% compared to 
normal control), which also resulted in lethality due to lack of IGF-2 turnover. IGF-2R 
serves towards turnover of IGF-2 and in its absence IGF-2 over-stimulates IGF-1R that 
leads to lethality [133]. These studies clearly demonstrated the function of the IGFs on 
growth.   
 
1.2.2.3.1 IGF-I in the Brain 
In the brain, it has been noted that IGF-1 can be either transported through the blood-brain 
barrier or produced locally. Several studies showed that IGF-1R modulates neuronal 
activity, resulting in the regulation of food intake, energy metabolism, reproduction and 
possibly cognitive functions. Studies in the early 1990s showed that IGF-1 stimulates 
proliferation of neuron progenitors, induces differentiation of oligodendrocytes and 
increases the survival of neurons and oligodendrocytes in vitro [134-136]. In homozygous 
mice, disruption of IGF-1 or IGF-1R genes produced pathological abnormalities and 
impairment of brain growth [137]. On the other hand, in transgenic mice over-expressing 
IGF-1 in the brain, the size and the weight of the brain increased markedly [138].  
 
1.2.2.3.2 IGF-1 in the Bone 
IGF-1 has also been implicated in bone formation and growth. Genetic disruption of the 
IGF-1 gene led to a short bone phenotype and low bone mineral density [139]. A more 
striking phenotype was observed in mice with targeted deletion of the IGF-1 gene in 
osteoblasts. These mice showed a significant defect in bone formation with reduced 
osteoblastogenesis. Overall the mice presented a dramatic reduction in bone 
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mineralization by three weeks of age, suggesting a role of IGF-1 in bone matrix 
mineralization [140].  
 
1.2.2.3.3 IGF-1 in the Skeletal Muscle 
The role of IGF-1 in skeletal muscle has been studied extensively with various isoforms. 
In skeletal muscle, the predominant IGF-1 mRNA variant expressed is initiated at exon 1 
(class1) with exon 4-6 spliced variant encoding the IGF-1 isoform containing Ea-peptide 
[122]. This isoform is often referred to as “local” isoform (IGF-1Ea) [122]. After exercise 
or muscle damage, an exon 4-5-6 splice variant is upregulated. This is called the Mechano 
Growth Factor (MGF), which presumably is the IGF-1Eb isoform (reviewed in [141]). 
The expression of MGF has also been detected in resting muscle although at a very low 
level compared to IGF-1Ea (reviewed in [141]). A study on a myogenic cell line, C2C12, 
suggested different roles of IGF-1Ea and MGF [142]. This study reported that MGF 
prolongs proliferation of these cells while IGF-1Ea promotes their fusion. MGF has also 
been reported to be involved in proliferation of myoblasts in humans [143] and rats [144].  
 
In vivo, mice over-expressing IGF-1Ea isoform in skeletal muscles showed increased fiber 
size, protein content, and nuclei within myofibers [122]. These features were accompanied 
by activation of Gata2, a novel marker of myocytes hypertrophy [145]. Moreover, this 
isoform of IGF-1 conferred muscle mass and strength during aging, in neuromuscular 
disease, and after injury [122]. Over-expression of human IGF-1 exclusively in skeletal 
muscle prevented age-related decline in the number of dihydropyridine receptors [146]. 
Dihydropyridine receptors are coupled to ryanodine receptors to conduct excitation-
contraction coupling mechanism in skeletal muscles. In ageing mammalian skeletal 
muscle weakness, a large number of ryanodine receptors are uncoupled to dihydropyride 
receptors. Expression of  human IGF-1 transgene prevented age-related decreases in 
dihydropyridine receptor number and in muscle force [146].  
 
1.2.2.3.4 IGF-1 in the Heart 
IGF-1 has been known to play a role in cardiac growth, function, apoptosis and 
remodelling. IGF-1 expression increases DNA and protein synthesis of myocardium [147, 
148] and it is required for entry into S-phase of the cell cycle. It has also been known to 
modulate the induction of genes that regulate the cell cycle [149, 150]. Transgenic mice 
over-expressing IGF-1 in cardiomyocytes have increased heart weight and number of 
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cardiomyocytes by 50% and 20-50% respectively [150]. On the contrary, loss of growth 
hormone or IGF-1 may lead to cardiac atrophy and decrease in cardiac function [151]. 
Cittadini et al. reported an improvement in cardiac function in normal adult rats by IGF-1 
[152]. Similarly, IGF-1 has been shown to improve functions of infarcted rat heart [153], 
chronic heart failure patients [154] and healthy human [155]. However, the mechanism of 
action of IGF-1 on cardiac function remains largely unclear.  
 
Studies show that IGF-1 may play a direct role in cardiac contractility [156, 157]. These 
studies noted that IGF-1 increases intracellular calcium ion concentration in parallel to its 
action on cardiomyocyte contractility. IGF-1 may enhance cardiac contractility by 
increasing synthesis of cardiac contractile proteins [158]. However various intracellular 
signalling pathways have been implicated which include the Phospho Inositol-3 (PI-3) 
kinase and Tyrosine kinase [158] that may be directly affecting the intracellular calcium 
ion elevation (reviewed in [159]). The cardiac contractility could be affected by IGF-1 
also without affecting the calcium ion level by simply increasing the sensitivity of the ion 
by the cell. IGF-1 has been implicated in ion channel function [160]. In 1998, Solem and 
Thomas reported that IGF-1 doubled dihydropyridine (DHP) sensitive calcium ion 
channel activity in cardiac myocytes, which could contribute to attenuation of contraction. 
The study suggests that the increased activity of calcium channels might lead to increased 
cardiac muscle contractility and cytosolic calcium transients [160].  
 
Cardiac myocytes are believed to be non-mitotic cells [161]. Upon prolonged ischemia, 
they suffer apoptotic death, after which the heart suffers from failure as there is no 
regeneration of the lost muscle mass [161]. IGF-1 being an anti-apoptotic factor was 
administered in a rat model of myocardial ischemic reperfusion where it was able to 
decrease myocardial death [162] by inhibiting leukocyte-induced cardiac necrosis and 
reperfusion-induced apoptosis of cardiac myocytes. In a myocardial infarction model 
caused by the occlusion of left descending coronary artery, transgenic mice over-
expressing IGF-1 demonstrated decreased cell death and ventricular dilation [163]. 
Similarly work from our laboratory performed with transgenic mice over-expressing IGF-
1Ea (IGF-1Ea) showed smaller scar size and better function after injury compared to wild 
type control animals [77]. Studies performed with higher mammals showed similar results. 
In higher organisms, IGF-1 plays a role in reducing the amount of apoptotic cells and 
increasing contractile function (reviewed in [159]). As a result of our previous findings 
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and known beneficial effects of IGF-1Ea expression on muscle cells reported by other 
groups outlined above, this study chose to study IGF-1Ea in the heart.  
 
1.2.2.4 IGF-1 signaling  
IGF-1 bio-availability is highly regulated by IGF1-binding proteins (IGFBPs) and its 
signal transduction occurs through the cell membrane by the IGF-1 receptor (IGFR), 
which forms dimers and shows tyrosine kinase activity upon ligand binding. There are two 
possibilities for the signaling event that follows the activation of the receptor.  It can either 
lead to Mitogen Activated Protein (MAP) kinase pathway via Ras activation or to insulin 
receptor substrate (IRS) 1 and 2 leading to Akt. Both of these pathways eventually activate 
different genes in the nucleus. MAP-kinase pathway has been implicated in cell 
proliferation, differentiation, survival and hypertrophy.  
 
Upon ligand binding, the intracellular kinase domain of the receptor becomes activated 
and in turn autophosphorylates the receptor. This autophosphorylation event leads to the 
recruitment of endogenous substrates, of which the IRS proteins-1 and the src-homology 
containing protein (SHC), an adaptor protein with src-homology 2 domains (SH2), play a 
major role [164, 165]. Binding of these proteins to the cytoplasmic domain of the IGF-1R 
phosphorylates the proteins, which then enable recruitment of other substrates that in turn 
activate different signal cascades [166]. Several other docking proteins that are recruited 
to an activated IGF-1R have been described (reviewed in [164]) and these provide a 
mechanism to activate distinct signaling cascades in a tissue- and cell-specific manner. 
Since the expression pattern of these proteins varies between tissues and throughout 
development, they might provide an explanation for the multiple functions of IGF-1. 
However, it is important to point out that most of the studies to unravel the intracellular 
signalling pathways induced by IGF-1 have been based on tissue culture. Therefore, the 
extent to which the information translates in vivo remains to be investigated.  Figure below 
(Figure 3) gives an overview on IGF-1 signaling. 
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Figure 3. Overview of IGF-1/IGF1R Signaling Pathway. Binding of the ligand IGF-1 to the receptor 
IGF-1R leads to the downstream activation of MAP-kinase, PI3K, CamK and Calcineurin pathways, 
coded with different colours. (Reprinted from Trends in Immunology, Mourkioti et al., IGF-1, 
inflammation and stem cells: interactions during muscle regeneration, Copyright (2005), with 
permission from Elsevier) 
 
1.2.2.4.1 MAP-kinase signaling 
MAP-kinase signaling has been suggested to be one of the major pathways of IGF-1 for 
mediating cell proliferation [167]. The activated IGF-1R leads to recruitment of the 
docking protein SHC to the receptor. This leads to association of SHC with growth factor 
receptor-bound protein 2 (Grb2) via their SH2 domains. Grb2 is an adaptor protein, which 
recruits the GTP-exchange factor Sos (Sons of sevenless) via an additional SH3 domain. 
As a result of the interaction between Grb2 and Sos, the small G protein Ras is recruited.  
In addition this also leads to the transition of the inactive Ras-GDP to active Ras-GTP. 
Activated Ras induces sequential activation of Raf-1, MAP-kinase kinase (MAPKK), and 
a family of MAP-kinases, namely ERK1, ERK2 (extracellular regulated kinase), Jun 
kinase, and p38 MAP-kinase (reviewed in [158]). The MAPKs phosphorylate 
transcription factors, which increases their ability to induce expression of molecular 
markers of cell cycle progression, like c-jun, c-fos, cyclin D1, and cdk4  (reviewed in 
[158]). Cyclin D1 and cdk4 play a critical role in mediating the phosphorylation of the 
retinoblastoma protein (Rb). Upon phosphorylation, Rb releases E2F, a transcription 
factor essential for activating the transcription of many proteins involved in the cell cycle. 
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Also IRS-1 is able to recruit Grb2 and thereby activates the MAP-kinase pathway. 
Inactivation of the MAP-kinase pathways by using the specific inhibitor PD098059 in 
L6A1 myogenic cells induced a ~90% reduction of IGF-1 stimulated proliferation [167].  
 
1.2.2.4.2 PI(3)-kinase signaling 
The PI(3)-kinase has been linked to cell differentiation, survival and hypertrophy. Upon 
IGF-1R activation by ligand binding, IRS-1 interacts with the PI(3)-kinase, a heterodimer 
composed of a 110 kDa catalytic subunit and an 85 kDa regulatory subunit (p85) 
containing a SH2 domain. The p85 regulatory subunit directly binds to activated IRS-1 
[168], phosphorylates and eventually triggers PI3-kinase activation. Activated PI3-kinase 
phosphorylates inositol phospholipids, which are required to induce several downstream 
targets, such as the serine/threonine kinase Akt, also known as protein kinase B. PI3-
kinase plays a critical role on myogenic response to IGF-1 [167, 169-171]. PI(3)-kinase 
together with its downstream effector Akt had been implicated in activating factors 
involved in muscle differentiation and muscle cell survival. One of the most important 
effects of IGF-1 in stimulating myogenesis is its ability to activate expression of the 
myogenin gene via the PI(3)-kinase and direct translocation of Akt into the nucleus 
(reviewed [158, 172]. Myogenin is directly associated with terminal myogenic 
differentiation [173].  
 
The PI(3)-kinase pathway has also been shown to induce the transcription of myocyte 
enhancer factor 2 (MEF2). MEF2 plays a role in activating muscle specific structural 
genes [174]. Activation of the PI(3)K/Akt pathway is crucial for regulation of protein 
synthesis in skeletal muscle cells as well as muscle hypertrophy [175, 176]. Muscle 
specific expression of constitutively active Akt in mice resulted in profound myofiber 
hypertrophy and decreased fat deposition [176]. Such muscle hypertrophy is observed in 
conditional transgenic mice, as well as when the transgene expression is induced in adult 
mice using tamoxifen-dependent recombination [176]. Activated Akt can lead to up-
regulation of protein synthesis by regulating enzymes involved in carbohydrate 
metabolism. A recent report by Song et al. however suggested that hypertrophic pathway 
downstream of PI3-kinase can take place without involvement of Akt. They demonstrated 
this by showing activation of phosphoinositide-dependent protein kinase (PDK-1) and 
several other molecules without affecting Akt activity in the hypertrophic muscles of 
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transgenic animals over-expressing Class 1 IGF-1Ea (IGF-1Ea) specifically in skeletal 
muscle [177].  
 
The PI(3)-kinase/Akt pathway also plays a role in inhibiting apoptosis by interacting with 
members of the Bcl-2 family of proteins [178] which have been shown to either inhibit or 
stimulate apoptosis. Following IGF-1 mediated stimulation, activated Akt can either lead 
to inhibition of pro-apoptotic Bcl-2 members and BAD at the earlier stage of apoptosis, 
and caspase 9 at later stages (reviewed in [172]), or to up-regulation of anti-apoptotic Bcl-
2 members [179-181]. Although it is clear that the Akt pathway is the main pathway by 
which the activated IGF-1R exerts its anti-apoptotic affect, there is evidence that the IGF-
1R has alternative pathways [182, 183]. Peruzzi et al. [183] showed a pathway which is 
dependent on mitochondrial translocation of Raf-1 and phosphorylation of BAD, which 
results in an anti-apoptotic event.  
 
1.2.2.4.4 Calcineurin pathway 
Calcineurin is activated by increased intracellular Ca2+ levels and causes 
dephosphorylation and nuclear translocation of cytoplasmic NF-ATc (nuclear factor of 
activated T cells) family members, which in combination with other transcription factors 
such as Gata2 activate transcription [184]. Two studies have linked the hypertrophic 
action of IGF-1 to calcineurin, although the calcineurin-mediated hypertrophy of skeletal 
muscle cells is not completely established. In one study, transfection of C2C12 myoblasts 
with plasmid encoding the IGF-1 gene induced mobilisation of Ca2+ within the cell, 
increased activation of calcineurin and resulted in nuclear translocation of the transcription 
factor NF-ATc1 [185]. This was associated with hypertrophy of the myotubes, a response 
that could be inhibited by addition of CsA or FK506, inhibitors of calcineurin [185]. 
However, the timing of IGF-1 addition mattered in driving the hypertrophy as hypertrophy 
occurred only when IGF-1 was added to proliferating culture or at the time of 
differentiation [185].  In a different study with L6E6 cells, which did not express 
endogenous IGF-1, transfecting the cells with IGF-1Ea led to hypertrophy of the cells 
associated with Gata2 and Calcineurin A accumulation [145]. However, the studies by 
Musaro et al. [145] and Semsarian et al. [185] were later questioned by Rommel et al. and 
Bodine et al. [175, 186]. They suggested that the reported inhibition of hypertrophy by 
addition of CsA could have been due to inhibition of fusion and differentiation of 
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myoblasts, as the inhibitor was applied to undifferentiated cells. These reports show 
discrepancies on the role of IGF-1 signaling on hypertrophy.  
 
1.2.3 Tetracycline regulated expression of IGF-1Ea  
The gene therapy fraction of this study was conducted via lentiviral transduction of rat 
IGF-1Ea gene into P19Cl6. The lentiviral expression vector carrying the IGF-1Ea gene 
(pLenti4/TO/V5-DEST) uses regulatory elements from the E.coli Tn10-encoded 
tetracycline (Tet) resistance operon. This allows tetracycline-regulated expression of IGF-
1Ea from the expression construct. Expression of IGF-1Ea in the expression vector is 
under the control of human cytomegalovirus (CMV) promoter, into which 2 copies of tet 
operator 2 (TetO2) sequence have been inserted. The two operator sequences are binding 
sites for Tet Repressor (TetR) molecules [187]. The tetR molecules are generated through 
another lentiviral vector (pLenti/TR) that is transduced into the cells, prior to the IGF-1Ea 
expression vector. Upon transduction, TetR is generated constitutively. TetR molecules 
form homodimers, which then bind to TetO2 sequence in the IGF-1Ea construct with 
extremely high affinity. The two TetO2 sites get bound with 4 TetR molecules in total. 
The binding of the TetR to the TetO2 sequences represses transcription of IGF-1Ea. Upon 
addition, tetracycline binds with each of the TetR and causes a change in their 
conformation. The change in conformation then leads to dissociation of tetracycline:TetR 
from the TetO2 sequence, which then allows induction of gene expression [187]. Figure 
below demonstrates how tetracycline regulation of IGF-1Ea occurs in this study (Figure 
4).  
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Figure 4. Mechanism of Tetracycline Regulated Expression of IGF-1Ea (mIGF-1) Gene. Expression of 
the tetracycline repressor (TetR) represses IGF-1Ea expression by tightly binding to the two 
tetracycline operator sequences (tetO2). Tetracycline treatment causes conformational change of the 
TetR homodimers causing the release of TetR from operator sequences and inducing transcription of 
IGF-1Ea. (Figure adapted from: ViraPower T-Rex Lentiviral Expression System, Invitrogen)  
1.2.4 Objectives of this study 
The objectives of this study were to (i) create tools to stably transduce pluripotent P19Cl6-
MLC2v-GFP cells with IGF-1Ea and regulate the gene expression via tetracycline 
treatment, (ii) study the effects of IGF-1Ea transduction and expression on properties of 
the cell before and after differentiation, (iii) test feasibility of the IGF-1Ea transduced 
cells in vitro for subsequent in vivo cell therapy and (iv) test if function of impaired hearts 
caused by myocardial infarction could be preserved by transplantation of the engineered 
cells and whether or not IGF-1Ea transduced cells confer better cell survival, engraftment 
and preservation of function than the control cells.  
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1.2.5 Aims of this study 
(i) Creating tools to stably transduce pluripotent P19Cl6-MLC2v-GFP cells with IGF-1Ea 
and regulate the gene expression via tetracycline treatment: The objective was met by 
cloning rat IGF-1Ea cDNA into lentiviral vectors of the Gateway system, where 
expression of the gene were driven by ubiquitous CMV promoter. For obtaining the 
tetracycline regulated expression of IGF-1Ea, P19Cl6-MLC2v-GFP cells were transduced 
with both IGF-1Ea and Tetracycline Repressor (TetR) lentiviruses, where TetR will bind 
to the IGF-1Ea operon sequences and repress expression of IGF-1Ea until activated. 
Expression of IGF-1Ea was induced upon tetracycline treatment. 
 
(ii) Studying the effects of IGF-1Ea transduction and expression on properties of the cell 
before and after differentiation: Viral transduction as well as transduction of IGF-1Ea 
gene could theoretically affect the properties of the transduced cells. Therefore, following 
viral transductions, the P19Cl6-MLC2v-GFP cells were examined for their pluripotent 
feature, nature of cell cycle and their ability to form ventricular myocytes. 
 
 (iii) Testing feasibility of the IGF-1Ea transduced cells in vitro for subsequent in vivo cell 
therapy: After establishing the tools for cell-based gene therapy, in vitro analyses were 
conducted to test feasibility of the IGF-1Ea transduced cells for cell therapy. Firstly, the 
efficiency of differentiation into ventricular cardiomyocytes was analyzed in order to 
determine whether or not a reasonable amount of cells could be obtained for 
transplantation. Contractility of the differentiated cells was investigated to ensure that the 
cells are capable of contributing to mechanical function once transplanted into injured 
hearts. The myocytes obtained from differentiation were analyzed for cardiac structural 
proteins, to ensure their presence as well as to understand their organization. Finally, to 
test whether or not IGF-1Ea expression confers protection to the donor and the recipient 
cells, the IGF-1Ea transduced cells and neonatal cardiomyocytes treated with IGF-1Ea-
cells conditioned media were assessed for cell viability following hypoxia exposure.  
 
(iv) Testing if function of impaired hearts caused by myocardial infarction could be 
preserved by transplantation of the engineered cells and whether or not IGF-1Ea 
transduced cells conferred better cell survival, engraftment and preservation of function 
than the control cells: Following the in vitro assessments, the cells were transplanted into 
murine myocardial infarcted hearts. For transplantation, the IGF-1Ea expressing 
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ventricular cardiomyocytes were FACS sorted to select a pure cell population from all 
other cell lineages resulting from differentiation of the P19Cl6-MLC2v-GFP cells. The 
FACS sorting ensured that only differentiated ventricular myocytes were selected to avoid 
teratoma formation that might result from transplantation of undifferentiated cells. 
Myocardial Infarction was induced in C57BL6/J, 3-4 months old mice by permanent 
occlusion of the descending Left Coronary Artery. Immediately after induction of 
myocardial infarction, each heart received 1 million FACS sorted cells in five different 
spots surrounding the ligated area.  Functional analyses were carried out before surgery, 
after 5 days and 2 months following induction of infarction and cell transplantation. 
Animals were sacrificed at 5 days or 2 months for molecular and histological analyses. 
Molecular analyses examined cytokines involved in inflammation, survival, vessel 
formation and homing of endogenous stem cells. Histological analyses studied scar size, 
cell engraftment and capillary densities.    
 
With transplantation of IGF-1Ea expressing P19Cl6-MLC2v-GFP-derived 
cardiomyocytes, this study anticipated to achieve a lasting preservation of function of the 
infarcted hearts. The expression of IGF-1Ea was expected to confer better survival of the 
donor and the recipient cells, leading to reduced death of at-risk myocardium and better 
engraftment of the transplanted cells resulting in lasting maintenance of function of the 
injured hearts.   
 
The following figure (Figure 5) outlines experimental plan, organized according to 
different chapters.  
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Figure 5. Outline of Experimental Plan  
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2.1 MATERIALS AND METHODS   
2.1.1 DNA preparation and quantification 
DNA for all the experiments were isolated by using QIAGEN plasmid purification Kits 
(QIAprep Spin Miniprep ® Kit #27106; Endofree Plasmid Maxi Kit #12362) according to 
the manufacturer’s instructions. Purified plasmids were eluted with sterile milliQ water 
and stored at -20°C. Concentration of the DNA was determined by spectrophotometric 
measurement of the absorbance (A) at 260 nm and 280 nm.  
 
2.1.2 RNA isolation and quantification 
2.1.2.1 Tissue Samples  
Total RNA was isolated from frozen tissue following the standard TRIzol protocol 
(Invitrogen #15596-026). All equipment used was pre-treated with RNAse ZAP (Ambion 
#9780;0782) to avoid damage of RNA by RNAse, which is ubiquitous. Tissues were 
homogenized with an electric homogenizer in the appropriate amount of TRIzol (50-100 
mg of tissue per 1 ml of TRIzol). The homogenized samples were left at room temperature 
for 5 minutes for complete dissociation of nucleoprotein complexes. Following the 
incubation, RNA was separated using the appropriate amount of Chloroform (Merck 
#UN1888) (0.2mL/1mL Trizol) by mixing it vigorously and centrifuging at 11000 rpm for 
15 minutes at 2-8oC. With centrifugation samples formed three phases.  The aqueous 
phase, the interphase and the red phenol phase. Aqueous phase was carefully pipetted out 
and RNA was precipitated with 0.5 mL Isopropanol/1 mL Trizol (BDH #102246L). The 
aqueous phase was left with Isopropanol at room temperature for 10 minutes and spun at 
11000 rpm for 10 minutes at 2-8oC.  The precipitated RNA was washed once with 75% 
Ethanol (Merck #UN1170), using 1mL ethanol for 1mL Trizol. Following washing, 
samples were centrifuged at 8600 rpm and RNA was air dried before adding water to re-
dissolve it. To ensure a clean preparation of RNA for quantitative Real Time PCR 
analyses, Trizol isolated RNAs were further purified using RNeasy mini-columns (Qiagen 
#74104). The RNA samples were made up to 100 µl with RNA grade water. 350 µl of 
lysis buffer containing recommended amount of B-mercaptoethanol and 250 µl of absolute 
ethanol were added sequentially. The content was mixed by pipetting and mixture was 
transferred to the mini-columns. The column was centrifuged at 13,000 rpm for a 15
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seconds and RNA purification was performed by adding RNase-Free DNase solution as 
described by the manufacturer (QIAgen #79254). Finally the purified RNA was dissolved 
in 30-50µl of RNAse/DNAse free water and stored at -80°C until used.  
 
Concentration of RNA was determined by spectrophotometeric measurement of the 
absorbance at A260 and A280 nm. A desired amount of RNA was diluted in TE buffer 
(10mM Tis, 1mM EDTA, pH 8.0) and the absorbance reading was taken using a double 
beam spectrophotometer which corrected for background absorbance by comparing the 
test cuvette with a reference cuvette containing the TE buffer. RNA concentration was 
determined using the formula that at 260nm, an OD of 1.0 represents 40 µg/ml RNA 
molecules.  RNA purity was measured at 280nm OD. A pure RNA sample shows twice 
OD value at 280nm compared to 260nm and the ratio of absorbance 260 to absorbance 
280 (A260/A280) is 2.0. Proteins absorb at 280nm therefore a ratio lower than 2.0 
indicates contamination of RNA with protein.   
 
2.1.2.2 Cultured cells 
For RNA isolation from adherent cell cultures, plates were washed twice with sterile PBS 
and scraped in 1ml of TRIzol per 10 cm culture dish and followed the trizol extraction 
method described above for tissue samples. Alternatively for non fibrotic cells, RNA 
extraction kit was used (Qiagen #74104). The PBS washed cultured cells were lysed with 
350 µl of lysis buffer. The cells were then scrapped off the plates and passed through a 
fine needle and syringe for homogenization. They were then added with 350 µl of 70% 
ethanol and mixed thoroughly before transferring to the mini-columns. The columns were 
then centrifuged at 13000 rpm for 15 minute to adsorb the RNA onto the silica membrane. 
Following this the DNA washing step was carried out by adding RNase-Free DNase 
solution as described by the manufacturer (QIAgen #79254) followed by RNA extraction 
and quantification as described above.    
 
2.1.3 mRNA quantification by Real-Time Polymerase Chain Reaction (qRT-PCR) 
Gene expression at transcript level was analyzed by using a real-time polymerase chain 
reaction. The analyses were performed using two separate systems for Reverse 
Transcription (RT) and PCR.  RT was performed to generate cDNA and this was followed 
by a real-time PCR analysis to quantify gene expression levels. Sections 2.1.4 and 2.1.5 
describe the methods for cDNA synthesis and real-time PCR analysis respectively. 
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2.1.4 cDNA synthesis 
cDNA was synthesized using the Taqman reverse transcription kit supplied by Applied 
Biosystems (Applied Biosystems #N8080234). RNA samples for reverse transcription 
were thawed thoroughly. For cDNA synthesis, 100 ng/µl concentration RNA samples 
were prepared using RNA-grade water. Samples and the reagents were kept on ice at all 
times and handled with gloves to avoid contamination of RNases. The enzymes were left 
at -20°C until immediately before use. The reaction mix was prepared by combining all 
the reagents listed in table below (Table 2) and aliquoted into 0.5 ml microtubes. The 
RNA samples and RNA-grade water at appropriate volumes were added to each tube 
separately. For cDNA synthesis, the tubes were then transferred to a standard thermal 
cycler. They were incubated at 25°C for 10 minutes for primer binding, 48°C for 30 
minutes for primer extension and 95°C for 5 minutes for enzyme inactivation. The 
synthesis was a single cycle. An aliquot of the synthesized cDNA was then diluted to 5x to 
get a concentration of 2 ng/µl for real-time PCR analysis. 
Table 2. cDNA Synthesis 
 
 
Reagent Final 
Concentration 
10 µl Rxn 20 µl Rxn 30 µl Rxn 
10X RT buffer 1X 1.0 2.0 3.0 
25mM MgCl2 5.5 mM 2.2 4.4 6.6 
dNTPs 500µM each 
dNTP 
2.0 4.0 6.0 
Random 
hexamers 
2.5 µM 0.5 1.0 1.5 
Rnase inhibitor 0.4 U/µl 0.2 0.4 0.6 
Multiscribe  
Reverse 
Transcriptase 
1.25 U/µl 0.625 1.25 1.875 
RNA-free water - 
RNA 10 ng/µl 
3.475 6.95 10.425 
 
 
 
2.1.5 Quantitative Real Time PCR (qRT-PCR)  
Following the cDNA synthesis, an aliquot of the 2ng/µl cDNA was thawed for real-time-
PCR analysis. The off-the-shelf assays for all the genes of interest were obtained from 
Applied Biosystems, ready-to-use. The catalogue numbers for all the genes analyzed are 
listed in the table below (Table 4). The reagents for real-time PCR, the 20X 18S assay 
(Applied Biosystems #4310893E), the 20X off-the-shelf assays (Applied Biosystems), and 
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the cDNA samples were thawed at room temperature. The assays were thawed protected 
from light. 2 X Taqman universal PCR master mix (Applied Biosystems #4604437) that 
consists all other components required for the PCR analysis was kept refrigerated until 
immediately before use. All the PCR tubes were optical grade (Applied Biosystems 
#403012). The PCR master mix was prepared by mixing all the reagents listed in (Table 3) 
in the required amount and aliquoted into the optical tubes. 3 µl of the 2ng/µl cDNA was 
pipetted into the optical tubes separately in duplicates. Real-time PCR was then performed 
in an ABI Prism 7700 Sequence Detection System (Applied Biosystems). The PCR cycle 
conditions are mentioned below. When the PCR run was over, data were collected and 
analyzed using Sequence Detection Software (Applied Biosystems, SDS). Data from SDS 
were exported into Excel and analyzed by using the comparative Ct method.  
Table 3. Recipe for Real Time PCR 
 
Reagent 1 Rxn Total Volume = 25 µl  
2x Universal Master Mix 12.5 µl 
20x off the shelf assay (primers and probes all mixed) 1.25 µl 
20x 18S control 1.25 µl 
cDNA 3 µl 
Water 7 µl 
 
 
Table 4: TaqMan off-the-shelf assays for Real Time PCR analyses 
 
TaqMan® Gene 
Expression assay 
Gene name Assay ID 
Mouse IL-10 Interleukin-10 Mm0043914_m1 
Mouse Myl2 Myosin Light Chain 2 Mm000440384_m1 
Mouse Nkx2-5 Nkx2-5 Mm00657783_m1 
Rat IGF-1 Insulin-like Growth Factor-1 Rn00710306_m1  
Mouse Gata4 Gata-binding Protein-4 Mm00484689_m1 
Mouse VEGFa Vascular Endothelial Growth Factor 
Alpha 
Mm01281449_m1 
 
Mouse IL-6 Interleukin-6 Mm00446190_m1 
Mouse SDF/ Cxcl12 
 
Chemokine (C-X-C motif) ligand 12 Mm00445552_m1 
Mouse bMHC Beta Myosin Heavy Chain Mm00600555_m1 
Mouse aSK Alpha skeletal actin Mm0080818_g1 
Mouse Eln Elastin Mm00514670_m1 
 
The comparative Ct method is a relative quantification technique which avoids use of 
standard curves and makes use of mathematical formulas [188]. This method relies on 
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approximately equal PCR efficiencies of the target and endogenous control genes. The 
formula used by this method to calculate abundance of a target mRNA by normalizing to 
an endogenous control and relative to a calibrator. The formula for relative expression is 
2^-ddCt, where ddCt = dCt of test sample-dCt of calibrator sample and dCt = target gene 
Ct (eg. IGF-1) - endogenous control gene Ct (eg. 18S). The 2 in the formula as the base 
number is derived from the assumption that the PCR efficiencies of a well designed assay 
will be close to 100% and result in a doubling of amplicon with each cycle.  
 
Stage 1: 50 0C for 2 min UNG incubation 
Stage 2: 95 0C for 10 min Activate DNA Polymerase 
Stage 3: 95 0C for 0.15 min Denature     
Stage 4: 60 0C for 1 min Anneal and Extend 
Stages 3 and 4 were run for 40 PCR cycles.  
 
2.1.6 Cloning of IGF-1Ea cDNA into lentiviral backbone 
IGF-1Ea rat cDNA was directionally cloned into a Gateway entry vector backbone 
pENTR Directional TOPO Cloning Kits (Invitrogen # K2400-20), using a blunt-end PCR 
product. The Gateway system allows cloning of the gene of interest into multiple vectors 
in a very efficient and rapid manner by recombination. Taking advantage of this property, 
after cloning into the entry vector, the gene of interest, IGF-1Ea, was cloned into a 
destination lentiviral backbone, pLenti4/TO/V5-DEST (Invitrogen # K4965-00). The IGF-
1Ea cloning from the entry vector into the destination vector was by site-specific 
recombination of attL and attR recombinant sites present on the entry and destination 
vectors respectively.  The generated expression vector was transformed into One Shot 
Stbl3 Chemically Competent E. coli cells and plated on LB- plates with 30µg/ml 
Chloramphenicol, where a true clone with IGF-1Ea inserted will be Chloramphenicol 
sensitive. The expression clone was maintained and propagated in LB medium containing 
100 µg /ml Ampicillin to select for resistant clones. The following are the vector maps for 
the IGF-1Ea and the TR genes (Figure 6). 
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Figure 6. Maps of Lentiviral Constructs. The pLenti4/TO/V5-DEST consists of two tet operator 
sequences (TO) that serve as binding sites for the tetracycline repressor (TetR). Zeocin resistance 
allows selection of IGF-1Ea vector transduced cells and Blasticidin for TR vector transduced cells. 
The recombination sites attR1 and attR2 are downstream of the CMV-TO promoter. The pLent6/TR 
lentiviral construct consists of a TR gene under the control of the ubiquitous promoter CMV to allow 
its expression in different cell types. (Figure adapted from ViraPower T-Rex Lentiviral Expression 
System, Invitrogen)   
2.1.7 Sequencing of IGF-1Ea  
To confirm the presence and orientation of the IGF-1Ea insert, as well as the integrity of 
the lentiviral pLenti4/TO/V5-DEST, restriction analysis and sequencing of the expression 
vector was carried out. Table 5 below shows primers used for sequencing of IGF-1Ea 
gene. Below the table is the sequence for rat IGF-1Ea mRNA. 
 
Table 5: IGF-1Ea sequencing Primers 
Forward External Primer 1: 5’CACCACGACGGCCAGTGAATTGGATTTA 3’ 
Forward Internal Primer 2: 5’ CCACAGGCTATGGCTCCAGCATT 3’ 
Reverse Internal Primer 3: 5’ AATGCTGGAGCCATAGCCTGTGG 3’ 
Reverse External Primer 4: 5’GACTCACTATAGGGAGACAAGGTTG 3’ 
 
Rat IGF-1Ea mRNA sequence [189] 
1 gaatgttccc ccagctgttt cctgtctaca gtgtctgtgt tttgtagata aatgtgagga 
61 ttttctctaa atccctcttc tgcttgctaa atctcactgt cgctgctaaa ttcagagcag 
121 atagagcctg cgcaatcgaa ataaagtcct caaaattgaa atgtgacttt gctctaacat 
181 ctcccatctc tctggatttc tttttgcctc attattcctg cccaccaatt catttccaga 
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241 ctttgtactt cagaagcgat ggggaaaatc agcagtcttc caactcaatt atttaagatc 
301 tgcctctgtg acttcttgaa gataaagata cacatcatgt cgtcttcaca tctcttctac 
361 ctggcactct gcttgctcac ctttaccagc tcggccacag ccggaccaga gaccctttgc 
421 ggggctgagc tggtggacgc tcttcagttc gtgtgtggac caaggggctt ttacttcaac 
481 aagcccacag gctatggctc cagcattcgg agggcaccac agacgggcat tgtggatgag 
541 tgttgcttcc ggagctgtga tctgaggagg ctggagatgt actgtgctcc gctgaagcct 
601 acaaagtcag ctcgttccat ccgggcccag cgccacactg acatgcccaa gactcagaag 
661 tcccagcccc tatcgacaca caagaaaagg aagctgcaaa ggagaaggaa aggaagtaca 
721 cttgaagaac acaagtagag gaagtgcagg aaacaagacc tacagaatgt aggaggagcc 
781 tcccgaggaa cagaaaatgc cacgtcaccg caagatcctt tgctgcttga gcaacctgca 
841 aaacatcgga acacctgcca aatatcaata atgagttcaa taccatttca gagatgggca 
901 tttccctcaa tgaaatacac aagtaaacat tccgacattg tctttaggag tgtttgttaa 
961 aaaaaaaaaa aaaaaaaaca aaaacaaaaa caaaaaaaaa aagctttgca ccttgcaaaa 
1021 gtggtcctgg cgtgggtaga ttgctgttaa tcctttatca ataacgttct atagagaata 
1081 tataaatata tatataatt 
 
2.1.8 Virus production 
Production of lentiviral stocks expressing IGF-1Ea, Tet repressor (TetR) and Empty 
vector (control virus without IGF-1Ea, with pLenti4/TO/V5-DEST backbone only) were 
performed as instructed by the manufacturer [187]. In brief, human embryonic kidney 
(HEK) 293 cells were grown in adherent culture overnight to get 90% confluency the next 
day. For transfection, DNA-lipofectamine 2000 (Invitrogen #11668-027) complexes were 
prepared as follows. In a sterile tube, 9 µg of packaging mix and 3 µg IGF-1Ea expression 
vector (a total of 12 µg) were mixed in 1.5 mL of Opti-MEM I Medium without serum 
(Gibco #31985-070). An optimized mixture of pLP1, pLP2, and pLP/VSVG plasmids 
formed the Packaging/Envelope Mix (Invitrogen #K4975-00). The packaging/envelope 
mix was provided in the ViraPower T-Rex Lentiviral Expression System. In a separate 
tube, 36 µl (3:1 lipofectamine to DNA ratio) Lipofectamine 2000 was mixed with 1.5 mL 
of Opti-MEM I Medium without serum. The solution was mixed gently and incubated for 
5 minutes at room temperature. Following the incubation, the DNA and lipofectamine 
dilutions were combined in one tube, mixed very gently and incubated for 20 minutes to 
form DNA-lipofectamine complexes. In the meantime, media was replenished for 293 
cells with Opti-MEM I Media containing 10% serum. When the incubation was over, the 
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3 mL lipofectamine-DNA complex containing medium was added to the 293 cells. Cells 
were then incubated overnight at 37°C and 5% CO2. The next day, lipofectamine 
containing culture media was replaced with small volume of complete culture media. 
Virus containing supernatant was harvested 48 hours post-transfection and stored in 1ml 
aliquots at -80 oC.    
 
2.1.9 Determining antibiotic sensitivity 
As the stably transduced cells were selected using Zeocin (Invitrogen #R250-05) and 
Blasticidin (Invitrogen #R210-01) resistance, the minimum concentration of the 
antibiotics to select the cell of interest within 10-14 days was to be determined before 
transduction was carried out. Antibiotic sensitivity was examined with Zeocin 
concentrations ranging from 50-1000 µg/ml and Blasticidin from 2-10 µg/ ml in human 
connective tissue fibrosarcoma cell line (HT1080) (ATCC # CCL-121) and P19Cl6 cells 
(Gift from Prof. C. Mummery, Netherlands). Typically these concentrations are enough to 
kill most of untransduced mammalian cell lines [187]. Cells were plated in 25% 
confluency, 10 plates per cell type, and allowed to adhere overnight. The following day, 
normal growth medium was substituted with media supplemented with Zeocin and 
Blasticidin to respective plates. Two plates were used as negative control where normal 
media was continued. The selective media was replenished every 3-4 days and the 
percentage of surviving cells was carefully observed. Appropriate concentrations of 
antibiotics for each of the cells types were determined by finding the concentration that 
killed the cells within 10-14 days.  
 
2.1.10 Lentiviral stock tittering 
The expression vector (Lenti4/TO/V5-DEST) and the Tet repressor construct (Lenti6/TR) 
containing Zeocin and Blasticidin resistance genes respectively, are necessary to select 
stably transduced cell clones and for titration of the lentiviral stocks. To analyse the 
minimum concentrations of Zeocin and Blasticidin necessary to select the cells that 
integrated the lentiviral constructs, concentrations ranging from 50-1000 µg/ml of Zeocin 
and 2-10 µg/ml of Blasticidin were tested. The minimum concentration of the antibiotics 
required to induce death of untransduced cells was determined 10-14 days after the start of 
antibiotic treatment. Titering was performed with HT1080 (ATCC # CCL-121). The cells 
were transduced with lentiviral supernatant in a 10-fold serial dilution (100 to 105). A plate 
was left untransduced as a mock control. Forty-eight hours post-transduction, cells were 
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treated with 10µg/ml Blasticidin or 1000 µg/ml zeocin. After 10-14 days of selection, the 
transduced cells were stained with 5ml/10cm-dish crystal violet (Sigma # 10010-023 in 
10% ethanol) for 10 minutes at room temperature and the titer of the virus was determined 
by counting Crystal violet-stained colonies as described in the instruction manual [187].  
 
2.1.11 Transduction of viral vectors  
Lentiviruses for the tetracycline operon system were transduced first into HT1080 
followed by the cell of interest, P19Cl6. Transductions were performed following the 
protocol provided by the company. In summary, both the cell types were transduced with 
Lenti6/TR first, on cells growing on 10cm culture dishes. On the day of transduction, a 
1ml vial of the TR virus was thawed and diluted with equal volume of culture media. The 
old culture media was replaced with 2 ml of virus containing media. Polybrene (Sigma 
#H9268) was added at 6 µg/ml concentration to the 2 ml media to maximize transduction. 
The transduced cells were incubated with TR virus for 24 hours until the next transduction 
of the Lenti4/TO/V5-DEST-IGF-1Ea constructs, to allow time for the Tet repressor protein 
to be expressed. Lenti4/TO/V5-DEST-IGF-1Ea virus was transduced the same way as TR 
virus except that the virus was diluted into 3 ml media instead of 2ml. This was to make 
sure that Lenti6/TR virus transduced at higher multiplicity of infection (MOI, i.e. number 
of virus particles per cell) than the Lenti4/TO/V5-DEST-IGF-1Ea virus to obtain 
Tetracycline regulated expression of the gene of interest. Media supplemented with 
Blasticidin (4 µg/ml for both HT1080 and P19Cl6) and zeocin (500 µg/ml for HT1080 and 
200 µg/ml for P19Cl6) was changed regularly for 10-14 days to select for stably 
transduced cells.  
 
2.1.12 Tetracycline regulated gene expression 
Stably transduced, positively selected HT1080 and P19Cl6 cells were treated with/without 
tetracycline (Invitrogen #Q100-19) to induce gene expression. Tetracycline was added in 
culture media to a final concentration of 1 µg/ml. Cells were left with tetracycline for 48 
hours to allow enough time for gene expression. Forty-eight hours after tetracycline 
treatment, RNA was extracted and qRT-PCR was carried out to determine IGF-1Ea 
transcript expression in the tetracycline treated versus untreated cells. From the remaining 
stably transduced P19Cl6 cells, 18 colonies were picked, expanded and stored for future 
analysis. The colonies were labelled clones 1-18. 
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2.1.13 Cell culture 
2.1.13.1 HT1080 
HT 1080 cells were obtained from ATCC and propagated in 10 cm plates with ATCC 
complete growth medium. The medium was ATCC-formulated Eagle's Minimum 
Essential Medium (EMEM) (# 30-2003). To make the complete growth medium, the 
EMEM was supplemented with 10% fetal bovine serum (Sigma #F7524). The cells 
became confluent every 2-3 days after which they were split into 1:4 ratio. They were 
incubated in a humidified chamber at 37°C and 5% CO2. 
    
2.1.13.2 293T 
293T cells were cultured for virus production purposes. They were plated in 10 cm tissue 
culture dishes without any coating. They were seeded at 2 * 10^6 cells per 10 cm tissue 
culture dishes and grown in media with high glucose DMEM (Gibco #D5546), 
supplemented with 10% FBS (Sigma #F7524), 1% Pen/Strep (Sigma #P0781), 1% MEM 
Non Essential Amino Acid (Gibco #11140) and 1% L-glutamine (Sigma #G7513). The 
cells became confluent after 2-3 days in culture after which they were trypsinized and split 
into 3 plates per confluent plate.  
 
2.1.13.3 P19Cl6-MLC2v-GFP-IGF-1Ea Culture and Differentiation 
The P19Cl6-MLC2v-GFP-IGF-1Ea cells were incubated in a humidified chamber at 37°C 
and 5% CO2. For growth of adherent cells, culture dishes and flasks were prepared by 
coating with 0.1% gelatine (Sigma #G9391). They were grown on media consisting of 
78% DMEM/F-12 (Ham) (1:1) (Gibco #31331-093), 10% Fetal Bovine Serum (Sigma 
#F7524), 1% Pen/Strep (Sigma #P0781), 1% MEM Non Essential Amino Acid (Gibco 
#11140) and 1% L-glutamine (Sigma #G7513). When they reached ~90% confluency they 
were washed with 1X PBS, trypsinized and re-plated. The remaining cells after 
trypsinization were frozen down in 10% DMSO (Sigma #D2650) containing culture media 
and stored in liquid nitrogen.  
 
Cell differentiation was carried out by supplementing normal culture media with a new 
serum (ATCC #30-2020) and 1% DMSO. Cells for differentiation were trypsinized and 
re-suspended in differentiation medium in density of 400,000 cells/ml. Cell suspensions 
were transferred to bacteriological Petri dishes without gelatin for 4 days to facilitate 
Embryoid Bodies (EBs) formation. Media was replenished after 2 days. After 4 days in 
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suspension, the EBs were transferred to tissue culture dishes with normal growth medium 
to allow cell attachment. Media was changed every two days and cells were carefully 
monitored throughout. 
 
2.1.13.4 Neonatal Rat Cardiomyocytes Isolation and Culture 
Myocyte preparation was performed under a sterile tissue culture hood. Neonatal rat hearts 
were collected in 50 ml chilled 1x Ads (3,4g NaCl, 2,4g HEPES, 0,06g NaH2PO4, 0,5g 
glucose, 0,2g KCl, 0,05g MgSO4, pH 7.35) solution and washed with the same buffer 
twice in a Petri dish to remove blood.  The hearts were minced finely into mm 3 pieces and 
transferred into an upstanding 75 cm2 culture flask.  The minced tissue was then treated 
with 10ml enzyme solution (Pancreatin, GIBCO, and Collagenase, Worthington 
collagenase Type II, cls2) for 5 minutes at 37 0C. Supernatant was collected, and 10ml of 
fresh enzyme was added to the tissue and incubated for 20 min at 37°C. The steps for 
enzyme digestion and cell collection are outline in the table below (Table 6). The collected 
cell supernatant was added to pre-warmed FBS aliquots.  
 
Each collection was resuspended in pre-warmed FBS and kept at 370C. Fibroblast 
contamination was minimized by cell pre-plating into 35mm culture dishes for 45 minutes. 
Myocytes were dislodged from the pre-plated dishes by tapping the dishes several times. 
Media containing the dislodged cardiomyocytes was collected into a falcon tube and 
added with 1xBrdu. Cells were then plated in 1% gelatinized dishes and kept in complete 
medium (Dulbecco’s Modified Eagle Medium (DMEM) containing 4.5g/L glucose 
(65.5%), 199 medium containing 25 mM HEPES (20%), heat inactivated horse serum, 
heat inactivated foetal calf serum (10%), 1X HEPES (2.5%), 1X L-glutamine (1%), 1X 
penicillin streptomycin(1%)). They were left in culture for two days to recover before they 
were used for cell viability experiment upon hypoxia. 
 
Table 6: Enzyme Digestion and Cell Collection 
1 2 3 4 5 
10 ml enzymes 8 ml enzymes 8 ml enzymes 6 ml enzymes 6 ml enzymes 
20 mins 25 mins 25 mins 15 mins 20 mins 
Collection #1 Collection #2 Collection #3 Collection #4 Collection #5 
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2.1.14 Immunofluorescence 
For Immunofluorescence, cells were cultured overnight in either two or four-welled 
culture dishes in low density to get about 30-40% confluency the following day. The next 
day, they were washed with cold 1x PBS thrice, 3 minutes per wash and fixed with 4% 
PFA for 10 minutes at room temperature. Following fixation, they were washed with 1x 
PBS for three times and treated with 0.1% Triton X-100 to permeabilize the cell 
membrane for 5 minutes at room temperature. In the mean time 3-5% blocking solution 
was prepared with serum of the animal where the secondary antibody was raised. Cells 
were blocked with blocking solution for an hour. After the incubation with blocking 
solution, they were treated with primary antibody, in blocking solution, in appropriate 
dilutions recommended by the company for 2 hours at room temperature. Following the 
two hours incubation, they were washed thrice again with 1x PBS and treated with 
secondary antibody diluted in the blocking solution at the concentrations recommended by 
the company for an hour at room temperature. The slides were then washed with 1x PBS 
and treated with either 1:1000 Hoechst or 1:20000 DAPI in PBS for nuclei staining for 10 
minutes. They were then washed with PBS and mounted in Mountant, PermaFlour 
(Thermo Scientific, #TA-030-FM) and analysed through a confocal or a fluorescence 
microscope.  
 
2.1.15 Hypoxia and normoxia induction 
To investigate the effect of IGF-1Ea constitutive expression on cells that undergo serum, 
glucose and oxygen deprivation, P19Cl6 cells transduced with empty vector or IGF-1Ea 
were exposed to either normoxia or hypoxia. Normoxia was obtained by treating cells 
with media without glucose and serum but normal oxygen (i.e. 20%) placed in an 
incubator at 37°C and 5% CO2. Hypoxia was induced by having the same conditions as 
normoxia except the cells were exposed to only 3% oxygen as opposed to 20% and placed 
in a special incubator (Sanyo #MCO-5M (UV)). The first experiment was carried out to 
determine the time when the cells start to die. Several treatment times were tested namely, 
1 minute, 0.5 hour, 1 hour, 2 hours, 4 hours and 24 hours. After each time point Lactose 
Dehydrogenase (LDH) release was measured following the protocol described below.   
    
2.1.15.1 LDH assay 
Cell death can occur either by apoptosis or by necrosis. Necrosis is accompanied by 
mitochondrial swelling and increased plasma membrane permeability, whereas apoptosis 
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involves cell shrinkage, condensation of their chromatin and some times breakdown of 
cell into membrane-bound apoptotic bodies [190]. Unlike necrosis, apoptosis avoids 
involvement of scavenging inflammatory cells [190]. Lactate Dehydrogenase (LDH) is a 
stable cytosolic enzyme that gets released only upon cell lysis either by necrosis or 
apoptosis [191]. LDH is impermeable to cell membrane without damage. It is therefore a 
marker for cell membrane damage. With CytoTox96 Non-Radioactive Cytotoxicity Assay 
(Promega #G1782), necrotic cell death was determined upon hypoxia and normoxia 
exposure. The LDH activity is determined by enzymatic activity. Firstly, the NAD+ is 
reduced to NADH/H+ by the LDH catalyzed conversion of lactate to pyruvate. The 
second step involves the catalyst diaphorase, which transfers the H/H+ from NADH/H+ to 
the tetrazolium salt 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium chloride 
(INT), which gets reduced to red formazan [192-194].  
 
96-welled plates were prepared for each time point; one for normoxia and one for hypoxia 
per time point. Twenty five thousand P19Cl6 cells, with or without IGF-1Ea were plated 
in triplicates in each of the plates and incubated overnight in normal media and culture 
conditions. The next day, using a multichannel pipette, the normal media was replaced by 
serum and glucose free media. Immediately after, the plates were placed either in 
normoxia or hypoxia. After 1 minute, the first set of plates was taken out and spun to 
sediment floating cells from the supernatant. An equal volume of supernatant was 
collected from both normoxia and hypoxia conditioned plates and stored in another 96-
welled plate for further analysis. To the remaining cells and supernatant, lysis buffer was 
added at 1:10 dilution and incubated at 37 °C for 45 minutes. After the incubation, the 
plates were spun again, and the same volume of supernatant as above was collected into 
the new 96-welled plate where the supernatant without lysis was collected, and the plate 
was kept protected from light until the 4-hour time point supernatants were collected.  The 
24 hour samples were analyzed the next day when the incubation was over. To the rest of 
the samples, required volume of substrate solution was added, incubated for 30 minutes 
followed by addition of necessary amount of stop solution. When the reaction was 
stopped, the plates were read by a microplate reader at 490nm wavelength.  
 
The percentage LDH Release was calculated relative to the 1 min exposure control (C1) 
for empty vector transduced cells, which was set to 0% LDH release.  
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In the subsequent experiments, which involved only 24 hour-exposure time, percentage 
LDH release was reported relative to the empty vector transduced cells with 24 hour-
exposure, which was set to 100% LDH release 
 
2.1.15.2 Hypoxia or normoxia treatment of neonatal rat cardiomyocytes with/without 
IGF-1Ea conditioned media  
To replicate the effects of IGF-1Ea release in native heart cells in vivo when P19Cl6 
with/without IGF-1Ea is transplanted following infarction, an in vitro model was setup 
where neonatal cardiomyocytes were treated with media from P19Cl6 cells lacking both 
glucose and serum under hypoxia. Neonatal cardiomyocyte cultures were prepared using 
the protocol described above in section 2.1.13.4 two days before the experiment. In the 
mean time, P19Cl6-IGF-1Ea or P19Cl6-empty cells were cultured and treated with serum 
and glucose free cardiomyocyte media for 24 hours to collect media with or without IGF-
1Ea. Cardiomyocytes were treated with the media collected and subjected to either 
normoxia or hypoxia condition for 24 hours. The conditions for hypoxia and normoxia 
were same as mentioned above. After 24 hours incubation, media and cardiomyocytes 
were collected. Protein was extracted from the cardiomyocytes and western blot analysis 
was carried out for cleaved-Caspase-3 (Cell Signaling #9664) to investigate apoptotic 
signalling in IGF-1Ea media treated versus empty vector media treated myocytes.  Results 
were normalized to total Caspase-3 (Cell Signaling #9662). Western blot was performed 
as described below. Primary and secondary antibodies were used at 1:500 and 1:1000 
dilutions respectively and blocking was performed with 5% BSA.  
 
2.1.16 Protein extraction 
Cultured cells were washed twice in sterile PBS and scraped in the appropriate volume of  
lysis buffer (20mM Tris pH 7.5, 5mM MgCl , 150mM NaCl, 1% SDS, 1mM NaVO4 , 
1mM NaF, 1mM PMSF; for 10ml of final lysis buffer, 1 tablet of cOmplete Mini EDTA-
free Protease Inhibitors (Roche #11836170001) and 1 tablet of PhosSTOP (Roche 
#04906845001) were added. Lysates were homogenized and centrifuged for 20 min at 4°C 
and 13000 rpm, and protein concentration of the supernatant was determined by Bradford 
assay. Protein extracts were stored at -80°C until needed.  
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2.1.17 Western Blot analysis 
For SDS-page, proteins were diluted in 2xSDS sample buffer (100mM Tris pH 6.8, 4% 
SDS, 20% glycerol, bromophenol blue), denatured by adding Beta-Mercaptoethanol and 
boiling for 5 min and subjected to gel-electrophoresis. Proteins were electrophoretically 
transferred onto a Trans-Blot Transfer Medium Pure Nitrocellulose Membrane (0.45um), 
(Bio-RAD Cat# 162-0115) and transfer was carried out in a wet transfer apparatus for 1.5 
hours at 100V in transfer buffer (14.45g Glycin, 3g Tris-base, 0.75g SDS, 200 ml 
methanol and bringing the final volume to 1000 mL with water). After the transfer, 
membranes were incubated in blocking solution (5% non-fat powder milk or 5% BSA 
dissolved in 1X TBST buffer (20mM Tris pH 7.5, 140mM NaCl, 0.1% Tween20) for 1 
hour at room temperature. Primary and secondary antibodies were diluted in blocking 
solution to the concentrations indicated by the suppliers. Membranes were washed 3 
times, 10 minutes per wash in PBS-Tween buffer between primary and secondary 
antibodies were added. To detect specific bands the enhanced chemiluminescence system 
(ECL ) Western  Blotting Detection Reagent  (Amersham  #RPN2106) was used, followed 
by the exposure to Hyperfilm  ECL films (Amersham #RPN3103K). 
 
2.1.18 Confocal Calcium transient analysis 
The Ca2+ sensitive fluorescent dye, Rhod2-AM (Molecular Probes #R1244), was used to 
monitor changes in cytoplasmic calcium concentrations. Differentiated P19EC cells were 
incubated with Rhod2-AM (10 µM) for 12 min and cells were allowed to de-esterify for at 
least 30 minutes prior to analysis by confocal microscopy. Experimental chamber was 
mounted on the stage of an Axioscope 2 Zeiss upright microscope with LSM 510 confocal 
attachment. Cardiomyocytes were observed through Zeiss water immersion Achroplan 
10X lens. Rhod2-AM was excited using the 488 nm line of an argon laser. Line scans 
were collected and analyzed by Image J NIH software.  
 
2.1.19 FACS Analysis  
The percentage of GFP positive reporter cells were determined by FACS analysis using 
the FACS Aria (BD, Bekton Dickinson). For the analysis, confluent adherent 
differentiated (14 days post differentiation) and undifferentiated cells were washed with 
1xPBS and trypsinized. Cells were collected and re-suspended in 3 mL 1x PBS and placed 
on ice. An aliquot with 106 cells was taken out, spun and re-suspended 300 µl 1xPBS. The 
cell suspension was filtered through 0.45 µm sieve to get rid of any lumps of cell and 
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added with 7AAD dye to discriminate any dead cells from analysis. Cells were left with 
the dye for 5 minutes and FACS analysis was carried out. 7AAD stained cells appear 
positive in pacific blue channel. They were discarded by gating for pacific blue negative 
cells. The gated population was then analyzed for width and height to discriminate any 
doublets. After discarding doublets, the final gated population was looked at FITC channel 
for GFP positive cells. Undifferentiated cells were used as negative control for deciding 
baseline for GFP positivity and the same gating was applied for differentiated cells to 
report percentage of GFP positive cells in differentiated population. For FACS sorting, the 
GFP positive population was gated and selected for sorting. The cells during sorting were 
released in 5 ml buffer for every 106. After every 106  cells were collected, the suspension 
was spun at 1300 rpm for 5 minutes, buffer discarded and the cells were re-suspended in 
50 µl of 1x PBS for cell injection.  At all times, cells were kept on ice to minimize cell 
death.  
 
2.1.20 PI Staining for DNA analysis using FACS 
PI intercalates between the bases in DNA by binding to the nucleotide pair of guanine and 
cytosine with a stoichiometry of one dye per 4–5 base pairs of DNA [195, 196].  Because 
it binds to guanine and cytosine that are also present in RNA molecule, PI also binds to 
double stranded RNA molecule therefore it is necessary to treat with RNAase to 
distinguish between RNA and DNA staining [195, 196]. PI is a fluorescent molecule. 
Once the dye is bound to nucleic acids, its fluorescence is enhanced 20- to 30-fold.  
 
For PI staining, P19Cl6 cells transduced with empty vector or IGF-1Ea were harvested 
from adherent cultures by trypsinizing and centrifuging at 1000 rpm (400 xg) at 4°C. The 
cells were resuspended in 10-12 mL sample buffer (1g glucose in 1 Litre of PBS without 
Ca2+ and Mg2+, filter through a 0.22um filter, store at 4 degree), washed twice with the 
buffer and counted. Following counting, the cell concentration was adjusted to 1-3 x 106 
cells/ ml for each sample. 1 mL of the cell suspension was taken out, centrifuged and 
supernatant was poured off leaving only 0.1ml/ 106 cells. The tubes were vortexed very 
well in the remaining buffer. While vortexing, 1ml of the chilled 70% Ethanol solution 
was added drop by drop to the cell suspension for fixing. The samples were then left at 
4°C to fix overnight.  
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The following day, the samples were vortexed very briefly and centrifuge at 3000 rpm for 
5 minutes. Higher centrifugation is required after ethanol fixation as cells become lighter. 
After centrifugation, ethanol was poured off leaving approximately 0.2ml ethanol/ 106 
cells. The cell pellet was gently vortexed in the remaining ethanol and added with 1 mL of 
PI staining solution (50µg/ml final concentration), drop by drop. RNAse A was added at a 
final concentration of 100U/ml to the PI solution. The samples were incubated at room 
temperature for at least 30 minutes, protected from light before FACS analysis. FACS 
analysis was performed for PI staining using PE-A channel, PI fluorescence at >/= 600nm 
wavelength.  
 
2.1.21 General animal husbandry 
Wild Type, male C57Bl6J mice at 12-16 weeks of age were obtained from Harlan. They 
were kept in IVC mouse racks at 22°C at a 12h/12h light-dark cycles. They were fed with 
pellet food and drinking water and beddings were changed every week. All the animal 
work was performed at European Molecular Biology Laboratory (EMBL), Monterotondo. 
The mouse procedures were approved by the EMBL Monterotondo Ethical Committee 
and were in accordance with national and European regulations.  
 
2.1.22 LCA ligation and cell injection 
2.1.22.1 Left-anterior Descending Coronary Artery (LCA) ligation 
The LCA ligation was performed as previously described [197] and as carried out 
routinely in Prof Rosenthal’s group at the EMBL. Half an hour prior to LCA ligation and 
cell injection immunosuppressive drug FK506 was administered at 5mg/kg/day 
concentration. The immunosuppressive was diluted 5% in absolute ethanol and further 
95% diluted in Soybean oil (Sigma Life Science #S7381) to get the 5mg/kg/25µl 
concentration. The immunosuppressive drug administration was performed 
intraperitonealy with 25µl volume. Animals were anaesthetized with 3% isoflurane and 
intubated. An incision on the skin and the muscles was made to the left of the sternum.  
Following this, another incision was made in between the 4th and the 5th ribs to get access 
to the heart. Pericardium was opened completely and the left-anterior descending coronary 
artery (LCA) was visualized running from the left atrium towards the apex [197]. LCA 
was occluded by placing an 8-0 Ethilon Polyamide suture (Ethicon #W2808) 1-2mm from 
the atrium to achieve an infarction size of 40-50% of the left ventricle. Following 
permanent occlusion, cell injection was performed at the border zone using a fine micro 
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injection syringe as described in the following section. Occlusion was confirmed 
immediately after ligation by the pallor of the anterior wall of the left ventricle. However 
for certainty, echocardiography after a week was used to confirm occlusion. For closure, 
retractors were removed carefully and the incision between the ribs was closed by using a 
6-0 Ethilon Polyamide suture (Ethicon #W1614T). The air in thorax cavity was squeezed 
out very gently during the closure. Muscle layers were then placed into their original 
position and the incised skin was closed also with the 6-0 Ethilon Polyamide suture. Mice 
were then moved to a different ventilator and a heat mat for recovery, where they were 
monitored carefully until awakening. Following their recovery, they were placed in cages 
individually.  
 
2.1.22.2 Cell Injection 
For cell injection, 10^6 ventricular cardiomyocytes per animal were collected by FACS 
sorting in 50µl 1XPBS and injected at the border zone of the animal after MI. A microliter 
syringe was used for delivering cells precisely in only 10µl volume of PBS per injection 
site (Hamilton Bonadus AG, #PB600-1). FACS selection of GFP positive ventricular 
myocytes was done in FITC channel. Sorted cells were injected into groups of animals, 
immediately after MI. This model was used to look at effects of cell transplantation on an 
acute model of MI. There were altogether three groups of animals. Nine animals received 
IGF-1Ea transduced cells, 11 animals received Empty vector transduced cells and 15 
control animals received only PBS. However, all three groups received LCA ligation and 
immunosuppressive drug on a daily basis.  
 
2.1.23 Functional analysis by Echocardiography 
Following surgery, animals were left to recover for 5 days. At 5 days and 2 months post 
surgery; echocardiography was performed to analyze function of the cell transplanted 
injured hearts. For echocardiographic analyses, animals were prepared by shaving their 
Hemi-thorax region and anaesthetized with 2% Isoflurane. They were placed in a 
temperature and ECG controlled platform which kept in control the body temperature and 
heart rate throughout the measurement period. For all the animals the body temperature 
was kept at 34-38°C and the heart rate at 450-550 beats per minute. To obtain clear 
images, ultrasound transmission gel was applied at the Hemi-thorax region (Parker 
Laboratories Inc.) and images were obtained at parasternal short-axis view. Functional 
analyses were taken from B-Mode and M-Mode measurements. The functional analyses 
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were done using Vevo 2100 (Visual Sonics). Data analyses were performed using Vivo 
2100 software (Visual Sonics).  Ejection Fraction (EF), Fractional Area Change variable 
(FAC) and Fractional Shortening (FS) were taken as parameters for measuring left 
ventricular function.  
 
2.1.24 Histological analyses 
Following functional analyses, animals were sacrificed for both RNA/ protein extraction 
or for histological analysis. For histological analysis, samples were perfused and fixed 
with 4% Paraformaldehyde (PFA) and paraffin embedded as follows. PFA fixed samples 
were left overnight at 4°C. The following day, the fixative was replaced and washed twice 
15min/wash with 1X PBS at 4°C. They were then dehydrated at 4°C by treating with 50% 
Ethanol (2x 30 min), 70% Ethanol (2x 30 min) and 95% Ethanol (1x 30 min). A complete 
rehydration was performed by treating the samples with absolute Ethanol (2x 1 hour) at 
room temperature. They were then placed in xylene (3x 30 min) followed by treatment 
with 1:1 mixture of xylene and wax at 56-58°C for 30 min- 1hour. After the incubation 
time, the mixture was replaced with wax and again incubated at 56-58°C for 30 min- 
1hour. The wax was changed once again before leaving it on wax overnight at the same 
temperature. The next day the samples were oriented in plastic molds and the wax was 
allowed to solidify at room temperature.  When the wax had solidified, samples were cut 
into 5/10 µm thick sections using a microtome and plated on Polysine microscope slides 
(VWR-International #631-0107). Slides were left to dry overnight at 45°C overnight.        
 
2.1.24.1 Masson’s Tri-chrome Staining 
Masson’s trichrome staining was employed to selectively stain collagen fibres and muscle 
cells. The muscle is stained red and the collagen blue. Trichrome staining is generally 
combined with iron haematoxylin staining to stain the nuclei of cells (Sigma).  Masson’s 
Tri-chrome staining was performed to visualize and quantify scar size following 
infarction. Heart sections were deparaffinized by three 5 minutes washes in Xylene, 
followed by 3 minute ethanol washes of decreasing percentage (100%, 95%, 80% and 
70%) and distilled water in chronological order. The sections were then fixed for 15 min 
at 56°C in Bouin’s solution (Sigma-Aldrich #HT10-1-32).  Nuclear staining was achieved 
by 5 min incubation in Weighert’s Iron Haematoxilin solution (Sigma-Aldrich #HT 1079-
1Set). Following hematoxylin treatment, slides were washed briefly in running tap water 
and rinsed in two changes of distilled water. The samples were then treated for 5 min in 
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Biebrich Scarlet-Acid Fucsin (Sigma-Aldrich #HT 1079-1Set) solution to stain for 
muscles and washed again thrice with distilled water. Slides were treated with Solution A 
for 10 min, which was composed of phosphotungstic/ phosphomolybdic acid solution. 
Sections were then stained for collagen for 5 min in Aniline blue (Sigma-Aldrich #HT 
1079-1Set). Immediately after the incubation with aniline solution, slides were transferred 
to 1% acetic acid solution for 1 minute. They were then rinsed quickly with two changes 
of distilled water and dehydrated by 2 ethanol washes of increasing percentage (70%, 
80%, 95%, and 100%), cleared in Xylene for 3min, and mounted using Aquatex (VWR 
International #363123S). They were left to dry overnight and afterwards visualized 
through a light microscope.  
 
Scar size analysis was performed with samples from comparable region of the heart. 
Papillary muscles were taken as a reference for selecting the sections for the analysis. Scar 
size was calculated by taking into consideration the epicardial and the endocardial scarred 
surface as described in [198]. The following formula was used for calculating the scar 
size.  
Scar Size (%) = ((Ratio Epicardial + Ratio Endocardial)/2) *100% 
Where, Ratio Epicardial = Scarred Epicardial left ventricular circumference/ Total 
Epicardial left ventricular circumference 
Ratio Endocardial = Scarred Endocardial left ventricular circumference/ Total Endocardial 
left ventricular circumference 
 
2.1.24.2 Anti-GFP Staining 
Anti-GFP staining was performed to trace the transplanted GFP positive ventricular 
myocytes. Paraffin embedded heart sections were deparaffinised in two washes of Xylene 
and rehydrated by treating with 2X 100 %, 1X 96 %, 1X 80%, 1X 70 % and 1X 50% 
Ethanol. Each treatment was done for 3 minutes. After the last ethanol treatment, the 
samples were washed twice with 1x PBS followed by antigen retrieval. Antigen retrieval 
was performed by treating the slides with Sodium Citrate (10mM, pH 6.0). Slides were 
dipped in Sodium Citrate solution and boiled in microwavable glass for a total of 5 
minutes. Boiling was constantly monitored. The slides were let to cool down for 15-20 
minutes. They were then washed once with 1xPBS followed by blocking. Blocking was 
performed with 5% serum in 1x PBS containing 0.1% Tween for 1 hour. After blocking, 
the samples were treated with 1:200 diluted, primary rabbit polyclonal anti-GFP antibody 
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(Abcam #ab290) in blocking solution. Following primary antibody treatment, slides were 
washed with TBS three times and treated with 1:1000 diluted biotin conjugated anti-rabbit 
secondary antibody. Streptavidin (BD, Bekton Dickinson) was added into the tissue 
samples and left to incubate for 30 minutes in humidified chamber. The Streptavidin 
solution was then decanted and the slides were washed again with TBS three times, 5 
minutes each. In the mean time DAB solution (Sigma #D7679) was prepared by adding 1 
drop Liquid Chrogen per ml buffer solution. DAB was applied to the samples very quickly 
and colour change was monitored very carefully. When the samples turned brown (1-2 
minutes), DAB was decanted and slides were washed in distilled water for at least 5 
minutes. Following this, slides were stained with hematoxylin for 30 seconds and 
immediately rinsed in running tap water for 5 minutes. The slides were then dehydrated 
with graded alcohol and finally treated with Xylene. They were then mounted with 
Permount (Fisher Scientific) and left to dry over night. The next day they were observed 
through a light microscope for brown stained, transplanted GFP expressing cells. Staining 
was analysed with a Leica microscope at 10X and 40X magnification. 
 
2.1.24.3  Isolectin-B4 Immunohistological Labelling for Capillary Density Quantification 
Isolectin B4 immunohistological labelling was performed to stain the endothelial cells. 
Isolectin B4 labelling is an excellent tool for quantifying vessel and capillary densities 
[199]. Paraffin sections were deparaffinised by treating them with Xylene (2X 
5min/treatment) and rehydrated with alcohol as mentioned in section 2.1.24.1. After the 
last 70% Ethanol, slides were treated with TBS buffer for 5 minutes before proceeding to 
antigen retrieval. Antigen retrieval was done with Sodium citrate 10mM (with 0.05% 
Tween) solution for 10-20 minutes boiling in a microwave. After the incubation, they 
were left to cool down for 20 minutes. The slides were then washed in 3 changes of 
distilled water for 5 minutes each. They were washed once with TBS for 5 minutes and 
treated with 3% hydrogen peroxide solution for 10 minutes to block endogenous 
peroxidases which could give false positive signal when incubated with DAB (3,3`-
diaminobenzidine). After this, they were washed with TBS buffer thrice, 5 minutes per 
wash. Blocking was performed with solution containing TBS/Triton 0.02%, 1mM MgCl2, 
1mM CaCl2 and 1mM MnCl2 for 1 hour followed by primary antibody treatment. Each 
tissue section was then circled with a Pan pen and biotinylated isolectin-B4 antibody 
(Sigma #L2140) was applied to the samples at 10 µg/ml concentration for 3 hours (or 
overnight) in humidified chamber. Slides were then washed with TBS three times as 
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mentioned above. Streptavidin was added into the tissue samples at the recommended 
amount by the company, BD Bekton Dickinson and left to incubate for 30 minutes in 
humidified chamber. The Streptavidin solution was then decanted and the slides were 
washed again with TBS three times 5 minutes each. In the mean time DAB solution was 
prepared and applied as described in section 2.1.24.2. Slides were then stained with 
hematoxylin for 30 seconds and immediately rinsed in running tap water for 5 minutes. 
They were dehydrated with graded alcohol and finally treated with Xylene. They were 
then mounted with Permount and left to dry over night. The next day they were observed 
through a light microscope for brown stained vessels which were counted for analysis.   
 
2.1.24.4 Wheat Germ Agglutinin (WGA) Staining for Assessing Cell Cross-sectional Area 
The role of cell transplantation on LV remodelling was analyzed by measuring cardiac 
cross-sectional area at the infarct border zone. A WGA staining was performed to analyse 
the morphology of cells at the border zone of an infarct after LCA ligation and cell/PBS 
injection. WGA is a carbohydrate-binding protein of approximately 36 kDa. It selectively 
recognizes sialic acid and N-acetylglucosaminyl sugar residues that are mainly found on 
the plasma membrane (Product information Invitrogen, #W6748). Paraffin sections were 
deparaffinised by treating them with Xylene (3X 5min/treatment) and rehydrated with 
alcohol as mentioned in section 2.1.24.1. After the last 70% Ethanol, slides were washed 
with running tap water for 5 minutes followed by antigen retrieval as described in section 
2.1.24.3. After the antigen retrieval, slides were washed with PBS/0.05%Tween solution 
for 5 minutes. Slides were then blocked with 3% BSA in PBS/0.05%Tween solution for 
30 minutes. Following incubation with blocking solution, 5ug/ml WGA solution, prepared 
in 1.5% BSA/PBS 0.05% Tween was added to the samples. The samples were incubated 
with WGA for an hour, protected from light. After the incubation, slides were washed 3X 
with PBS and treated with DAPI (1:20000) for 5 minutes. The samples were then mounted 
in Perma-Flour and examined through fluorescent microscope for cell membranes 
emitting green fluorescence for measuring the cross-sectional areas of each cell.   
 
2.1.25 Statistical analysis: 
Statistical analyses were done using either Prism or Excel. For quantitative Real Time 
PCR, expression of gene was analyzed by normalizing with ribosomal 18S transcripts. To 
transfer Ct values to linear expression values, the following formula was used:  
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Relative Expression = 2^ -(∆Ct- Ct(constant)) 
Where, ∆Ct = Ct(gene)-Ct(18S) 
And Ct(constant) = Ct of one constant sample across all Cts for the same gene 
For experiments with only two groups to compare, Mann-Whitney test (unpaired, 2-tailed) 
was applied whereas for experiments with more than three groups to compare, one way 
ANOVA was used (non-parametric, Kruskal-Wallis Test). Values are expressed as mean 
relative expression or mean fold induction ± standard error of the mean (SEM). p<0.05 
was considered statistically significant and was given *, p< 0.01 ** and p< 0.001 ***. 
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3.1 SECTION I: CREATING TOOLS FOR STABLE TRANSDUCTION OF IGF-1Ea 
INTO PLURIPOTENT P19CL6 CELLS AND TETRACYCLINE REGULATED 
EXPRESSION OF THE GENE  
 
3.1.1 INTRODUCTION 
 
The study aimed at a tetracycline controlled delivery of the IGF-1Ea gene through a cell-
based therapy approach. The gene of interest was stably transduced into P19Cl6-MLC2v-
GFP cells via a lentiviral system. Lentiviral vectors are at the forefront of gene delivery 
systems for research applications. This is mainly due to their ability to transduce dividing 
and non-dividing cells, to insert large genetic constructs into the host chromatin and to 
sustain stable long-term transgene expression [200]. A Gateway system was used to 
directionally clone rat IGF-1Ea cDNA into a lentiviral vector Lenti4/TO/V5-DEST at a 
specific site. Following cloning of the gene into the expression vector, restriction digest 
and sequencing analyses were carried out to confirm integrity of the vector and the gene, 
as well as to verify that cloning occurred at the correct site and orientation. A true 
expression clone with IGF-1Ea would be Chloramphenicol sensitive and Ampicilin- and 
Zeocin-resistant, therefore an antibiotic selection was performed to exclude any false 
positive clones. Prior to transduction of the viral vectors into HT1080 and P19Cl6 cells, an 
antibiotic sensitivity experiment was carried out to determine the minimum concentration 
of antibiotic required to select the transduced cells within 10-14 days of antibiotic 
treatment. The antibiotic sensitivity assessment was essential for a reliable selection of 
positively transduced cells as well as for obtaining an idea on toxicity of antibiotics, which 
could potentially kill even the positively transduced cells if used in excess amount. After 
determining the optimum antibiotic dose for positive selection, viral titre was investigated. 
Determination of viral titre was crucial as this study aimed at controlled expression of 
IGF-1Ea through tetracycline treatment, which is dependant on the TR-vector. Therefore, 
for transduction, it was imperative to obtain an optimal ratio of the Lenti4/TO/V5-DEST-
IGF-1Ea and Lenti6/TR viruses that would deliver a tight regulation of the gene 
expression, generate reproducible expression and control the copy number of lentivirus 
integration into the genome. Experiments were performed to achieve this optimal ratio. 
Following these assessments, the viral vectors were transduced first into HT1080 human 
fibrosarcoma cells, as recommended by Invitrogen, to test whether the system was 
functional, followed by the P19Cl6-MLC2v-GFP cells. Control cells were transduced with 
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an empty vector consisting of only the Lenti4/TO/V5-DEST backbone (Lenti4/TO/V5-
DEST-Empty) and Lenti6/TR. Gene expression was then induced by tetracycline 
treatment.  
  
3.1.2 RESULTS 
 
3.1.2.1 Cloning and Sequencing of IGF-1Ea 
Restriction digest and sequencing analyses of IGF-1Ea lentiviral vector confirmed that 
IGF-1Ea was cloned into the vector in the correct site and orientation. The integrity of 
both the vector and the gene were conserved. Following these analyses, viruses were 
generated and their titres determined.  
 
3.1.2.2 Determining Antibiotic Sensitivity 
After successful cloning, Lenti4/TO/V5-DEST-IGF-1Ea, Lenti4/TO/V5-DEST (empty) 
and Lenti6/TR viruses were generated. Before proceeding to transduction of the viruses 
into P19Cl6 cells, an antibiotic sensitivity assessment was performed.  The analysis was 
performed on HT1080 cells, provided by the supplier as a control cell, and P19Cl6 cells. 
The antibiotic sensitivity test examined how the cells responded to the antibiotics, 
Blasticidin and Zoecin, which would be used for their selection following transduction of 
the viruses. The responsiveness of HT1080 and P19Cl6 cells to the two antibiotics were 
different. The assessment on HT1080 cells revealed that 500 µg/ml of Zeocin and 4 µg/ml 
of Blasticidin were enough to induce death of untransduced HT1080 cells by 14 and 10 
days of antibiotic treatment respectively. These amounts of antibiotics were then used to 
select for positively transduced cells in further experiments utilizing HT1080 cells. The 
P19Cl6 cells were however more sensitive to the antibiotics. Cell death of untransduced 
P19Cl6 cells could be induced with 200 µg/ml Zeocin and 4 µg/ml Blasticidin within 10-
14 days of antibiotic treatment. These concentrations of antibiotics were then used for 
further experiments with P19Cl6 cells.  
 
For both the cell types, the Zeocin method of killing was very different from that of 
Blasticidin. The Zeocin-killed cells increased in size with empty vesicles in the cytoplasm 
(Figure 7). In addition, the cells did not detach from the plates for a very long time and 
exhibited abnormal shape. Blasticidin treated cells on the other hand became round and 
detached from the plates immediately when they died (Figure 8).  
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Figure 7. Antibiotic Sensitivity Assessment of HT1080 Cells treated with Zeocin. A) Control without 
antibiotic treatment B) Zeocin 50 µg/ml C) Zeocin 100 µg/ml D) Zeocin 500 µg/ml. Day 14 following 
antibiotic treatment. Zeocin killed cells showed vast increase in size, abnormal cell shape and large 
empty vesicles in the cytoplasm. 
 
 
Figure 8. Antibiotic Sensitivity Assessment of HT1080 cells Treated with Blasticidin. A) Control 
without antibiotic treatment B) Blasticidin 4 µg/ml. Day 10 following antibiotic treatment. Blasticidin 
killed cells rounded up and detached from plates.   
 
3.1.2.3 Viral Titre Determination 
Viral titres for all the three viruses were determined by an average number of crystal violet 
positive colonies in plates of transduced HT1080 cells, which were treated with lentiviral 
supernatants at 10 fold serial dilutions. The titres were determined as transduction units 
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per ml (TU/ml). Lenti6/TR, Lenti4/TO/V5-DEST-empty and Lenti4/TO/V5-DEST-IGF-
1Ea viral titres were 1.17*10^6 TU/ml, 1.0*10^6 and 3*10^5 respectively (Figure 9).  
 
Figure 9. Determining Viral Titre. A) TR virus B) IGF-1Ea Virus. Top panels from left to right: Virus 
dilutions 10^-1, 10^-2, 10^-3. Bottom Panels from left to right: Virus dilutions 10^-4, 10^-5 and Mock 
without transduction. 
3.1.2.4 Tetracycline Regulated Expression of IGF-1Ea  
To test whether the tetracycline system employed in this study was effective, HT1080 
cells were transduced with the Lenti6/TR and Lenti4/TO/V5-DEST-IGF-1Ea vectors. 
Real-time PCR analysis was performed to quantify the expression of IGF-1Ea. The 
analysis revealed that tetracycline treatment induced regulated expression of IGF-1Ea in 
the cells treated with tetracycline compared to control cells (4.5+/-0.13 vs. 0.60+/-0.03), 
demonstrating that the TetOn system was effective in the HT1080 cells (Figure 10).  
 
Figure 10. Tetracycline regulated IGF-1Ea expression on HT1080 cells. HT1080 cells showed 
tetracycline regulated expression of IGF-1Ea transcript (4.5+/-0.13 vs. 0.60+/-0.03 with or without 
tetracycline respectively). IGF-1Ea transcript expression was induced 24 hour post tetracycline 
treatment. 18S rRNA was used as internal reference gene. Values are presented as Mean +/- SEM. 
The values are average of 2 independent experiments.  
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However, experiments on P19Cl6 cells revealed that tetracycline treatment was ineffective 
in regulating expression of IGF-1Ea in this cell type. There was a very high constitutive 
expression of the gene (352.98+/-6.16 vs. 320.38+/-8.34), for both the tetracycline treated 
and untreated cells (Figure 11). 
 
Figure 11. Loss of tetracycline regulated expression of IGF-1Ea in transduced P19Cl6 cells. 
Tetracycline treatment had no effect on regulation of IGF-1Ea transcript expression. Cells treated 
with/without tetracycline showed similar expression levels of IGF-1Ea transcript (352.98+/-6.16 vs. 
320.38+/-8.34 with or without tetracycline respectively). 18S rRNA was used as internal reference 
gene. The results are mean relative expression with respect to the untransduced P19Cl6 cells. Values 
are presented as Mean +/- SEM. 
 
As P19Cl6 cells showed no tetracycline regulated IGF-1Ea gene expression, insufficient 
repressor activity might be the cause. The integration event of lentivirus into the genome 
is random therefore depending upon the influence of surrounding genomic sequence at the 
site of integration and varying amount of TR virus transduction, different levels of Tet 
repressor expression might be obtained. Tetracycline regulated IGF-1Ea gene expression 
is controlled by the availability of the TR protein in the selected cells. Therefore, 18 TR 
and IGF-1Ea virus transduced P19Cl6 clones (named clones 1-18) were picked and a 
number of them analyzed for IGF-1Ea expression.  None of the analyzed clones numbered 
5, 6, 11, 12, 15 and 16 showed Tet repressor activity that was sufficient to repress IGF-
1Ea expression in the absence of tetracycline. All the clones expressed in a constitutive 
manner high levels of IGF-1Ea transcripts compared to the untransduced P19Cl6 cells 
(ranging from 200-800 fold) (Figure 12).     
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Figure 12. Constitutive IGF-1Ea expression. Stably transduced P19Cl6-IGF-1Ea/TR clones 
contitutively expressed IGF-1Ea transcripts. Tet repression was not sufficient to repress IGF-1Ea 
expression in the absence of tetracycline. 18S rRNA was used as internal reference gene for 
normalization. Values are Mean +/- SEM. 
 
 
3.1.3 DISCUSSION 
 
The Lenti4/TO/V5-DEST-IGF-1Ea Lenti4/TO/V5-DEST-empty and Lenti6/TR viruses 
were produced and transduced successfully into mammalian cell lines. When transduced 
into HT1080 cells, the expression of the IGF-1Ea gene occurred in a tetracycline-regulated 
manner. In the absence of tetracycline, cells that were transduced with both 
Lenti4/TO/V5-DEST-IGF-1Ea and Lenti4/TR showed minimal basal expression of the 
gene, suggesting effective repression of the transgene by TetR. However, in P19Cl6 cells 
although the transduction conditions were maintained identical to the one used for 
HT1080 cells, the result obtained was completely different. The transduced P19Cl6 cells 
showed a very high constitutive IGF-1Ea expression, suggesting that Tet repression in 
P19Cl6 cells was not effective as in the HT1080 cells. This could arise either from lack of 
or insufficient Tet Repressor activity in this cell type. The integration event of lentivirus 
into the genome is random and depending upon the influence of surrounding genomic 
sequence at the site of integration, varying levels of Tet repressor expression might be 
obtained. Although several P19Cl6 clones were further analysed, the Tet repressor activity 
in the absence of tetracycline was insufficient to repress IGF-1Ea expression in all the 
analyzed clones. A possible explanation for this observation could be that P19Cl6 cells 
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have an endogenous mechanism, such as a molecule that resembles tetracycline, which is 
capable of binding to the Tet repressor molecule. It has been recently reported that Gata 
transcription factors, which are expressed in embryonic and many adult cell types, 
compete with TR in binding the tetracycline operator repeats (TO) present on the lentiviral 
vectors. The Gata motif is located within the central core of the tetO, therefore Gata 
transcription factors have the potential to compete with TetR binding. The endogenous 
Gata factors may therefore influence the degree of gene regulation by the tetracycline 
system between different cell types [201]. Future analyses could be conducted at 
examining the Gata factor expression in HT1080 and the P19Cl6 cells to understand if 
these factors conferred this outcome. In addition, it would be interesting to investigate if 
the tetracycline system works on other pluripotent cells and if the failure of the system is 
unique to P19Cl6 cells. 
 
Although a controlled expression of IGF-1Ea could not be achieved on P19Cl6 cells, the 
objective to stably transduce P19Cl6 with IGF-1Ea vector was achieved. Moreover, the 
IGF-1Ea expression by the transduced cells was highly efficient, making it possible to 
utilize these cells for analyzing IGF-1Ea signaling.  Most importantly, the IGF-1Ea 
transduced cells could be utilized for in vivo cell transplantation, which was the prime 
objective of this study, to analyse the effects of IGF-1Ea over-expression on donor cell 
engraftment and its role on modulating function and morphology of infarcted hearts. 
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3.2 SECTION II: EFFECTS OF IGF-1Ea TRANSDUCTION AND CONSTITUTIVE 
EXPRESSION ON PROPERTIES OF P19CL6 CELLS BEFORE AND AFTER 
DIFFERENTIATION  
 
3.2.1 INTRODUCTION 
 
P19Cl6 cells transduced with the (i) Lenti4/TO/V5-DEST-IGF-1Ea Lenti6/TR and (ii) 
Lenti4/TO/V5-DEST-empty Lenti6/TR viruses were cultured and expanded. Following 
the examination of IGF-1Ea expression, the cells were analysed for their pluripotent status 
by Oct3-4 staining before proceeding to their differentiation. Oct3-4 is a POU-domain 
transcription factor encoded by the POU5F1 gene that lies in the centre of a gene 
regulatory network which maintains pluripotency and self renewal in embryonic stem 
cells. An alteration in the expression of Oct3-4 leads to loss of pluripotency and initiation 
of differentiation [202]. IGF-1 has been reported to play a role in proliferation and 
differentiation of skeletal and neuronal cells [131, 203, 204] and induction of 
differentiation of adipose-derived mesenchymal stem cells into chondrocytes-like cells 
[205]. Moreover, a study on the role of IGF-1Ea-mediated muscle regeneration following 
injury, Musaro et al. reported that expression of IGF-1Ea (mIGF-1) improved muscle 
regeneration by increasing the Sca-1+ bone marrow stem cell population at the injury site 
and by promoting their differentiation towards a myogenic lineage [131]. Likewise, cell 
culture experiments by An et al. revealed that the IGF-1Ea isoform promoted myogenic 
differentiation and cell hypertrophy, resulting in enlarged myofibers [206].  
 
A study on embryonic stem cells by Klinz et al. [207] showed a role of 
phosphatidylinositol-3-kinase (PI3-kinase) on development of embryonic cardiomyocytes. 
Treating early Embryoid Bodies (EBs) with an inhibitor of PI3-kinase, LY294002, 
blocked the growth and induced apoptosis as well as necrosis of D3 ES cells. Treatment of 
the EBs in the later stage from day 3 to day 7 with the inhibitor on the other hand resulted 
in a massive loss of alpha-actinin-positive cardiomyocytes after plating the EBs for 
additional 7 days. In addition, they observed a strong decrease in the number of beating 
cardiomyocytes in the EBs, whereas the formation of endothelial cells was unaffected, 
suggesting that the PI3-kinase inhibitor was cardiomyocyte development specific. The role 
of PI3-kinase on cardiomyocyte development was later supported by Sauer et al. [208] 
who observed that treatment of EBs with LY294002 and wortmannin abolished cardiac 
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commitment and down-regulated Reactive Oxygen Species (ROS). They suggested that 
cardiotypic development might be regulated by ROS and PI3-kinase might be involved in 
regulating intracellular redox state [208]. As PI3-kinase is one of the downstream 
molecules involved in IGF-1 mediated signaling (refer to section 1.2.2.4 for IGF-1 
signaling), it is possible that IGF-1 plays a role in cardiac commitment and development. 
As the Lenti4/TO/V5-DEST-IGF-1Ea Lenti6/TR transduced P19Cl6 cells produced IGF-
1Ea in a constitutive manner, it was vital to examine proliferative and differentiation 
characteristics of these cells.  
 
A study by Laflamme et al. showed that cardiomyocytes derived from human ES cells 
proliferate via IGF/PI3K/Akt pathway [209]. Therefore, to check if IGF-1Ea transduction 
and constitutive expression caused changes in cell cycle of the transduced P19Cl6, a cell 
cycle analysis was performed by propidium iodide (PI) staining. Cell cycle analysis can be 
achieved by labelling the nuclei of cells in suspension with fluorescent dye like the PI and 
then analyzing the fluorescence properties of each cell in the population. PI intercalates 
between the bases of the DNA by binding to the nucleotide pair of guanine and cytosine 
with a stoichiometry of one dye per 4–5 base pairs of DNA [195, 196]. Cells at quiescent 
(Go) and G1 stages of the cell cycle will have one copy of DNA and will therefore have 
1X fluorescence intensity.  Cells in G2/M phase of the cell cycle will have two copies of 
DNA (just before mitosis has occurred) and accordingly will have 2X intensity.  The cells 
at S phase, which refers to the synthesis phase as the cells are synthesizing new strands of 
DNA, will have fluorescence values between the 1X and 2X populations [196]. 
Depending on the amount of DNA present at a particular stage of the cell cycle, different 
amount of PI molecules bind with DNA, giving rise to emission of specific fluorescence 
intensity, enabling analysis of the cell cycle.  
 
Oct3-4 and PI staining were performed with both the IGF-1Ea and empty vector 
transduced cells. These analyses were followed by cell differentiation, which was 
performed by supplementing the culture media with 1% DMSO and forming embryoid 
bodies (EBs). Upon differentiation into cardiogenic lineage, the differentiated cells were 
microscopically analysed for occurrence of GFP positive cardiomyocyte clusters. Also, a 
quantitative Real Time PCR was carried out with the differentiated cells to verify and 
quantify the expression of cardiac specific markers namely, Nkx2-5, MLC2v and Gata4.  
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Following analysis of the cardiac marker expression and the pluripotency features of the 
transduced cells, the efficiency of differentiation into ventricular myocytes was 
determined for both IGF-1Ea and empty vector transduced cells using FACS analysis. 
Percentage of GFP positive ventricular cells derived from the IGF-1Ea transduced cells 
were compared with the empty vector transduced P19Cl6 cells to determine if IGF-1Ea 
constitutive expression led to enhanced cardiac lineage differentiation.  
 
In addition to the qualitative and quantitative analyses on expression of cardiac markers, 
differentiated cells were stained for sarcomeric alpha-actinin (Sigma, Cat# A7811) to 
investigate the organization of the sarcomeric apparatus that is central for contractile 
function. Alpha-actinin is an actin-binding protein present in both muscle and non-muscle 
cells [210]. However, the sarcomeric alpha-actinin is specific for only alpha skeletal and 
alpha cardiac muscle actinins. It stains the Z lines in the muscles [211]. For a successful 
cell therapy, upon delivery into infarcted tissue, the cells for transplantation must improve 
overall mechanical functions. Therefore, expression of structural protein responsible for 
mechanical function such as the sarcomeric alpha-actinin is vital. Furthermore, an 
additional IGF-1Ea transcript expression was examined by quantitative real time PCR 
(qRT-PCR) to ensure that the transgene over-expression was not lost during 
differentiation.  
 
From all the IGF-1Ea and empty vector transduced P19Cl6 clones (described in Section I), 
only clone 6 was chosen for the following analyses as some of the other clones failed to 
form EBs that seemed important for their efficient cardiac lineage differentiation. The 
failure in EB formation could be resulting from the site of integration of the viral vector or 
due to the level of IGF-1Ea expression.      
 
3.2.2 RESULTS 
 
3.2.2.1 Staining for Pluripotency Marker Oct3-4 
P19Cl6 cells transduced with IGF-1Ea- or empty-vectors were cultured for a day and 
stained for Oct3-4, to verify that the pluripotency was retained following transduction of 
the viral vectors. Both the cell types stained positive for Oct3-4 antibody. Oct3-4 being a 
transcription factor, staining was observed mainly localized in the nucleus and moderately 
in the cytoplasm marked by the red staining in Panels A and C in the figure below (Figure 
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13). The staining was specific for Oct3-4, which was verified by absence of staining in the 
control cells in Panels B and D. Control cells were treated with only the secondary 
antibody. No difference was observed in Oct3-4 expression and localization between the 
IGF-1Ea- and the empty-vector transduced cells. The analysis illustrated that transduction 
of viral vectors and the IGF-1Ea gene maintained undifferentiated state of P19Cl6 cells.  
 
Figure 13. Staining for Pluripotency Marker Oct3-4. (A) empty-cells (B) Antibody control for empty-
cells (C) IGF-1Ea-cells D) Antibody control for IGF-1Ea-cells.  Nuclei were stained with DAPI. Scale 
bars are 50µm.  
 
3.2.2.2 Cell cycle analysis by Propidium Iodide (PI) Staining 
PI staining was conducted to understand the cell cycle characteristics of IGF-1Ea- and 
empty-vectors transduced cells. Clone 6 P19Cl6 cells were fixed with 70% ethanol, 
permeabilized and stained with 50 µg/mL Propidium Iodide solution followed by FACS 
analysis. The analysis resulted in a histogram consisting of three populations: two 
Gaussian curves for Go/G1 and G2/M phases (1X and 2X peaks) and the S-phase 
population.  Before obtaining the final results, any doublet and cell debris were excluded 
from the analysis. The three cell populations obtained in the histogram overlapped each 
other, therefore a modeling program (Flow Jo) was utilized to seclude the individual 
populations and to assign percentage values to each population. Clone 6 P19Cl6 
transduced with IGF-1Ea- and the empty-vector showed similar percentages of cells in 
their S phases (12.8% vs. 15.1%), indicating similar proliferation profiles between the two 
cell types. The analysis showed that viral transduction as well as transduction of IGF-1Ea 
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gene did not alter proliferation of the P19Cl6 cells. Figure below shows the FACS plots 
for the IGF-1Ea and empty transduced clone 6 P19Cl6 cells (Figure 14).  
 
Figure 14. Cell Cycle analysis by Propidium Iodide Staining. Cell Cycle analysis of undifferentiated 
Clone 6 P19Cl6 cells, transduced with either empty (Blue) or IGF-1Ea (Red) viral vectors. Percentage 
of cells in S phase for Clone 6 for both IGF-1Ea and the empty vector transduced were similar (12.8 
vs. 15.1). PI was used at 50 µg/mL concentration, samples were treated with RNAase A to exclude 
double stranded RNA from analysis. FACS analysis was performed at PE-A channel and results 
obtained using Flow Jo. The X-axis represents percentage of cells and y-axis, fluorescence intensity.  
3.2.2.3 Differentiation of P19Cl6 Cells into Cardiomyocytes 
Clone 6 P19Cl6 cells transduced with both IGF-1Ea and empty vectors were successfully 
differentiated into spontaneously beating cardiomyocytes. The differentiation into GFP 
positive ventricular myocytes was very efficient, which was demonstrated by appearance 
of abundant GFP positive clusters and quantitatively revealed by the FACS analysis in 
Section 3.2.2.4. The GFP positive cells appeared in clusters of different morphologies and 
exhibited spontaneous beating. The spontaneously beating colonies appeared in cultures 
from day 9 after induction of differentiation. The beating was recorded up to day 21, after 
which the cultures were terminated for molecular analyses. From the day of their 
differentiation, the intensity of GFP expressed by the clusters improved gradually up to 
15-16 days after which the expression became stabilized (data not shown). The figure 
below (Figure 15) shows the differentiated clone 6 P19Cl6 cells.  
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Figure 15. Representative Confocal Images of Differentiated P19Cl6-MLC2v-GFP Cells. (A) 
Undifferentiated, (B) (C) (D) Differentiated. The GFP positive spontaneously beating cluster of cells 
appeared in different morphologies for both IGF-1Ea and empty vector transduced cells. The images 
above are representative images from clone 6 P19Cl6 IGF-1Ea-cells showing morphologically 
different clusters. Images were taken at day 16 after differentiation. Scale bars are 100 µm.  
 
Furthermore, analysis of the expression of cardiac specific protein was performed using 
qRT-PCR. Nkx2-5 (a cardiac transcription factor), MLC2v (a cardiac structural protein) 
and Gata4 (a mesodermal transcription factor) expressions were analyzed. The analyses 
were performed as relative expression compared to the undifferentiated control P19Cl6 
cells. Nkx2-5 and MLC2v transcripts increased in IGF-1Ea vector transduced, 
differentiated P19Cl6 cells (Figure 16) compared to control differentiated cells. Gata4 
expression however seemed to be higher for control differentiated P19Cl6 cells than IGF-
1Ea transduced P19Cl6 cells. At undifferentiated state, the IGF-1Ea transduced cells 
expressed similar levels of Nkx2-5, MLC2v and Gata4 to the control cells. The analysis 
further proved differentiation of the cells into cardiomyocytes. The expression levels of 
both Nkx2-5 and MLC2v were higher in IGF-1Ea transduced cells, suggesting that IGF-
1Ea together with DMSO could trigger differentiation towards cardiac lineage.  
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Figure 16. A quantitative Real Time PCR analysis for cardiac specific marker expression by IGF-1Ea 
untransduced and IGF-1Ea transduced P19Cl6 cells with or without differentiation. A) Nkx2-5 
expression B) MLC2v expression C) Gata4 expression. Differentiation led to higher expression of 
Nkx2-5, MLC2v and Gata4 compared to undifferentiated cells. Upon differentiation, IGF-1Ea 
transduced cells expressed higher levels of Nkx2-5 and MLC2v compared to the IGF-1Ea 
untransduced differentiated cells. Gata4 expression was higher for IGF-1Ea untransduced 
differentiated cells compared to IGF-1Ea transduced differentiated cells. RNA was obtained on day 22 
following differentiation of cells. 18S ribosomal RNA was used as an internal reference gene.  
 
3.2.2.4 FACS Analysis to Quantify GFP Positive Ventricular Cardiomyocytes  
Clone 6 P19Cl6-IGF-1Ea or clone 6 empty vector transduced cells were differentiated and 
FACS analyzed at day 19 to determine their efficiency of differentiation into ventricular 
cardiac myocytes. Ventricular cardiac myocytes were marked by GFP expression, which 
was under the control of ventricular cardiomyocyte-specific marker MLC2v. The GFP 
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expression was utilized as a tool to quantify the ventricular myocytes. FACS analyses 
showed remarkably high efficiency of differentiation into ventricular myocytes for both 
IGF-1Ea and empty vector transduced P19Cl6 cells (29.60+/- 4.87 vs. 35.16+/- 6.66 
respectively, where n=5). There was however no significant difference in the amount of 
GFP positive cells between the IGF-1Ea and empty vector transduced groups, p= 0.55. In 
the figures below (Figure 17), panels (A) and (B) show FACS plots for Clone 6 P19Cl6 
IGF-1Ea transduced cells with or without differentiation. In panels (A) and (B), 
population 5 (P5) represents the parent population from where the viable cell population 
(P1), the single cell population (P3) and GFP positive population (P2) were obtained by 
gating out the dead cells, the doublets and the non-GFP positive cells respectively.  The 
GFP positive cells (P2) were sorted for cell transplantation. Panel (C) shows quantitative 
measurement of the GFP positive ventricular cardiomyocytes obtained from 
differentiation of clone 6 P19Cl6 IGF-1Ea or empty vector transduced cells. The analysis 
revealed no significant difference in the amount of GFP positive ventricular cardiac 
myocytes between the IGF-1Ea and empty vector transduced cells suggesting that IGF-
1Ea gene over-expression did not trigger ventricular cardiac lineage differentiation. 
Nevertheless, the very high efficiency of differentiation into ventricular cardiomyocytes 
was optimal for obtaining large quantities of cells for cell transplantation experiments that 
followed.  
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Figure 17. Quantification of GFP Positive Ventricular Myocytes by FACS Analysis. Representative 
FACS plots for A) Undifferentiated Clone 6 P19Cl6 IGF-1Ea-cells B) Differentiated Clone 6 P19Cl6 
IGF-1Ea-cells. Panels A and B show gating of the GFP positive population for sorting. Populations P2 
in the two cell types represent the GFP positive cells. The tables show the percentage of GFP positive 
P2 population with respect to the parent population.  P5 are the parent population from which P1, P2 
and P3 were gated out. P3 represent the single cells, P1 are the cells that are viable. C) Percentage of 
GFP positive cells derived from IGF-1Ea-cells versus empty-cells (29.20+/- 3.82 vs. 35.12+/- 5.91) 
respectively, where n=5, p = 0.55. FACS analysis performed on day 19 after differentiation. Values are 
Mean +/- SEM.   
 
3.2.2.5 Sarcomeric alpha-actinin Staining 
As the quantitative FACS analysis on GFP positive cells revealed no difference in the 
amount of GFP positive cells even though the molecular analyses on Nkx2-5 and MLC2v 
showed higher transcript expression for IGF-1 transduced cells, a protein level analysis 
was performed to visualize structural protein alpha-actinin in the differentiated 
cardiomyocytes.  Analysis of cardiomyocyte specific sarcomeric alpha-actinin was 
necessary to understand if (i) cardiomyocytes resulting from IGF-1Ea transduced cells 
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possessed higher amount of structural protein than the control cells and (ii) whether the 
cardiomyocytes were structurally mature and possessed structural machinery for 
mechanical function. Nineteen days after induction of differentiation, IGF-1Ea and empty-
vector transduced cell-derived cardiomyocytes were stained for sarcomeric alpha-actinin 
and analyzed using a confocal microscope. As a positive control, neonatal rat 
cardiomyocytes, maintained in culture for five days, were used. The negative control was 
treated with the secondary antibody only. All the samples, the positive control neonatal 
cardiomyocytes, the IGF-1Ea-cell-derived cardiomyocytes and the empty-vector cell-
derived cardiomyocytes stained positive for alpha-actinin. The Z lines in the muscles were 
clearly stained by the antibody marked by red striations, seen in Panels A, C and D. The 
secondary antibody was specific for primary alpha-actinin antibody as shown by the lack 
of staining in the negative control that received only the secondary antibody (Panel B, 
(Figure 18). The alpha-actinin positive clusters were positive also for GFP indicating that 
the clusters were ventricular cardiomyocytes. The analysis illustrated that cardiomyocytes 
obtained from differentiation of both IGF-1Ea and empty vector transduced P19Cl6 cells 
expressed cardiac structural protein alpha-actinin that is necessary for their mechanical 
function and vital for cell therapy approach. 
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Figure 18. Sarcomeric alpha-actinin Staining. Differentiated cells were stained for sarcomeric alpha 
actinin to confirm presence of the cardiac structural protein and investigate its organization. Panel 
(A) is a representative image of the positive control neonatal cardiac myocyte, maintained 5 days in 
culture. Panel (B) is a representative image of the negative control that received only the secondary 
antibody. Panel (C) shows a cluster of empty-cells derived cardiomyocyte cluster and Panel (D) 
represents IGF-1Ea-cells derived cardiomyocyte cluster. GFP expression verifies that the cluster were 
ventricular cardiomyocytes. Images were acquired using confocal microscope at day 19 following 
differentiation. n=1 and scale bars are 20µm.  
 
3.2.2.6 IGF-1Ea Expression Following Differentiation 
Before proceeding to further in vitro analyses and cell transplantation studies, IGF-1Ea 
expression was analyzed at mRNA level to understand if differentiation of the transduced 
cells affected IGF-1Ea over-expression. The analysis showed that IGF-1Ea expression was 
retained in the gene transduced cells even after differentiation. However, also the control 
P19Cl6 cells expressed IGF-1 upon differentiation. When compared to the 
undifferentiated IGF-1Ea over-expressing cells, the differentiated IGF-1Ea cells expressed 
double the amount of IGF-1Ea, suggesting that induction of differentiation of P19Cl6 cells 
caused expression of the endogenous IGF-1. Indeed, IGF-1 levels increased significantly 
in control cells upon differentiation. The analysis revealed that differentiation of P19Cl6 
cells with DMSO alone led to expression of IGF-1. Although the IGF-1Ea transduced 
cells expressed higher amount of IGF-1 than the control cells after differentiation, both the 
cell types expressed high amount of the gene. Figure below shows the mean relative 
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expression of the gene with or without differentiation by IGF-1Ea transduced or 
untransduced cells (Figure 19).  
 
Figure 19. IGF-1Ea Transcript Expression in Differentiated Cells with/without IGF-1Ea 
Transduction. IGF-1Ea is expressed by both IGF-1Ea transduced and untransduced cells following 
differentiation. Results are expressed as Mean +/- SEM. 18S rRNA was used as internal reference 
gene. 
 
 
3.2.3 DISCUSSION 
 
Expression of Oct3-4 by both the IGF-1Ea and empty vector transduced cells illustrated 
that transduction of viral vectors and the IGF-1Ea maintained undifferentiated state of 
P19Cl6 cells. When differentiated, both the cell types efficiently formed GFP positive 
ventricular myocytes illustrated by the confocal and the FACS analyses. The efficient 
differentiation into ventricular cardiomyocytes even after in vitro manipulations of the 
cells was a remarkable finding for the cell therapy objective of this study. Large quantities 
of cells could be readily obtained for cell transplantation, which remains a challenge with 
many candidate cell types that are being studied to date [33, 65]. The molecular analysis 
on the cardiac-specific markers, Nkx2-5, MLC2v and Gata4 expression further proved 
differentiation of the cells into cardiomyocytes. The expression levels of both Nkx2-5 and 
MLC2v were higher in IGF-1Ea transduced cells, suggesting the possible role of IGF-1Ea 
over-expression on driving differentiation towards cardiac lineage. However, as the 
expression levels of cardiac markers were not enhanced in the IGF-1Ea-cells at 
undifferentiated state, the enhanced cardiac marker expression was not dependant on IGF-
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1Ea alone, but may be triggered by the action of IGF-1Ea and DMSO together. The 
quantitative analyses performed using FACS however was unable to show a significant 
difference in the amount of GFP positive cells obtained from IGF-1Ea- and empty-cells, 
indicating that IGF-1Ea over-expression did not enhance differentiation of P19Cl6 cells 
into cardiomyocytes. The molecular and FACS analyses together indicated that IGF-1Ea 
over-expression either enhanced expression of cardiac proteins without increasing their 
differentiation efficiency (as it occurs during hypertrophy) or accelerated cardiac 
differentiation of P19Cl6 cells. A time-course analysis on cardiac marker expression 
following differentiation of IGF-1Ea transduced and untransduced control cells would be 
able to show whether IGF-1Ea expression caused acceleration of cardiac lineage 
differentiation of P19Cl6 cells.   
 
Klinz et al. [207] treated EBs with PI3-kinase inhibitor and observed a massive loss of 
alpha-actinin-stained cardiomyocytes. The PI3-kinase pathway has been shown to induce 
the transcription of myocyte enhancer factor 2 (MEF2) and MEF2 plays a role in 
activating muscle specific structural genes [174]. Also, activation of the PI(3)K/Akt 
pathway is crucial for regulation of protein synthesis in skeletal muscle cells as well as in 
muscle hypertrophy [175, 176] and IGF-1 is one of the activators of the PI3-kinase 
pathway. Considering the observations of these studies, it is likely that over-expression of 
IGF-1Ea leads to increased PI3-kinase and MEF2 activities resulting into increased 
protein synthesis. To test this, an alpha-actinin staining was performed on the 
cardiomyocytes derived from empty- and IGF-1Ea-cells. There was no apparent difference 
in the amount of sarcomeric protein expression between the IGF-1Ea transduced 
compared to the untransduced cells. However, the sarcomeric apparatus appeared to be 
better organized in the cardiomyocytes derived from the IGF-1Ea transduced cells 
compared to the untransduced cells suggesting that the over-expression of IGF-1Ea might 
be involved in organization of the alpha-actinin protein structure rather than increasing 
their amount. However, more analysis is required to verify this observation as this 
examination was based on one analysis. The positive staining for the alpha-actinin 
nonetheless demonstrated that the differentiated cells resulting from the IGF-1Ea and 
empty vector transduced cells were structurally mature and suitable for transplantation 
studies. 
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Interestingly, differentiation of P19Cl6 cells by DMSO alone led to induction of 
endogenous IGF-1 expression. Upon differentiation, also the control cells expressed high 
amount of IGF-1 to the levels comparable to the undifferentiated IGF-1Ea transduced 
cells. This indicated that differentiation of P19Cl6 cells into cardiomyocytes is associated 
with IGF-1 expression. As observed previously, treatment of embryonic stem-cell 
aggregates with PI3-Kinase inhibitor LY294002 abolished cardiac commitment in ES 
cells [208] without affecting endothelial cell formation [207] indicating that activation of 
PI3-K signaling by specific growth factors such as IGF-1, FGF or TGFβ promote 
development of cardiomyocytes in a selective manner [207].  This could be investigated 
further by inhibiting IGF-1Ea action on the transduced cells by blocking IGF-1R by IGF-
1R inhibitors.  
 
The proliferation analyses of clone 6 P19Cl6-IGF-1Ea or -empty vector transduced cells 
showed similar proliferation profiles for both the cell types, indicating that an excess of 
IGF-1Ea isoform did not affect proliferation of the transduced P19Cl6 cells.  
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3.3 SECTION III: TESTING FEASIBILITY OF THE IGF-1Ea TRANSDUCED 
CELLS IN VITRO FOR IN VIVO CELL THERAPY 
 
3.3.1 INTRODUCTION 
 
The previous sections focused on engineering P19Cl6 cells for cell-based gene therapy. 
The first part outlined the tools and methods that were applied to create a stable clone of 
P19Cl6 cells that over-expressed the IGF-1Ea gene. The second section analyzed the 
effects of IGF-1Ea stable transduction on properties of the P19Cl6 cells. Following 
successful completion of the above two objectives, the focus of this section was to conduct 
tests for examining feasibility of the transduced cells for cell transplantation therapy in an 
in vitro system. To do so, the donor cells for transplantation were tested in vitro for their 
cardiogenic potential. The functionality of the IGF-1Ea over-expressing transduced cells 
were investigated by electrophysiological analyses, followed by the examination of the 
role of IGF-1Ea over-expression on cell viability and protection.   
 
Electrophysiological analyses were carried out to examine calcium handling by the 
differentiated transduced cells. Calcium handling is fundamental to the function of heart, 
as excitation - contraction coupling of the muscle cell is mediated by changes in 
cytoplasmic calcium [212-214]. In a cardiac myocyte, arrival of an action potential leads 
to membrane depolarization. The depolarization causes activation of voltage-dependant L-
type Ca channels, which leads to influx of Ca2+ into the cytosol.  Ca2+ influx then 
triggers the release of Ca2+ from sarcoplasmic reticulum (SR) via Ca2+ release channels 
such as the ryanodine receptors. This mechanism by which influx of calcium ions through 
the L-type receptor triggers release of more calcium ions into the cytosol from the SR is 
commonly known as calcium-induced calcium-release (CICR) mechanism. Calcium ions 
released via the CICR mechanism diffuse through the cytosolic space. In the cytosol there 
are the sarcomeric proteins, which are the contractile proteins of a myocytes [214]. A 
sarcomere is a region of a myofilament between the two Z lines, composed of a thin 
(Actin, tropomyosin and troponin) and a thick (Myosin) filament. Interactions between the 
actin and myosin cause the sarcomere length to shorten causing the myocyte to contract 
during the process of excitation-contraction coupling. This interaction is dependent on 
chemical and physical interactions between calcium ions and the thin and the thick 
filament proteins such as the myosin, troponin C and troponin I. Troponin C serves as a 
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binding site for Ca2+ and troponin-I inhibits the myosin binding site on the actin. Upon 
binding of Ca2+ to troponin C, a conformational change occurs in the troponin complex.  
This causes exposure of a site on the actin molecule that is able to bind to the myosin 
ATPase located on the myosin head. This binding results in hydrolysis of ATP that 
supplies energy for a conformational change to occur in the actin-myosin complex, that 
triggers the sliding of thin and thick filaments causing cell shortening and force 
generation. The troponin complex recommences its inactivated state, inhibiting myosin-
actin binding, when Ca2+ is removed from the Troponin-C. Recovery occurs as Ca2+ is 
pumped out of the cell by the Na+/ Ca2+ exchanger (NCX) or is returned to the 
sarcoplasmic reticulum (SR) by sarco(endo)plasmic Ca2+  -ATPase (SERCA) pumps 
[214].  
 
Calcium-Induced-Calcium Release mechanism can be visualized by performing a confocal 
Ca2+ analysis by treating cardiac myocytes with fluorescence conjugated calcium indicator 
dye such as Rhod-2AM. Rhod-2 AM is a rhodamine-based (Rhod) dye with 
acetoxymethyl (AM) ester, which is cell permeable. The dyes bind to the calcium ions in 
the cytosol. Binding of the calcium ion leads to release of the fluorescence. Therefore, the 
fluorescent intensity depends on the amount of dye that binds to the calcium ions [215]. 
The increase of cytoplasmic [Ca2+] leads to contraction and extrusion from the cell brings 
relaxation [216]. Therefore right before contraction, the cells express the highest amount 
of fluorescence and when it relaxes, the lowest. This analysis not only verifies the 
presence of CICR mechanism in the cells but also sheds idea on the frequency of 
contraction.  
 
The next objective of this section was to study the role of IGF-1Ea over-expression on 
survival signaling. When IGF-1 was administered in a murine model of myocardial 
ischemic reperfusion it was able to decrease myocardial apoptosis [162]. In a myocardial 
infarction model caused by the occlusion of left descending coronary artery, transgenic 
mice over-expressing IGF-1 demonstrated decreased cell death and ventricular dilation 
[163]. Similarly work from our laboratory performed with transgenic mice over-
expressing IGF-1Ea (IGF-1Ea) showed smaller scar size and better function after injury 
compared to the wild type control animals [77]. This study engineered IGF-1Ea 
transduced P19Cl6 cells for cell therapy to be utilized in myocardial infarction model. As 
the cells were transplanted into infarcted hearts, it was essential to engineer cells that were 
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capable of surviving the hostile environment upon injection. Therefore, the next analysis 
was performed on cell survival signaling upon hypoxia and normoxia treatment by 
Lactose Dehydrogenase (LDH) release assay.  
 
Lactate Dehydrogenase (LDH) is a stable cytosolic enzyme that is released upon damage 
to cell membrane as a result of necrosis and some times apoptosis [191]. Cell death can 
occur by apoptosis or necrosis. Apoptosis is referred to as a programmed cell death, which 
involves cell shrinkage, condensation of cellular chromatin and some times breakdown of 
cells into membrane-bound apoptotic bodies [190]. Unlike apoptosis, necrosis is un-
programmed death and is accompanied by mitochondrial swelling and increased plasma 
membrane permeability. Apoptosis avoids involvement of scavenging inflammatory cells 
[190] to protect tissues from damaging events that result from the inflammatory cells 
whereas homing of inflammatory cells is one of the components of necrotic cell death. For 
LDH release assay, the IGF-1Ea and empty vector transduced P19Cl6 cells were exposed 
to either normoxia or hypoxia. In normoxia, the cells were deprived of glucose and serum 
but given normal amounts of carbondioxide (5%) and oxygen (20%), whereas in hypoxia 
they were deprived of both nutrients and oxygen, which was reduced to only 3%. This 
study was performed to investigate whether over-expression of the survival factor IGF-
1Ea could provide the transduced cells with better protection from cell death. In addition, 
to investigate whether or not IGF-1Ea release could protect native cardiomyocytes from 
cell death in the context of cell therapy in vivo, neonatal rat cardiomyocytes were treated 
with normoxia and hypoxia conditions in the presence of conditioned media from empty- 
or IGF-1Ea transduced cells.  
 
3.3.2 RESULTS  
 
3.3.2.1 Confocal [Ca2+] Transient Analysis 
IGF-1Ea transduced and untransduced cells were differentiated and analyzed for their 
calcium handling through confocal microscopy. Cytoplasmic calcium ion changes were 
measured during contraction/relaxation. The [Ca2+] changes were examined using the Ca2+ 
sensitive fluorescent indicator Rhod-2AM.  Upon binding to the cytoplasmic calcium ions, 
Rhod-2AM fluorescence intensity showed an oscillation that corresponded with the 
spontaneous rhythmic contraction of cardiomyocyte clusters. In the figure below (Figure 
20), panel (A) demonstrates representative confocal images of a beating cluster derived 
Chapter 3: In vitro analyses 
 99 
from empty vector transduced P19Cl6 cells, showing the oscillations of Rhod-2AM 
fluorescence intensity during relaxation and (B) contraction (light red image vs. bright red 
image). Panel (C) shows that the contracting cells were also GFP positive. Panel (D) 
shows a bright field image of the beating cluster. Below the confocal images are the 
fluorescent oscillations recorded at a certain plain of the cluster where panels (E and F) 
show Rhod-2AM fluorescence intensity (Y-axis) at a particular time in seconds (X-axis) 
during contraction and relaxation. IGF-1Ea-cells derived beating clusters showed similar 
CICR mechanism (data not shown). The calcium transient analysis illustrated that the 
cardiomyocytes derived from P19Cl6 cells transduced with both IGF-1Ea and empty 
vectors exhibited CICR mechanism proving that they are functionally active and capable 
of contributing to functional improvement upon their transplantation.  
 
Figure 20. Confocal Ca2+ Transient Analysis. Representative confocal images of a beating cluster 
derived from P19Cl6 untransduced cells. The images show the oscillations of Rhod-2AM fluorescence 
intensity during relaxation (A) (light red) and contraction (B) (bright red). The beating cluster 
expressed GFP (C). Image (D) shows a bright field image of the beating cluster. Figures (E and F) 
show the amplitude of fluorescent intensity and oscillations in fluorescence intensity during relaxation 
and contraction respectively.  The oscillations in fluorescence intensity were recorded at a certain 
plain of the beating cluster.   
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3.3.2.2 Cytotoxicity Assessment 
The normoxia-hypoxia exposure study began with a cytotoxicity assessment.  The 
cytotoxicity determination was essential to confirm occurrence of hypoxia. It was 
conducted by exposing cells to hypoxia or normoxia for varying amounts of time as 
described in materials and methods. After each treatment time, LDH release was measured 
and cytotoxicity was determined by comparing the amounts of LDH released by empty-
cells with the IGF-1Ea-cells. Percentage LDH release (% LDH release) was obtained as a 
relative expression, achieved by comparing to the LDH released at 1 minute normoxia 
exposure. At 1 minute normoxia, %LDH release was set as 0% as there would be 
no/minimal cell death at this time point.  Both the normoxia and hypoxia treatments 
resulted in no cell death up to 4 hour (240 min) exposure time-point, illustrated by no 
difference in the %LDH release in the empty (blue curve) and IGF-1Ea (pink curve) 
vector transduced cells. At 24 hour however, in both the treatments, very high levels of 
LDH release were detected, confirming occurrence of cell death. There was higher LDH 
release in the samples that were exposed to hypoxia than normoxia as expected, which 
confirmed occurrence of hypoxia. As LDH release was observed at 24 hour exposure time, 
subsequent experiments were conducted at 24 hour time-point. The figure below shows 
the results obtained for normoxia (A) and hypoxia (B) treatments (Figure 21). The X-axis 
shows exposure time in minutes and the Y-axis, %LDH release.  
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Figure 21. Determining Cytotoxicity following Normoxia or Hypoxia Treatment. Cytotoxity 
determination of IGF-1Ea and empty vector transduced cells following exposure to normoxia or 
hypoxia. Both the IGF-1Ea and empty vector transduced cells showed no LDH release at exposure 
time below 240 minutes (4 hours). Upon 24 hour exposure, there was a massive induction of LDH 
release. IGF-1Ea transduced cells showed lower LDH release at 24 hour compared to the empty 
vector transduced cells in both normoxia and hypoxia treatments.   
3.3.2.3 Effect of IGF-1Ea over-expression on cell survival 
After determining the exposure time to achieve cytotoxicity from the hypoxia and 
normoxia treatments, the transduced P19Cl6 were exposed to 24-hour treatment for 
subsequent experiments. After 24 hours hypoxia and normoxia, percentage LDH release 
was measured relative to the LDH released by the empty-cells, for which the value was set 
as 100%. Below are the bar graphs showing LDH release for normoxia (A) and hypoxia 
treatments (B) (Figure 22). Upon normoxia treatment, the IGF-1Ea transduced cell 
cultures released approximately 25% less LDH (99% +/- 9% empty-cells vs. 74% +/- 
2.7% IGF-1Ea-cells), indicating 25% higher cell viability for IGF-1Ea transduced cells 
compared to the empty vector transduced cells in normoxia treatment. In the hypoxia 
treatment (shown in panel B), IGF-1Ea provided even higher protection (100% +/- 7.8% 
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LDH release for empty-cells vs. 41% +/- 5.5% LDH release for IGF-1Ea-cells) than the 
normoxia treatment. Transduction of IGF-1Ea vector therefore conferred higher cell 
viability to the transduced cells exposed to 24 hour hypoxia and normoxia. The higher 
survival capability of the transduced cells would be beneficial for their transplantation into 
ischemic tissue.    
 
Figure 22. Effect of IGF-1Ea Over-expression on Cell Survival in vitro. P19Cl6 transduced with IGF-
1Ea or empty vector were exposed to normoxia (A) or hypoxia (B) to investigate the effects of IGF-
1Ea over-expression on cell survival. Upon normoxia, IGF-1Ea transduced cell cultures released 25% 
less LDH (99% +/- 9% empty vs. 74% +/- 2.7% IGF-1Ea). In the hypoxia treatment, IGF-1Ea 
conferred even higher cell survival (100% +/- 7.8% LDH release for empty vs. 41% +/- 5.5% for IGF-
1Ea transduced). Percentage LDH release was determined relative to the LDH released from empty 
vector transduced cultures at 24-hour as 100%.  
3.3.2.4 Effect of IGF-1Ea conditioned media on cardiomyocyte survival  
IGF-1Ea over-expression showed enhanced survival of transduced P19Cl6 cells. To 
analyse whether release of IGF-1Ea may affect survival of cardiomyocytes exposed to 
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hypoxia and normoxia, the conditioned media of IGF-1Ea-cells and control cells was used 
to treat neonatal cardiomyocytes. Hypoxia or normoxia were induced for 24 hours as 
performed with P19Cl6 cells. The following day, protein was extracted from the cultures 
and western blot analysis was performed for the apoptotic marker cleaved-caspase 3. The 
western blot analysis revealed higher expression of cleaved-caspase 3 (3 fold to 1.5 fold), 
for neonatal cardiomyocytes treated with empty- conditioned media compared to IGF-
1Ea-condioned media (Figure 23). As a control, protein from untransduced P19Cl6 was 
loaded, which showed minimal cleaved-caspase 3 expression.  
 
 
Figure 23. Effects of IGF-1Ea Conditioned Media on Cardiomyocyte Survival. (A) Western blot 
analysis on cleaved caspase-3 expression for hypoxia and normoxia exposed neonatal rat 
cardiomyocytes (CM) treated with conditioned media from IGF-1Ea and empty vector transduced 
P19Cl6 cells. (B) Cleaved caspase-3 expression was higher in CM treated with empty-conditioned 
media (approximately 3 fold induction in both the treatments) compared to IGF-1Ea treated media 
(approximately 1.5 fold induction in both the treatments). The relative expression was obtained by 
comparing with normally grown CM, n=1.     
 
3.3.3 DISCUSSION 
 
The aims of this section were to test the functionality of transduced differentiated cells by 
studying calcium transients and to analyze the practicability of using the transduced cells 
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for cell transplantation therapy, in an in vitro system. Calcium transients were in the 
differentiated cells derived from both transduced cell types, confirming that transduced 
P19Cl6-derived cardiomyocytes would make a suitable candidate for cell transplantation 
therapy, to potentially achieve an improvement of the mechanical function of the injured 
region.    
 
The most imperative goal of this project was to engineer pluripotent P19Cl6 capable of 
surviving better upon exposure to an injury. To accomplish this, P19Cl6 cells were 
transduced with the IGF-1Ea gene. Upon successful transduction of the gene, an in vivo 
ischemic injury model was mimicked in vitro whereby the transduced cells were exposed 
to nutrient and oxygen deprivation (hypoxia). The objective was to analyze the robustness 
of the transduced cells to survive the hostile host environment. Cytotoxity determination 
showed that in general, the P19Cl6 cells were very robust cells, showing LDH release 
only after a prolonged exposure (24 hour) to both the treatments. Interestingly, IGF-1Ea 
cells survived the treatments better compared to their controls, which was marked by 
lower LDH release in the IGF-1Ea transduced versus the control cells. Considering the 
outcome of the cytotoxicity assay and the robustness of these cells, the 24-hour time point 
was taken as the choice of exposure time for further analyses. Even at the prolonged 
exposure to hypoxia or normoxia, IGF-1Ea over-expressing cells showed approximately 
25% (normoxia) and 50% (hypoxia) higher cell viability when compared to the control 
cells. The control cells were more susceptible to hypoxia induced injury than the IGF-1Ea 
transduced cells. As the cell viability analysis was a relative analysis to the control cells 
and because higher amount of control cells died at hypoxia than normoxia exposure, 
relatively higher number of IGF-1Ea-cells survived hypoxia injury than the control cells. 
This robust nature of the IGF-1Ea over-expressing cells was a valuable property that the 
P19Cl6 cells acquired through the transduction of the gene, which made them an excellent 
candidate for cell therapy.  
 
Following the cytotoxicity analyses, transduced P19Cl6 cells were examined for their 
possible role in maintaining cultured cardiomyocyte viability, to determine whether upon 
transplantation into infarcted hearts, they would confer protective signaling to the at-risk 
myocardium. Indeed neonatal rat cardiomyocytes treated with IGF-1Ea conditioned media 
demonstrated tendency for higher cell viability upon hypoxia and normoxia treatments. 
However, whether the observed effect was a direct effect of IGF-1Ea expression or an 
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indirect effect of IGF-1Ea transduction was not tested. Functional analyses are being 
carried out in the laboratory to analyze whether the treatment of IGF-1Ea conditioned 
media led to expression of IGF-1 signalling mediators such as Akt, PDK1 and 
MAPkinases. Directly or indirectly, IGF-1Ea transduction conferred higher survival upon 
hypoxia and normoxia exposure, suggesting that the transduced cells make suitable 
candidate for transplantation into ischemic tissue that suffers from similar deleterious 
conditions.  
 
Taken together, these data showed that deprivation of nutrients and oxygen as normally 
occurs after coronary occlusion, leads to both necrotic and apoptotic cell death and that 
transduction of IGF-1Ea vector has the potential to protect P19Cl6 cells and 
cardiomyocytes from both the deleterious events.  
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4.1 TO TEST IF FUNCTION OF IMPAIRED HEARTS COULD BE IMPROVED BY 
TRANSPLANTATION OF THE IGF-1Ea TRANSDUCED P19CL6 CELLS  
 
4.1.1 INTRODUCTION 
 
Despite significant advancements in gene therapy and stem cell biology, treatment for 
myocardial infarction remains unresolved, although optimism persists. Exciting new 
strategies for endogenous and exogenous regeneration of the damaged myocardium have 
evolved. However, whether these strategies can provide enough contractile cell mass to 
adequately restore the lost mechanical function remains unanswered [217]. During 
myocardial infarction and heart failure the mechanical function is affected due to loss of 
contractile cells and introduction of stiff scar. A successful therapy targeted at improving 
the impaired mechanical function must target both of these components in order to repair 
the total function [27].   
 
Realizing the importance of the two components, this project aimed at conducting a cell 
therapy exploiting a combinatorial approach whereby pluripotent P19Cl6 were transduced 
with IGF-1Ea gene and the ventricular cardiomyocytes derived from the transduced cells, 
transplanted into infarcted murine hearts. IGF-1Ea has been shown by our laboratory to 
restore cardiac function by reducing scar size, modulating inflammatory response and 
increasing anti-apoptotic signaling [77]. With the transplantation of IGF-1Ea over-
expressing cells, the project anticipated to maintain functions of injured hearts. The IGF-
1Ea component was expected to enhance survival of the donor and the at-risk native 
myocardial cells. With increased cell survival of both the donor and the recipient cells, 
tissue regeneration, reduction of scar size and consequently preservation of function were 
anticipated.     
 
In the earlier chapters, the P19Cl6 cells over-expressing IGF-1Ea were generated 
successfully. The engineered cells continued to produce large quantities of 
cardiomyocytes, which were mechanically active and possessed structural properties 
resembling mature cardiac myocytes. The IGF-1Ea over-expressing cells showed 
increased resistance against cell death upon hypoxia and normoxia treatments compared to 
the control cells, proving that they would make excellent candidates for transplantation 
studies.
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For cell transplantation, purification of cardiomyocytes is required to avoid cancer 
formation. Therefore, P19Cl6 cells, expressing GFP under the control of the MLC2v 
promoter [100], were purified by fluorescence-activated cell sorting (FACS). Following 
cell sorting, GFP positive ventricular myocytes transduced with IGF-1Ea or empty vector 
were injected into wild type C57BL6-J mice to exploit an allogeneic transplantation. The 
use of allogeneic transplantation, which required immune suppression, was to emulate 
clinical set-up. Cell transplantation was performed in an acute model of myocardial 
infarction induced by permanent occlusion of the left-anterior descending coronary artery.  
Following transplantation, functional analyses were carried out at 5 days- and 2 month-
time points to account for both the short and the long-term effects of cell transplantation.  
 
Functional analyses were performed using Echocardiography by means of the B-and M-
Mode measurements at 5-days and 2-months time points. Ejection Fraction (EF), 
Fractional Shortening (FS) and Fractional Area Change (FAC) parameters were used for 
measuring the left ventricular regional functions. Following the functional analyses, 
animals were sacrificed for various histological and molecular analyses. The 5-day 
samples were collected for molecular analyses only, whereas the 2- month samples were 
collected also for the histological analyses.  
 
The 5-day and 2-month samples were used for molecular analysis of some paracrine 
factors implicated previously in stem cell transplantation studies. Paracrine factors are 
generally released from endogenous cells of the heart locally in response to injury. These 
may include growth/ survival factors and cytokines that support neovascularisation (eg. 
VEGF, SDF-1), cell protection (eg. IGF-1), modulate inflammation (eg. IL10, IL6), 
reduce fibrosis (eg. IGF-1) [218] or modulate contractility. Elastin is one of the 
extracellular matrix components that offers compliance to the contracting myocardium 
[29]. These factors (eg. SDF-1) may also signal via the circulation, bone marrow or tissue 
to the site of injury, thus aiding in tissue repair [218, 219]. In addition to the endogenous 
cells, exogenously transplanted cells have also been reported to secrete paracrine factors 
[218]. Paracrine factors resulting from either of the cell types may contribute to an 
improvement of function, therefore their expression profiles were analyzed.  
 
The molecular analyses on the 5-day samples were followed by histological and molecular 
analyses of the 2 months samples. The histological analyses included scar size, cell 
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engraftment and capillary density measurements of the injured hearts using the masson’s 
trichrome, anti-GFP staining and Isolectin B4 labelling respectively on paraffinized tissue 
sections. Additionally, the role of cell transplantation on LV remodelling was briefly 
analyzed by measuring cardiac cross-sectional area at the infarct border zone and 
molecular analysis of alpha skeletal actin (aSK) and beta myosin heavy chain (bMHC). 
 
4.1.2 RESULTS 
 
4.1.2.1 Survival Analysis of Surgical Animals 
Twelve to 16 weeks old C57BL6-J mice were subjected to permanent occlusion of the 
descending left coronary artery. The animals were divided into four groups that were 
named 1) non-ligated, wild type control (WT), 2) ligated, saline injected (Saline), 3) 
ligated, empty vector transduced cells transplanted (empty-cells) and 4) ligated, IGF-1Ea 
vector transduced cells transplanted (IGF-1Ea-cells). Groups received cells or saline 
injections immediately after the occlusion of the left coronary artery. All groups, except 
the WT, received immunosuppressive an hour before the occlusion of the left coronary 
artery. The total intra- and early post myocardial mortality (between 0-3 days) was 
34.92% (22 out of 63). The survival percentage to surgical procedure was determined by 
considering deaths that occurred up to 5 days post-myocardial infarction induction. The 
total number of animals that survived the surgical procedure for 5 days was 41 giving the 
surgical procedure 65% survival rate (41 out of 63). However, six animals died between 5-
7 days, leading to only 35 survivors. A 55.56% final surgery survival rate was 
accomplished.  
 
4.1.2.2 Functional Analyses 
Following induction of myocardial infarction and cell transplantation, animals were left to 
recover for 5 days. At 5 days and 2 months, functional analyses were performed using 
echocardiogram to examine the short- and the long-term effects of cell injection on 
function of the injured hearts. Echocardiographic analyses were performed under 
anaesthesia obtained with 2% Isoflurane by constantly monitoring the body temperature 
and ECG of the subjects. Images were obtained at parasternal short-axis view. Functional 
analyses were taken from B- and M-Mode measurements using the Vevo 2100 (Visual 
Sonics) and data analyses performed with Vivo 2100 software (Visual Sonics).  Ejection 
Fraction (EF), Fractional Area Change variable (FAC) and Fractional Shortening (FS) 
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were taken as parameters for measuring left ventricular function. Figure below (Figure 24) 
shows the parasternal short axis view for M-Mode and B-Mode measurements.  
 
Figure 24. Echocardiographic Images of M-Mode and B-Mode. (A) A representative image for B-
Mode analysis where diastolic endocardial wall circumference is marked for FAC measuement. (B) A 
representative image for B-Mode analysis where systolic endocardial wall circumference is marked 
for FAC measurement. (C) A representative image of M-Mode, where the anterior wall, the LV 
chamber and the posterior wall are labelled. In panel C, label D marks for anterior and posterior wall 
thickness and chamber dimension at diastole and S the systolic wall and chamber dimension 
measurements. Images were acquired with Vivo2100 and data analyses performed with Vivo 2100 
software (Visual Sonics).   
4.1.2.2.1 Ejection Fraction (EF) 
The Ejection Fraction (EF) analyses at 5 days revealed a significant difference in the 
function of WT animals compared to the saline injected animals. The following table 
summarizes functional data for EF, FS and FAC (Table 7). The saline treated animals 
showed significantly reduced EF, p= 0.0098, suggesting induction of substantial 
myocardial infarction. Interestingly, both the IGF-1Ea- and empty- cells transplanted 
hearts showed no significant reduction of EF compared to the non-ligated WT controls, 
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although there was decrease in function in both of these groups compared to the wild type 
controls. Similarly, both the IGF-1Ea- and empty- cells treated animals did not show 
significantly higher EF compared to the saline only treated animals.  
 
At two months, the saline injected animals continued to show a significantly reduced EF 
compared to the WT.  There was still no significant difference in the EFs between the 
saline-treated and empty- and IGF-1Ea- cells transplanted animals. However, at 2 months, 
also the empty- and IGF-1Ea-cell treated groups showed significantly reduced EF 
compared to the WT animals. Taking together the 5 day and 2 months EF data, EF was 
mildly preserved, although for short time, in cell transplanted hearts compared to the 
saline treated hearts. No significant difference was observed in ejection fraction between 
the IGF-1Ea- and the empty- cells transplanted animals, suggesting that IGF-1Ea 
expression did not have any effect in the EF of the IGF-1Ea-cells transplanted hearts. One-
way ANOVA was utilized for statistical analysis between the different groups. Panels A 
and B (Figure 25) demonstrate the results described for both the 5 days and 2 months EF 
analyses.    
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Figure 25. Ejection Fraction (EF) Analyses upon Myocardial Infarction Induction and Cell 
Transplantation. Panel (A) EF at 5 days. EF was significantly reduced in the saline injected animals, 
p= 0.0098 compared to the wild type animals. EF of animals that received cell transplantation was also 
reduced but not significantly compared to the WT control, p>0.05. Similarly, there was no significant 
difference between the cells and saline injected hearts and IGF-1Ea- and empty- cells injected hearts. 
The n values for WT, Saline and IGF-1Ea-cells injected are 4, and empty-cells injected 3, for the 5 day 
EF analysis. (B) EF at 2 months. At 2 months, there was significant difference between the WT and 
the saline injected hearts (p= 0.0010), the WT and the IGF-1Ea-cell injected hearts (p= 0.0010), and 
the WT and the empty-cells injected animals, p< 0.05.  There was no significant difference between the 
saline treated to the cells-injected hearts and the IGF-1Ea- and the empty- cells injected animals 
p>0.05. One-way ANOVA was used for statistical analysis. The n values for the 2 months analyses 
were: n=4 WT, n=7 Saline, n=5 IGF-1Ea-cells, n=4 empty-cells.    
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Table 7: Functional Analyses of Infarcted Cell/Saline Injected Hearts 
 EF (%) Mean +/-SEM FS (%) Mean +/-SEM FAC (%) Mean +/-SEM 
 5 days 2 months 5 days 2 months 5 days 2 months 
WT no 
ligation 
68.70 +/- 
1.83 
68.70 +/- 
1.83 
38.00+/- 
1.41 
38.00+/- 
1.41 
48.40 +/-
2.86 
48.40 +/-
2.86 
Saline 
ligated 
42.35 +/- 
5.79 
48.12 +/- 
2.89 
20.95 +/- 
3.33 
23.65 +/- 
1.69 
27.40 +/- 
1.27 
28.24 +/- 
1.35 
empty-
cells 
ligated 
50.23 +/- 
5.34 
50.4+/- 
3.55 
27.90 +/- 
3.62 
25.45 +/- 
2.23 
31.40 +/- 
6.23 
 
36.50 +/- 
2.72 
IGF-
1Ea-cells 
ligated 
51.25 +/- 
4.56 
44.15 +/- 
3.85 
25.77 +/- 
2.94 
23.76 +/- 
2.27 
35.55 +/- 
5.05 
37.38+/-
1.09 
 
4.1.2.2.2.Fractional Shortening (FS) 
Fractional Shortening (FS) analyses were also carried out at 5 day and 2 month time 
points, using the M-Mode analysis as the EF analysis.  The analysis showed that FS of 
saline treated animals was significantly lower compared to the WT control animals, p= 
0.01. No significant difference was observed in the FS between the cells-treated and the 
WT or cell-treated and the saline-treated animals, p>0.05.  The results for 5-day analysis 
are shown in panel (A) below. Panel (B) illustrates FS at 2 months. The numerical data is 
presented in table 7 together with EF and FAC. At 2 months, FS of saline-treated animals 
was significantly lower than the WT control, p= 0.0004. Interestingly, FS of the cell-
injected hearts decreased significantly compared to the WT control at 2 months, with 
p<0.01 for WT compared to empty-cell treated hearts and p<0.01 for WT and IGF-1Ea-
cells transplanted hearts, suggesting that cell transplantation did not preserve function of 
infarcted hearts at long-term. There was no significant difference in fractional shortening 
between the IGF-1Ea- and empty-cells treated groups suggesting no effect of IGF-1Ea on 
function at long-term. One-way ANOVA was used for statistical analysis. The figure 
below (Figure 26) illustrates the results described above.  
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Figure 26. Fractional Shortening (FS) Analyses upon Myocardial Infarction Induction and Cell 
Transplantation. (A) FS at 5 days post treatment. FS of saline-injected animals was significantly lower 
than the WT control, p= 0.01. There was no significant difference between the cell injected and the 
WT or the saline-injected animals, p>0.05. (B) FS at 2 months. FS of saline -injected was significantly 
lower compared to WT control, p= 0.0004. FS of the cell-injected was significantly lower than the WT, 
p<0.01. There was still no significant difference between the saline treated and the cell transplanted 
groups. One-way ANOVA was used for statistical analysis.  The n for 5 days analyses was equal to 4 
for all groups. The n values for the 2 months analyses were: n=4 WT, n=7 saline no cells, n=5 IGF-1Ea 
cells, n=4 empty cells.  
4.1.2.2.3 Fractional Area Change (FAC) 
Unlike EF and FS, FAC was analyzed using the B-Mode echocardiography. FAC 
measurements were obtained at 5 days and 2 month after infarct induction and cell/saline 
injection as the EF and the FS. Panel (A) below illustrates the FAC results obtained for the 
5-day analysis and Panel (B) illustrates the 2-month analysis. The saline-treated group 
showed significantly lower FAC compared to the WT control animals, p= 0.02. No 
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significant difference was observed between the WT and cell-injected groups as well as 
the saline-injected and the cell-transplanted groups, p>0.05.  
 
At the 2-month analysis, FAC of saline treated group remained significantly lower than 
the WT group, p= 0.0006. The FACs of the cell-treated groups were also significantly 
lower than the WT controls, p< 0.01. As EF and FS, FACs of cell-injected hearts were not 
statistically different from the saline-injected group, p>0.05. There was also no significant 
difference in the FACs between the IGF-1Ea- and empty-cells transplanted hearts, p> 
0.05. Statistical analysis was performed using the One-way ANOVA test. Table 7 
summarizes the numerical data for FAC. The figure below shows the results summarized 
above (Figure 27). 
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Figure 27. Fractional Area Change (FAC) Analysis upon Induction of Myocardial Infarction and Cell 
Transplantation. (A) FAC analysis at 5 days post treatment. The saline only treated group 
demonstrated significantly lower FAC compared to the WT control animals p= 0.02. No significant 
difference was observed between the other groups, p>0.05. (B) FAC analysis at 2 months post 
treatment. FAC of saline-injected hearts remained significantly lower than the WT group, p= 0.0006. 
The FACs of IGF-1Ea- and empty-cell treated groups also went down to give a significantly lower 
value than the WT, p<0.01. FAC of the cells-injected groups were not significantly higher than the 
saline-injected group, p>0.05. Statistical analysis was performed using the One-way ANOVA test. The 
n for 5 days analyses was equal to 4 for all groups. The n values for the 2 months analyses were: n=3 
WT, n=7 saline, n=4 IGF-1Ea cells, n=4 Empty cells. Values are Mean +/- SEM 
Taking together the EF, FS and FAC data at 5-day time point, cell transplantation 
conferred a tendency for maintenance of function of the infarcted hearts. A significant 
decrease in function was observed in the saline treated hearts compared to the WT controls 
whereas there was no significant decrease in the cells treated hearts compared to the WT. 
In long-term analyses, the cell-transplanted hearts showed significant decline in EF, FS 
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and FAC compared to the WT control and there was no significant difference between the 
saline-injected compared to the cell-transplanted hearts. The short- and long-term 
functional analyses data for all three variables together suggested that cell transplantation 
mildly protected hearts from decline of function at short-term, although it was not 
statistically significant. At long-term however, cell transplantation did not confer any 
beneficial effects on function.   
 
To investigate the factors that could have contributed to this differential functional 
response at the short and the long term analyses, survival, inflammatory and angiogenic 
factor expression levels were analysed by quantitative real time PCR.  
 
4.1.2.3 Molecular Analyses of Short-term Samples   
IGF-1, Elastin, VEGF, SDF-1, IL6 and IL10 have been implicated as paracrine factors to 
conduct different functions during myocardial injury and cell transplantation. Real time 
quantitative PCR analyses were carried out to analyse at mRNA level the expression of 
the above mentioned paracrine factors. The mRNA analyses on all of these genes revealed 
no significant difference between any of the 4 experimental groups p>0.05. There was a 
tendency for higher IGF-1, Elastin, IL6 and IL10 expression in the infarction induced 
groups (both cells and saline treated) compared to the wild type uninjured group. In 
addition, no significant difference was observed between the IGF-1Ea- and empty-cells 
transplanted hearts p>0.05, suggesting no role of IGF-1Ea on expression of the examined 
paracrine factors. The IGF-1 mRNA was detected in all the injured hearts treated with 
both the cells and saline, suggesting induction of endogenous IGF-1 production upon 
injury. There was no significant difference in the expression of VEGFa and SDF-1 
between any of the four experimental groups. The figure below summarizes the outcome 
of the gene expression analyses for all 6 genes (Figure 28). Values are represented as 
Mean +/- SEM and statistical analyses were performed using the non-parametric one-way 
ANOVA (Kruskal Wallis Test). 
Chapter 4: In vivo analyses 
 118 
 
Figure 28. Mean Relative Paracrine Factor Expression. Real time PCR analyses were performed with 
5 day infarcted, cells/saline treated left ventricle samples. For all the treatment groups n=3. (A) IGF-1, 
(B) Elastin, (C) VEGF, (D) SDF-1, (E) IL6 and (F) IL10 mean relative expressions. No significant 
difference was observed between the WT control versus the infarcted cell/saline treated groups; IGF-
1: p=0.09, Elastin: p=0.07, VEGF: p=0.7, SDF-1: p=0.18, IL6: p=0.15 and IL10: p=0.06. There was a 
tendency for increased IGF-1, Elastin, IL6 and IL10 expressions in the infarcted hearts. Statistical 
analyses were performed using the non-parametric One-way ANOVA (Kruskal-Wallis Test) in Prism. 
Values are Mean +/- SEM.   
Taken together, these data showed that the paracrine molecules normally implicated in 
cardiac recovery that are released either by the donor or the native cells after injury and 
cell transplantation, were not significantly modulated at 5 days after myocardial infarction. 
However, the lack of statistically significant difference in the expression profiles of IGF-1, 
Elastin, IL6 and IL10 between the injury induced and WT animals indicated that possibly 
the high variations in animals within groups might be accountable for such outcome. 
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4.1.2.4 Histological Analyses of Long-term Samples 
Following the functional analyses at 2 months, animals were sacrificed for histological 
and molecular analyses. The histological analyses were performed (i) to examine the 
morphology of the scar, (ii) to assess engraftment of the transplanted cells, (iii) to analyze 
capillary density and (v) to examine morphology of the native cells at the border zone 
after injury induction and cell/saline injection. 
 
4.1.2.4.1 Scar Size Analysis 
Scar size analysis was performed using the Masson’s Trichrome Staining. Trichrome 
allowed visualization of cardiac muscle fibers (red) and fibrotic scar tissue (blue) by 
staining the collagen. Representative pictures are shown in the figure below (Figure 29) 
panels A-C. Scar size assessment revealed that the myocardial infarction model produced 
scar size of approximately 35-50% of the left ventricle (panel D). There was no significant 
difference in the scar size between the saline –treated and the empty- and IGF-1Ea-cells 
transplanted groups (45.42 +/-9.74% saline vs. 47.30 +/- 3.64% empty-cells transplanted 
and 45.42 +/-9.74% saline vs. 41.59 +/- 1.50% IGF-Ea-cells transplanted, p>0.05, n = 3 
per group). Similarly, the scar sizes of the IGF-1Ea- and the empty-cells injected hearts 
were not significantly different (47.30 +/- 3.64% empty-cells vs. 41.59 +/- 1.50% IGF-Ea-
cells transplanted, p>0.05, n = 3 per group).  
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Figure 29. Scar Size Analysis by Trichrome Staining. 3-4 months old WT C57BL6-J mice were 
subjected to myocardial infarction and saline/cell transplantation. 2 months after the treatments, 
samples were collected for histological analysis. 10µm transverse sections were cut and trichrome 
staining was performed. Representative images of saline (A), empty-cells (B) and IGF-1Ea-cells 
treated infarcted hearts. Image (D) illustrates quantitative analysis of the scar size. Three hearts were 
analyzed per group (n=3) and scar size is presented in percentage. The analysis revealed no significant 
difference in the scar size between the cell transplanted and the saline treated hearts, p>0.05. 
Similarly, there was no significant difference between the IGF-1Ea-cells treated hearts compared to 
the empty-cells treated hearts, p>0.05. Images were captured using LEICA MZFLIII microscope at 
1.25X magnification. Statistical analysis was conducted using the non-parametric one-way ANOVA 
test (Kruskal-Wallis Test). Values are Mean +/- SEM.  
In summary, the findings suggested that MI caused induction of 35-50% left ventricular 
scar. The size of the scar could not be reduced by transplantation of cells, possibly due to 
lack of/ insufficient engraftment of the transplanted or native stem cell population at the 
site of injury. The following analyses were conducted to trace the transplanted cell by anti-
GFP staining. 
 
4.1.2.4.2 Cell-engraftment Assessment 
The heart samples were examined for engraftment of the GFP positive donor cells. This 
was conducted through both immunofluorescence and immunohistochemistry with anti-
GFP staining. 10µm transverse sections of the hearts were de-paraffinized and subjected to 
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antigen retrieval as described in materials and methods. The immunofluorescence 
examination showed that the saline-injected samples ((Figure 30), panels A and B), which 
did not receive GFP cell-injection, were highly positive for the staining due to auto-
fluorescence resulting from the samples. Autofluorescence can result from artefacts 
introduced during injury induction and inflammation of the tissue, immune activation and 
cell death (reviewed in [220]). Van Laake et al. [220]have reported a method based on 
examining emission wavelength spectra of GFP (peak at 515nm) and autofluorescent dead 
cells (peak at 550nm). The method successfully eliminates autofluorescence resulting 
from the dead cell artefacts. As it was not possible to conduct cell-engraftment assessment 
on paraffin embedded tissue sections using traditional fluorescence technique, future 
analysis should utilize the technique described above for eliminating background 
fluorescence, on cryo-sections instead of paraffin sections. Due to lack of technical 
success, immunofluorescence was then replaced by immunohistochemical analysis for 
tracing the transplanted cells.  
 
Figure 30. Cell Engraftment Assessment by anti-GFP Staining using Immunofluorescence Technique. 
Panel (A) is a representative image of negative control of saline treated sample. Panel (B) saline 
treated sample treated with both the primary and secondary antibodies. Images (C) and (D) were 
empty-cell and IGF-1Ea-cell transplanted hearts respectively. Images were acquired at the border 
zone. Scale bars are 100µm and DAPI was used for staining cell nuclei. 
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Through immunohistochemical analyses, immunoreactivity was observed to the GFP 
antibody in cells-injected hearts (Figure 31 , panels B and C).  Saline-injected hearts 
presented a pale aspecific staining for GFP (panel A) whereas, IGF-1Ea and empty-cells 
injected hearts showed specific staining for GFP (left lane, panels B-C compared to the 
centre lane B-C). The IGF-1Ea-cells injected hearts showed higher number of GFP 
positive cell clusters than the empty-cells injected hearts (right lane, panels B and C). The 
quantification of engrafted cells was performed only visually on tissue sections. For better 
understanding of the amount of engrafted cells, future study should utilize quantification 
methods that involve isolation of cells after transplantation. One such approach could be 
FACS analysis and sorting of the transplanted cells. Although GFP positive cells were 
retained in the scar tissue of the transplanted hearts, they did not appear to integrate 
physically with the recipient tissue. They were in clusters and presented a spherical shape 
(right lane, panels B and C). Negative controls (centre lane, panels A-C) were treated only 
with biotin-conjugated secondary antibody. The results showed herein were produced 
from two animals per group (n=2). The figure below shows representative images for the 
different treatment groups.  
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Figure 31. Cell Engraftment Assessment by anti-GFP Staining using Immunohistochemical 
Technique. Panel (A) are a representative images of saline treated sample. Panel (B) and (C) were 
IGF-1Ea- and empty-cells transplanted hearts respectively. For all the figures, left and central panels 
are taken at 10X magnification, whereas right panels at 40X magnification. Central panels showed 
control samples stained with only the secondary antibody. Images were acquired at the scar region. 
Scale bars are 100µm and haematoxylin was used for staining cell nuclei. n= 2 per sample type. 
In summary, the immonohistochemical analysis showed that IGF-1Ea over-expressing 
cells engrafted better than the empty-cells, possibly due to their greater survival ability to 
deleterious environment previously observed in vitro (Chapter 3, Section III). However, 
the level of engraftment achieved did not confer function preservation at long-term and 
reduce scar size. Nevertheless, following the assessments of scar size and cell 
engraftment, the histological samples were utilized for capillary density analysis to 
examine whether injury and cell transplantation affected capillary density.  
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4.1.2.4.3 Capillary Density Assessment    
Capillary density assessment was performed by immunohistochemical labelling of the 
endothelial cells by Isolectin B4. Three fields of 500um^2 area each per sample was 
considered for counting the Isolectin B4 positive capillaries at the border zone. Panel A 
shows a representative image of a border zone. Although there was a tendency for higher 
Isolectin B4 staining in the cell transplanted samples, no significant difference was 
observed between the capillary densities of the saline or cells transplanted groups, p=0.16. 
IGF-1Ea-cells transplanted hearts showed 79.10 +/- 21.70 Isolectin B4-positive capillaries 
(panel D), empty- cells transplanted hearts showed 64.50 +/- 20.80 (panel C) and saline-
injected hearts showed 58.30 +/- 11.85 (Panel B). Figure below (Figure 32) illustrates 
these findings. The Isolectin B4 stained capillaries are stained brown, and nuclei blue.  
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Figure 32. Capillary Density Assessment. Capillary density analysis was performed by Isolectin B4 
immunohistochemical labelling of the 2 month tissue samples. Samples were 10um paraffin sections. 
Panel (A) is a representative image of the border zone, where the capillary density assessment was 
performed. Three fields of 500µm^2 area each were considered per sample for the assessment. Panels 
(B), (C) and (D) are representative images of one of the fields analyzed for Saline, empty-cells and 
IGF-1Ea-cells treated hearts respectively. Panel (D) illustrates the non-parametric one-way ANOVA 
analysis showing no significant difference in the capillary density between all of the three groups 
analyzed, p=0.16. n = 3 per group. Values are Mean +/-SEM. Scale bar for image (A) is 100µm and 
50µm for the rest of the images. 
The capillary density assessment also showed no significant difference between the 
different treatment groups, corroborating with the functional and scar size analyses. In 
addition to the histological analyses, long-term samples were examined also for the 
expression of the paracrine factors examined at short-term to understand whether there 
were changes in the expression profiles of these factors at long-term compared to the 
short-term time-point.  
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4.1.2.5 Molecular Analyses of Long-term Samples 
Real time PCR analyses were performed with the 2-month infarction induced and 
cells/saline injected hearts to analyse at mRNA level, the expression of the paracrine 
factors IGF-1, Elastin, VEGFa, SDF-1, IL6 and IL10. No significant difference was 
observed between the WT control versus the infarcted cell/saline treated groups: p=0.08 
for IGF-1, p= 0.08 for Elastin and p=0.17 IL6 genes. Interestingly, VEGFa expression was 
significantly higher in IGF-1Ea-cells transplanted hearts than the WT controls and the 
saline-treated hearts, p=0.02. No significant difference was observed in VEGFa expression 
between the empty-cells transplanted hearts compared to the WT and saline-treated hearts 
as well as between the IGF-1- and empty-cells transplanted hearts, p>0.05. SDF-1 
expression on the other hand was significantly lower in IGF-1Ea transplanted hearts 
compared to all other groups.  There was no difference in SDF-1 expression between all 
the other groups. IL10 mean relative expression was significantly higher in the empty- 
cells transplanted hearts compared to the WT controls, p=0.03 whereas there was no 
significant difference between all other groups. Statistical analyses were performed using 
the non-parametric one-way ANOVA (Kruskal-Wallis test) in Prism. Values are Mean +/- 
SEM. For all the treatment groups n = 3. The figure below (Figure 33) illustrates the 
findings.  
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Figure 33. Mean Relative Paracrine Factors Expression with 2-month Samples. Real time PCR 
analyses were performed with 2 months post infarction and cells/saline treated hearts. For all the 
treatment groups n=3. (A) IGF-1, (B) Elastin, (C) VEGFa, (D) SDF-1, (E) IL6 and (F) IL10 mean 
relative expressions. No significant difference was observed between the WT control versus the 
infarcted cell/saline treated groups (p>0.05) for IGF-1, Elastin and IL6 genes. VEGFa expression was 
significantly higher in IGF-1Ea-cells transplanted hearts compared to the WT controls and the saline 
treated hearts, p<0.05. The SDF-1 expression was significantly lower in IGF-1Ea-cells transplanted 
hearts compared to all other groups, p<0.01= ** and p<0.001= ***. There was no difference in SDF-1 
expression between the other groups. IL10 mean relative expression was significantly higher in the 
empty-cells transplanted hearts compared to the WT controls, whereas there was no significant 
difference between all other groups. Statistical analyses were performed using the non-parametric 
One-way ANOVA test (Kruskal-Wallis test) in Prism. Values are Mean +/- SEM.  
Taking together the capillary density assessment and the molecular analysis on paracrine 
factor expression, transplantation of IGF-1Ea-cells modulated the transcript levels of pro-
angiogenic factors, VEGFa and SDF-1 without altering capillary density. The activity of 
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these factors could therefore be important after injury induction in regulating the response 
of cardiomyocytes, rather than endothelial cells. It has been previously shown that VEGFa 
and SDF-1 may contribute to cardiomyocyte hypertrophy [221, 222]. In cardiomyocytes, 
VEGF drives cardiac hypertrophy or its regression, depending on its binding to VEGF2R 
(also known as KDR) or VEGF1R (also known as Flt-1), respectively Therefore, 
molecular and histological analyses were carried out to examine the properties of the 
native cells after injury and cell/saline injection.  
 
4.1.2.6 Molecular and Histological Analysis of the Recipient Tissue for Hypertrophic 
Response 
The histological analysis examined cell-cross sectional area of the border zone cells and 
the molecular analysis investigated expression of VEGF2R (KDR) at protein level and 
beta Myosin Heavy Chain (bMHC) and skeletal actin (aSK) at mRNA levels as markers of 
hypertrophy. Real time PCR analyses were conducted to quantify expression levels of aSK 
and bMHC (Figure 34, panels A and B). The data showed that aSK expression was 
significantly up-regulated in the empty cell-injected hearts compared to the WT, IGF-1Ea-
cell and saline-injected hearts (Panel A). bMHC expression on the other hand, was 
significantly up-regulated in saline treated animals compared to the WT controls and the 
IGF-1Ea-cells injected animals (Panel B). Although not significant, the empty-cells 
transplanted samples also showed reduced bMHC expression compared to the saline 
injected hearts.  
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Figure 34. Molecular and Histological Analyses for Hypertrophic Response. Real time PCR analyses 
were performed with 2 months post infarction (LAD ligation) and cells/saline treated hearts. For all 
the treatment groups n=3. (A) aSK and (B) bMHC. Real time PCR was performed with Applied 
Biosystems probes as indicated in Material and Methods. Panel (C) shows analysis of cross-sectional 
area (CSA) of cardiomyocytes measured by Wheat Germ Agglutinin staining on 5 µm tissue samples 
of WT, saline, empty- and IGF-1Ea-cells (mIGF-1) injected hearts. The open lines mark the border 
for the scar from the non-scar tissue. Nuclei were stained with Hoechst dye. Images were acquired by 
a Nikon digital Camera DXM1200F. Statistical analyses were performed using the One-way ANOVA 
in Prism and shown in Panel D. Values are Mean +/- SEM. (E) KDR expression by western blot 
analysis. KDR was normalized with alpha-tubulin and its quantification was performed with n=2 per 
experimental group.* indicates p<0.05, ** p<0.01 and *** p<0.001.   
 
The response to hypertrophy in cardiomyocytes exposed to VEGFa expression could be 
explained by the regulation of VEGFa receptor KDR. Western blot analysis showed 
mildly lower KDR expression for IGF-1Ea-cells transplanted heart samples compared to 
the saline and empty-cells treated hearts (Panel E). Cross-sectional area (CSA) analysis 
showed that cardiomyocytes bordering the scar tissue in the hearts that received IGF-1Ea-
cells had significantly lower CSA compared to the saline and the empty cell-injected 
hearts (Panels C and D). The CSA of cardiomyocytes bordering the scar tissue of the 
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empty-cells injected hearts on the contrary were significantly higher than the WT, saline 
and IGF-1Ea-cells treated hearts.  
 
In summary, these data showed that myocardial infarction induced by occlusion of the left 
coronary artery led to left ventricular (LV) remodelling, which was marked by 
hypertrophic cells and up-regulation of hypertrophic markers. Transplantation of empty-
cells had no effect on LV remodelling however, transplantation of IGF-1Ea-cells resulted 
in lower hypertrophy compared to the empty-cells transplanted hearts suggesting that IGF-
1Ea cells might play a role on modulating LV remodelling by directly or indirectly 
involving VEGFa and/or SDF-1 molecules.  As the molecular analysis of 2 month heart 
samples on IGF-1 transcript expression (Figure 28) did not show a difference between the 
empty- and IGF-1Ea-cells transplanted hearts, the observed LV remodelling effect 
however might be resulting from other factors than IGF-1Ea as a result of transduction of 
IGF-1Ea vector.  
 
4.1.3 DISCUSSION 
 
The objective of this chapter was to test if function of impaired hearts caused by 
myocardial infarction could be improved by transplantation of the IGF-1Ea transduced 
P19Cl6 cells. The myocardial infarction induction and cell transplantation were 
successfully performed. First analysis was performed on survival of surgical animals 
following myocardial infarction and cell transplantation. The total intra- and early post 
myocardial infarction mortality was considered as reported by Fuchs et al. to be occurring 
between 0 and 3 days following surgery [223]. It was found to be 34.92% in this study (22 
out of 63). The total number of animals that survived the surgical procedure for up to 2 
months was 35 out of 63, (55% survival rate for the procedure).  
 
The echocardiographic analyses on Ejection Fraction, Fractional Shortening and 
Fractional Area Change revealed that cell transplantation mildly preserved cardiac 
function at short-term, although statistically not significant. The functions of hearts 
receiving the IGF-1Ea- and empty-cells were not significantly different from one another 
indicating that transplantation of both the cell types contributed similarly to heart function 
at short-term. Possible explanation for the lack of difference in functional preservation 
between the two cell types could be attributed to their similarities, for instance both the 
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transplanted empty and IGF-1Ea transduced cells expressed IGF-1 (Figure 19). Further 
analyses on the properties of the two cell types would be necessary to understand if the 
cells shared other features that led to this outcome. The long-term functional analyses 
showed further significant reduction in the function of the cell transplanted hearts to the 
level of the saline-injected hearts, indicating that cell transplantation did not preserve 
function at long-term.  
 
Studies have reported that transplantation of cells leads to release of paracrine factors 
either directly from the transplanted cells or indirectly from the native tissue, resulting in 
better survival of the native tissue, reduction of scar size, enhanced homing of stem cell 
population from other sources and improved left ventricular systolic function. To 
investigate whether the paracrine factors described by previous studies to induce cardiac 
function recovery, such as IGF [224, 225], Elastin [29], SDF-1 [219], VEGFa [226], IL10 
[227] and IL6 [228] were altered, mRNA level analyses were performed with both the 
short-term and the long-term samples. The tendency on function observed at short-term 
could not be conferred to the factors analyzed. It has been reported that release of specific 
factors, such as SDF-1, is time-dependent and increased levels of SDF-1 have been 
observed three days after myocardial infarct induction [222]. Therefore, earlier time points 
after myocardial infarct induction than 5 days should be analysed to explain the effect on 
short-term function we have observed. There was also no significant difference in the 
expression patterns of these molecules between the saline-treated versus the cells-treated 
hearts, suggesting that the tendency in preservation of function observed in this specific 
time-point was not induced by the particular factors. We can speculate that other factors of 
neurohumoral origin or released by the renin-angiotensin web system could have a higher 
impact in cardiac function by regulating contractility. Therefore, to understand what other 
factors, if any, than the ones analyzed could contribute to the tendency for short-term 
maintenance of function, a gene array analysis should be utilized. In addition, it would be 
imperative to analyze GFP gene expression to show that the cells engrafted at short-term 
as well as long-term at mRNA level, which would additionally support the histological 
observation that at long-term cells engrafted.  
  
The cell engraftment analyses using immunofluorescence and immunolabeling techniques 
on paraffin sections were both challenging due to autofluorescence encountered from 
artefacts, which could be tackled in future by using the method described earlier in section 
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4.1.2.4.2. Despite the observed problem, transplanted GFP positive cells were detected in 
the scar tissue of some hearts, although quantification of the actual number of engrafted 
cells with certainty was not possible in the paraffin embedded tissue sections. The 
transplanted cells were not organized in a syncitium, indicating that integration with the 
remaining cardiomyocytes was not achieved. Intramyocardial injection of the cells was 
successful with regard to cell maintenance in the injured site and the combination of the 
pro-peptide IGF-1Ea enhanced homing of the transplanted cells, based on tissue 
observation. As seen in the in vitro analysis (Chapter 3), IGF-1Ea over-expression could 
have conferred higher protection to the cells from deleterious events in vivo, leading to 
their enhanced homing compared to the empty-cells. However, cells did not integrate and 
contribute to maintain long-term cardiac function, even having a ventricular origin. Given 
the relative lack of efficacy in this study and previous cardiac regeneration studies, it is 
clear that future cell therapy approach must improve the efficiency and integration of the 
transplanted cells to the injured tissue to achieve a lasting maintenance of function. Future 
analysis to quantify cell engraftment must also consider re-isolating the transplanted cells 
and conduct analyses to confirm their number and existence to avoid technical problems 
encountered by the present study, and most importantly for quantification which is not 
solely based on tissue observation. 
 
Scar measurement analysis showed no significant difference in scar size between the cell-
transplanted and the saline treated groups. Although cell tracing assessment was able to 
detect homing of the donor cells, the extent of homing was not enough to reduce scar size. 
Reduction of scar size could be obtained by improving retention of the transplanted cells. 
Study by Hattori et al. have reported that cells get instantly washed out upon 
transplantation via the coronary circulation leading to their lower availability for 
engraftment [229].  They reported that 30-50% of the injected cells were washed out of 
the heart within 10 minutes of cell injection. This study was supported by an in vivo study 
conducted on rats.  Dow et al. injected directly into the left ventricular wall of either re-
perfused or permanently occluded rat hearts [230]. The cell injections were performed at 
15 and 75 minutes post treatments respectively with 5*10^6 cells. The study recovered the 
donor cells in both the heart and the lungs in 100% of the animals.  Furthermore, cells 
were also discovered in capillaries, kidney and spleen suggesting that the direct injection 
of cardiomyocytes does not represent the ideal mode for cell transplantation studies. 
Taking these studies into account, it is likely that donor cells were instantly washed out in 
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this study, resulting into insufficient homing and lack of improvement in scar size. 
Therefore, future cell transplantation studies could be performed with cell sheets or 3D 
engineered tissues that are harder to disperse than single cells. Transplantation of 3D cell 
sheets would in addition also aid cell tracing analyses, which is still a big challenge for 
cell transplantation studies.   
 
Despite homing of the donor cells, the capillary density, scar size and functional analyses 
were all unaffected by transplantation of cells. Analysis of the paracrine factors with the 
long-term samples on VEGFa, SDF-1 and IL10 however showed a significant difference 
between the saline- and the cell-injected hearts. VEGFa was up-regulated in IGF-1Ea cell-
injected group compared to the other groups, whereas SDF-1 was significantly down-
regulated. Moreover, the differential modulation of these pro-angiogenic factors did not 
correlate with capillary density, which showed no significant difference between the saline 
treated and cell transplanted groups. The activity of these factors could therefore be 
important after injury induction in regulating the response of other cell types, rather than 
endothelial cells. It has been previously shown that VEGFa and SDF-1 may contribute to 
cardiomyocyte hypertrophy [221, 222]. In cardiomyocytes, VEGF drives cardiac 
hypertrophy or its regression by regulating availability of VEGF1R or VEGF1R by 
binding to VEGF2R (also known as KDR) or VEGF1R (also known as Flt-1) [221]. 
Molecular and histological analyses on hypertrophic response of the recipient tissue 
revealed that IGF-1Ea cell transplantation led to less hypertrophic native cells and 
decreased bMHC, aSK and KDR expression. These findings suggested that transplantation 
of IGF-1Ea transduced cells may preserve cells from hypertrophy by modulating VEGFa 
and SDF-1 expression. However, to understand whether the observed lowering of 
hypertrophy was due to direct effect of IGF-1Ea cell transplantation on VEGFa and SDF-1 
expression or indirect effect via involvement of other factors, further investigation 
employing inhibition of VEGFa and SDF-1 would be necessary. The molecular analysis of 
2 month heart samples on IGF-1 transcript expression (Figure 32) did not show a 
difference between the empty- and IGF-1Ea-cells transplanted hearts. This suggested that 
the observed LV remodelling might be resulting from other factors released from the IGF-
1Ea transduced cells. In vitro studies involving analysis of conditioned media from IGF-
1Ea and empty-cells will be necessary to answer what other factors, might be involved to 
protect cells from hypertrophy.  In addition, further analysis should be conducted to 
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understand whether IGF-1Ea alone could confer this beneficial effect or a combinatorial 
therapy employing cell and IGF-1Ea is necessary to achieve this.   
 
The empty-cells transplanted hearts expressed significantly higher IL10 than the other 
treatment groups. IL10 could in part protect the heart from further damage. IL10 
modulates endothelial cell proliferation and it has been shown to protect the heart from 
deleterious cardiovascular remodelling by decreasing the amount of T lymphocytes in 
cardiac tissue after infarct and by regulating cardiac hypertrophy [227]. Burchfield et al. 
[227] showed that transplantation of Bone Marrow Mononuclear Cells (BM-MNCs), 
which released IL10, contributed to improved LV function after myocardial infarction, by 
decreasing T lymphocyte accumulation, reducing reactive hypertrophy and myocardial 
collagen deposition. With respect to cell cross-sectional area measurement, hearts 
receiving empty-cells showed significantly higher area than the wild type and IGF-1Ea-
cell transplanted hearts suggesting that transplantation of these cells, unlike IGF-1Ea cells, 
did not preserve native cells from hypertrophy. Increased IL10 expression in the empty-
cells transplanted hearts therefore did not lower cardiomyocyte hypertrophy. The lack of 
reduction on cardiac hypertrophy correlated with their long-term functional analyses that 
there was no preservation of function. Even though IGF-1Ea cell transplanted hearts 
showed lower hypertrophy than the empty-cells transplanted hearts, functional analyses at 
long-term for IGF-1Ea cells transplanted hearts also did not show any maintenance of 
function suggesting that reduction of hypertrophy alone probably does not confer better 
function.      
 
In summary, the present study was able to achieve a tendency for maintenance of function 
at short-term upon both the empty- and IGF-1Ea-cells transplantation. It was however not 
able to show similar effect at long-term, although the cell transplanted hearts continued to 
show a tendency for better function than the saline-injected hearts. Nonetheless, 
combinatorial P19Cl6 and IGF-1Ea therapy was able to confer protection to cardiac cells 
from hypertrophy that could be beneficial to the recipient hearts. Therefore, this study 
proposes a novel mechanism that could regulate cardiac repair and induce beneficial 
cardiovascular remodelling in cell/ growth factor therapy. However, regeneration of the 
scar tissue to improve its function is still a challenge to be met. Figure below (Figure 35) 
shows the mechanism proposed by our hypertrophy analysis. 
Chapter 4: In vivo analyses 
 135 
 
Figure 35. Mechanism of P19Cl6 cells and IGF-1Ea mediated amelioration of injured tissue. IGF-1Ea 
over-expressing cells conferred protection against hypertrophic response. IGF-1Ea-cell 
transplantation decreased cardiomyocytes cross-sectional area and induced a molecular signaling 
modulating the expression of vascular endothelial growth factor (VEGFa) and stromal-derived factor 
1 (SDF-1). Down-regulation of SDF-1, up-regulation of VEGFa expression and down-regulation of 
VEGF2R (KDR) led to a differential cellular response independently of vessel formation and possibly 
regulating hypertrophic signaling. The green arrows show the signaling mechanism observed so far. 
Direct pathway refers to pathway that is conferred directly by IGF-1Ea and indirect pathway by 
involving other factors between IGF-1Ea and VEGFa/SDF1, which regulate expression of VEGFa and 
SDF1 upon interaction with IGF-1Ea. A direct regulation of KDR promoter by IGF-1Ea protein can 
not be excluded. 
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5.1 GENERAL DISCUSSION 
 
This was the first study that attempted to engineer pluripotent P19Cl6 cells to express 
IGF-1Ea for cell-based regeneration of infarcted hearts. The study utilized cell-based 
delivery of IGF-1Ea instead of pharmaco- or gene-therapy to obtain a controlled and 
sustained expression of the gene. The principal objectives addressed were: (i) stable 
transduction of P19Cl6-MLC2v-GFP cells with IGF-1Ea gene and tetracycline regulation 
of the gene expression, (ii) study the effect of IGF-1Ea transduction on properties of the 
engineered cells, (iii) test feasibility of the engineered cells for cell therapy in an in vitro 
system and (iv) test if transplantation of IGF-1Ea over-expressing cells improves function 
of the injured hearts and if they are superior to the control cells.   
 
I was successful in engineering P19Cl6-MLC2v-GFP cells over-expressing IGF-1Ea 
through stable transduction of the gene using a lentiviral vector. Tetracycline -regulated 
expression of IGF-1Ea could not be accomplished in the P19Cl6 cells but was achieved in 
HT1080 cells, the reasons for which remain unknown. Nevertheless, the gene expression 
was successfully achieved at high amount in a constitutive manner, which fulfilled the 
goal of producing sustained IGF-1Ea expression. The engineered cells maintained 
efficient differentiation into ventricular cardiac myocytes. The resulting cardiac myocytes 
exhibited structured organization of the sarcomeric alpha actinin protein that is vital for 
contractile function and the differentiated cell clusters showed calcium induced calcium 
release mechanism, which is essential for conducting electromechanical function. 
Additionally, in vitro analyses revealed that the IGF-1Ea over-expression conferred 
increased survival to the cells against prolonged hypoxia exposure. Likewise, the IGF-1Ea 
conditioned media was efficient to protect neonatal cardiac myocytes from apoptosis, 
indicating that the constitutively expressed IGF-1Ea granted more than self-protection.  . 
Taken together, the in vitro data indicated that IGF-1Ea-transduced cells represented an 
attractive candidate for cell therapy. With the exogenous delivery of the cells and potential 
prevention of further damage from IGF-1Ea over-expression, the transplantation of the 
IGF-1Ea transduced cells appeared to hold potential for preserving function of hearts after 
infarction.  
 
As the in vitro analysis of the IGF-1Ea-transduced cells on their feasibility for cell 
transplantation therapy proved successful, the engineered cells were then transplanted into 
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allogeneic wild type murine hearts with acute myocardial infarction. The goals here were 
to analyze whether the impairment of function owing to the injury could be prevented by 
cell transplantation and if IGF-1Ea over-expressing cells were superior to the control cells 
with regard to efficiency of engraftment, tissue regeneration, scar size reduction and 
function preservation.  
 
Functional analyses were conducted at short- and long-term (5 days and 2 months 
respectively) post-infarction induction and cell transplantation. The short-term analyses 
revealed a trend for prevention of deterioration of function for cell transplanted animals 
compared to the saline treated animals, but there was no significant difference between the 
empty-cells treated compared to the IGF-1Ea-cells transplanted hearts, suggesting that the 
observed effect on function was merely a result of cell transplantation and not IGF-1Ea 
expression. The absence of differences in function between the IGF-1Ea-cells and the 
empty-cells transplanted hearts could have resulted from the in vitro observation (Figure 
19) that also the control cells produced high amounts of endogenous IGF-1 following their 
differentiation. This outcome was not initially anticipated.  Therefore, to be able to deduce 
that the observed functional maintenance in short-term studies was solely due to cell 
transplantation and not due to IGF-1Ea expression, future studies must utilize an 
additional cell type as a control that is unable to produce IGF-1 upon their differentiation. 
 
The effect of cell transplantation on function at short-term was further investigated at 
molecular level. Cell transplantation studies utilizing foetal cardiomyocytes [231-233], 
ESC [67-69, 234, 235], skeletal myoblasts [56, 57, 236], MSC [43, 45-47, 237-239], CPC 
[36] and iPS cells [60-62] have been conducted in various model systems. Some of these 
studies have demonstrated that the transplanted cells differentiated into cardiomyocytes 
and survived after cell transplantation [67, 69, 71, 233, 240], subsequently improving 
function of the injured hearts. However, in some of these studies, the improved function 
could not be directly linked to the transplanted cells and their number therefore a paracrine 
effect has been suggested [43, 45-48]. Therefore, to understand the tendency in short-term 
maintenance of function, paracrine effect was investigated at molecular level.  
 
Paracrine factors namely, IGF-1, Elastin, VEGFa, SDF-1, IL6 and IL10 were analyzed by 
qRT-PCR. Interestingly, the expression of none of these factors was significantly different 
in the cell transplanted compared to the saline treated hearts. Similarly, there was also no 
Chapter 5: General Discussion and Conclusion 
 139 
significant difference in their expressions between the injured and the wild type controls, 
although a tendency was observed for increased expressions of IGF-1, Elastin, IL6 and 
IL10 in all the injured hearts, independent of cell or saline transplantation. This tendency 
was merely due to injury as there was no difference in expressions of these factors 
between the saline treated compared to the cells transplanted hearts. It is reported in 
several studies that some of the paracrine factors studied here are modulated by induction 
of myocardial infarction. Circulating levels of IL6 are up-regulated post-myocardial 
infarction [223], where the level peaks at days 1 and 2 and remains higher than the 
physiological level even after 12 weeks [241]. Similarly, Reiss et al. reported in an acute 
myocardial infarction model, enhanced expression of both IGF-1 receptor and IGF-1 from 
12h up to 7 days post injury induction [242].  
 
Taking the findings of these studies, it is possible to conclude that the observed tendency 
for up-regulation of some of these factors was due to injury. Comparing the short-term 
functional analyses to the short-term molecular analyses, the observed tendency for 
maintenance of function with cell transplantation could not be linked to the examined 
paracrine factors. The reason for this observation in function could be due to paracrine 
factors other than the ones investigated, which could be understood better with a gene 
array analysis. It could very well be due to engraftment of cells, which was not analyzed at 
short-term. Histological analysis at 2 months showed homing of the transplanted cells 
therefore, the tendency for maintenance of function was most likely due to cell homing. It 
is important to emphasize however that the number of animals used for the molecular 
analyses was only 3 per group, which resulted into a very high standard deviation. 
Therefore, future study should employ more animals per experimental group to account 
for the variability, which results from individual differences and LCA ligation. In addition, 
at 5-day time-point, the functional analysis is not very reliable as the injured tissue is 
undergoing remodelling events that lead to immense disturbance in data acquisition. 
Therefore, it is likely that the tendency in function maintenance observed at short-term is 
due to great variability in data acquisition rather than a true observation.  
 
At long-term however, even the tendency for maintenance of function observed at the 
short term analyses was lost, which could have resulted from numerous factors. It could be 
due to insufficient engraftment of the transplanted cells, lack of coupling of the 
transplanted cells with the host tissue or due to expansion of the damage such that the 
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transplanted cells suffered from the expansion. The cell tracing analyses showed that the 
transplanted cells were retained in the tissue and that IGF-1Ea over-expression enhanced 
cell homing. However, coupling of the donor cells with the host myocardium was not 
achieved and the cells remained in the scar tissue as separate cell clusters. Therefore, the 
deterioration of long-term function observed in this study could be attributed to lack of 
coupling of the transplanted cells with the recipient tissue.  
  
Cell transplantation studies show discrepancies regarding engraftment of transplanted cells 
and functional improvement. Studies that utilized fetal, neonatal rat and embryonic 
cardiomyocytes transplantation into infarcted rat hearts reported engraftment of all of 
these cell types [232, 243, 244]. On the contrary, Watanabe et al. when transplanted fetal 
and neonatal pig cardiomyocytes and cardiac-derived HL-1 cell line into injured and 
uninjured pig hearts, found no survival and grafting of the transplanted cells [75]. Very 
recently however, more studies have shown long-term engraftment and enhancement of 
function [71, 93, 245]. However, van Laake [93] reported that even with long-term 
survival of the graft, the observed maintenance of function was lost at 12 weeks 
suggesting that the graft size could still be a limiting factor. The discrepancies observed in 
these studies might have resulted from differences in their animal models, donor cell types 
and their differentiation states, and on the status of the host myocardium at the time of cell 
transplantation and grafting.  
 
Taking these discrepancies into consideration Reinecke et al. [246] studied the effects of 
developmental state of donor cells and of myocardium at the time of engraftment. They 
injected fetal, neonatal and adult cardiomyocytes into both cryo-injured and uninjured 
hearts and reported that the adult cells did not survive in any of the grating tissues at day 6 
of analyses. They then analyzed the adult cell engraftment at day 1 and identified only few 
surviving cells. The neonatal and fetal cardiomyocytes however successfully formed grafts 
in both injured and the uninjured hearts indicating that the developmental stage of donor 
cells does influence graft survival. In contrast to the above study, Smits et al. [245] 
reported that transplantation of human cardiomyocyte progenitor cells and the 
cardiomyocyte progenitor cells-derived cardiomyocytes into immunodeficient mice 
following myocardial infarction. They observed no significant difference in the grafting 
efficiencies of the differentiated and the undifferentiated cells, observing only 3.5 +/- 
1.8% and 3.0 +/- 0.8% cells engraftment for undifferentiated and differentiated cells 
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respectively. These studies displayed discrepancies on engraftment of differentiated versus 
the undifferentiated cells. Van Laake et al. [93] observed long-term engraftment of donor 
cells in immunodeficient mice with improvement of function in the cardiaomyocyte 
engrafted animals compared to non-cardiomyocytes engrafted. However, at long-term the 
conferred improvement in function by cardiomyocytes dropped to the same level as the 
non-cardiomyocytes engrafted hearts indicating lack of prolonged improvement of 
function, even with the evidence of cell engraftment. This study utilized fully 
differentiated ventricular cardiomyocytes as donor cells. Cells were successfully retained 
in the scar tissue but were not able to integrate in the host myocardium and confer lasting 
function preservation as described in van Laake et al. [93].   
 
Interestingly, Hattori et al. [229] demonstrated that co-transplantation of ES-derived 
cardiomyocytes with fibroblast synergistically enhanced the survival of cardiomyocytes. 
They reported that when highly enriched cardiomyocytes generated from ES cells were 
transplanted together with embryonic fibroblasts into immunodeficient mouse hearts, 
histological analyses revealed that <1% of cardiomyocytes and 50% of the fibroblasts 
remained in the injured myocardium 24 hour after transplantation. This study clearly 
demonstrated the importance of adhesive qualities of cells for transplantation. Similarly, 
Kolossov et al. reported that transplantation of 3*(10^4) to 3*(10^5) ES cell-derived 
cardiomyocytes into syngeneic infarcted murine hearts resulted in poor engraftment of the 
cells [67]. This observation was altered when they transplanted ES-cell derived 
cardiomyocytes co-cultured with syngeneic fibroblast, highlighting the role of fibroblast 
cells in facilitating engraftment. In the same study, transplantation of the later cell type 
improved function of the infarcted hearts compared to the sham injected controls at 3-4 
weeks post surgery. In a different approach to cell injection, Laflamme et al. [92], 
introduced a pro-survival cocktail cell therapy whereby they injected cells together with 
pro-survival molecules such as IGF-1, cyclosporine A, pinacidil together with Matrigel 
and observed enhanced survival of the cells, attenuation of ventricular dilation and 
preserved regional and global contractile function.  
 
In retrospect, transplantation of highly enriched ventricular cardiomyocytes into 
allogeneic infarcted wild type mice, without any adhesive molecules possibly was one of 
the weaknesses that led to insufficient engraftment of the cells in the present study. 
Although the transplanted cells utilized by this study also expressed one of the survival 
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factors (IGF-1Ea) described by Laflamme [92], IGF-1, probably more than one factor is 
required for better engraftment and survival of the transplanted cells to be able to confer 
lasting preservation of function.  
 
Hattori et al. also analyzed the mechanisms that could underlie the loss of transplanted 
cells leading to their lower availability for engraftment [229]. They investigated the 
amount of cells that get instantly washed out upon their transplantation via the coronary 
circulation. Murine hearts were re-perfused ex vivo and injected with highly enriched, 
GFP labelled cardiomyocytes. They then collected fluid drained out of the coronary sinus 
to count the drained labelled cells. From seven different experiments, it was reported that 
30-50% of the injected cells were washed out of the heart within 10 minutes of cell 
injection. This study was supported by an in vivo study conducted on rats.  Dow et al. 
injected directly into the left ventricular wall of either re-perfused or permanently 
occluded rat hearts [230]. The cell injections were performed at 15 and 75 minutes post 
treatments respectively with 5*10^6 cells. The study recovered the donor cells in both the 
heart and the lungs in 100% of the animals.  Furthermore, cells were also discovered in 
capillaries, kidney and spleen suggesting that the direct injection of cardiomyocytes does 
not represent the ideal mode for cell transplantation studies. Additionally this approach 
holds a risk of dispersing the injected cells into other organs in the body. Although cell 
tracing were not carried out in other organs than the hearts, in the present study the loss of 
function at long-term could be due to loss of cells into coronary circulation leading to 
lower amount of cells for engraftment. To minimize this problem, cell transplantation 
could be performed with cell sheets or 3D engineered tissues that are harder to disperse 
than single cells. Transplantation of 3D cell sheets would in addition also aid cell tracing 
analyses, which is still a challenge for a lot of cell transplantation studies.   
 
Amelioration of the regional function of hearts after injury could be achieved by re-
vascularization and decreasing pathological hypertrophy. Although efficiency of 
contractile cell engraftment holds potential for overall function improvement, a study by 
van Laake et al. suggests that improvement of cardiac function correlates with vascularity 
rather than graft size [247]. They reported that transplantation of human ES cells derived 
cardiomyocytes enhanced vascularisation and improved function of the recipient hearts 
after myocardial infarction and interestingly smaller graft size conferred better functional 
outcome than bigger grafts. Smits et al. [245] transplanted human Cardiomyocyte 
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Progenitor Cells (hCMPC) and hCMPC-derived cardiomyocytes (hCMPC-CM) in 
infarcted murine hearts and reported that transplantation of these cells lead to preservation 
of long-term function. They observed higher vessel density for hCPMCs than the hCPMCs 
derived cardiomyocytes transplanted hearts. Their further in vitro analyses confirmed that 
the undifferentiated progenitor cells-conditioned media contained VEGF whereas the 
differentiated cells-conditioned media did not. Both of van Laake and Smits et al. [245, 
247] studies implicated that enhanced vessel density correlates with enhanced functional 
outcome, although in the study by Smits et al., the hCMPC-derived cell transplantation led 
to comparable enhancement of function to the undifferentiated progenitor cell transplanted 
hearts even though their vessel density was lower. This finding in general implicated that 
the differentiated and undifferentiated cells could possibly secrete different paracrine 
factors exerting dissimilar effects in modulating the injured tissue.  
 
The current study conducted a capillary density assessment in the long-term samples and 
showed no significant difference in the capillary densities between the cells transplanted 
and the saline-injected groups. As Smits et al. [245] reported the reason for this could be 
that the donor cells in the present study were fully differentiated cells that did not release 
sufficient amount of pro-angiogenic factors for making new vessels. Interestingly, the 
mRNA analysis of VEGFa expression in the 2-month samples was significantly higher in 
IGF-1Ea transplanted hearts compared to the WT controls but not in the empty-cells 
transplanted hearts. Although not statistically significant, the IGF-1Ea-cells transplanted 
hearts also had a tendency for higher capillary density. It is therefore likely that the IGF-
1Ea-cells released insufficient amount of paracrine factor VEGFa, to make adequate new 
vessels to maintain their function at long-term. The capillary density assessment in the 
present study correlates very well with the functional and the scar size analyses. The 
preservation of function was not lasting in the cell transplanted hearts as the scar size 
could not be reduced and vessel density enhanced.    
 
The apparent discrepancy observed between no change in capillary density and increased 
VEGFa transcript expression in the IGF-1Ea samples can be explained by considering the 
pleiotropic function of VEGFa. Apart from being pro-angiogenic factor, VEGFa is 
implicated in modulating hypertrophy. Hearts transplanted with IGF-1Ea cells showed 
significantly higher and lower expression of VEGFa and SDF-1 respectively. Although 
the actual mechanism of IGF-1Ea mediated modulation of VEGFa and SDF-1 expression 
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has not been found, the IGF-1Ea cell transplanted hearts showed down-regulation of 
VEGF receptor, KDR, down-regulation of aSK and bMHC in IGF-1Ea-cell transplanted 
hearts suggesting that IGF-1Ea cell transplantation may directly or indirectly confer 
protection against LV remodelling. It is not known how SDF-1 could contribute to the 
IGF1-Ea-induced modulation of hypertrophy therefore further study in our laboratory will 
examine in detail this signaling. 
 
Although the hearts receiving IGF-1Ea-cells showed lower hypertrophic response than the 
hearts transplanted with empty –cells, this effect was not sufficient to confer a 
preservation of long-term function. Nonetheless, this study proposed a novel mechanism 
that could regulate cardiac repair and induce beneficial cardiovascular remodelling in cell/ 
growth factor therapy. However, for regeneration of the scar tissue to improve overall 
function, sufficient homing and integration of new contractile muscle mass would be 
necessary and modulation of hypertrophic response alone seemed not sufficient to achieve 
this.   
 
5.2 LIMITATIONS AND FUTURE DIRECTION 
 
Cell-based gene therapy of IGF-1Ea transduced P19Cl6-MLC2v-GFP cells was not able 
to confer lasting preservation of function of infarcted murine hearts. There are several 
factors which could have led to this outcome. One of the major limitations of the study 
was small number of subjects for in vivo cell transplantation, which led to high standard 
deviation within groups. The small number of subjects resulted from very high mortality 
observed from permanent LCA ligation utilized by the study to induce myocardial 
infarction. To improve the number of animals for similar study in future one should either 
improve animal survival by employing alternative myocardial infarction models such as 
the cryo-injury, cardiotoxin-injury or temporary ischemia- reperfusion models that have 
lower mortality or alternatively increase the total number of animals for the study. The 
temporary LCA ligation- reperfusion model will not only confer higher survival but will 
also be clinically more relevant than the permanent occlusion model.    
 
Although the use of P19Cl6 cells for therapy was mainly a proof of principle, future 
studies should utilize safer cells such as embryonic, cardiac progenitor or iPS cells, which 
are clinically relevant as opposed to the carcinoma cells. In addition, the study observed 
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insufficient engraftment of the transplanted cells, which could have resulted from the use 
of allogeneic transplantation approach. The allogeneic transplantation model required 
long-term immunosuppression and long-term immunosuppression in mice has been 
described to be very difficult without inducing toxicity and local irritation (mentioned in 
[220]). Due to the adverse effects that could potentially be obtained from 
immunosuppression alone, the fate of the transplanted is very difficult to address in an 
allogeneic model. Therefore, future cell transplantation study should be carried out in 
immunodeficient mice. The insufficient engraftment could also have resulted from the 
differentiation state of the transplanted cells and the number of donor cells for 
transplantation. Future studies should therefore comprise donor cells of immature, mid-
mature and fully mature types, in various numbers to investigate the optimal 
differentiation state and number for enhanced engraftment, as a previous study suggests 
that immature cells such as foetal cardiomyocytes survive better after injection in the 
hearts than the adult cardiomyocytes [246].  
 
Previous study from our laboratory on transgenic mice over-expressing IGF-1Ea in the 
heart showed that the hearts preserved their function after injury, formed smaller scar and 
showed lower cell death compared to wild type hearts [77]. Despite the inability of this 
study to distinguish the endogenous and exogenously expressed IGF-1, the present study 
observed an increase in IGF-1 expression (although not significant, p=0.08) in all the 
injury induced hearts, independent of cell injection. However, this natural induction of 
IGF-1 was not able to protect the hearts from deleterious events caused by MI. This leads 
to hypotheses that (i) IGF-1 expression possibly confers prevention of damage rather than 
cure to MI-induced injury, (ii) if IGF-1 does have curative function, it is possible that 
persistent expression of the gene is important for protection as it is the case in transgenic 
mice but this might not be the case in the wild type after infarction and (iii) alternatively, 
it might be the level of IGF-1 expression after injury induction that is not enough in the 
wild type hearts to confer protection. To test these hypotheses, future cell therapy study 
could be conducted on transgenic mice over-expressing IGF-1Ea versus wild type 
animals. In addition, to address the inability of the present study to distinguish endogenous 
and exogenously introduced IGF-1, a custom RT-qPCR probe needs to be designed. The 
commercially available probe of rat IGF-1, which was used in this study was not specific 
to the species. Therefore for future work, a custom designed probe that incorporates parts 
of the vector backbone, is necessary.  
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The detection of IGF-1Ea did not only suffer from lack of rat IGF-1Ea specific RT-qPCR 
probe but also from species- and isoform- specific antibody. Despite several trials using 
western blot and direct ELISA methods, it was not possible to test at protein level, 
production of IGF-1Ea by the transduced cells. Although the in vitro cell survival 
assessment clearly showed that the IGF-1Ea transduced cells had a positive effect on cell 
survival compared to the empty-vector transduced cell, this effect could not be directly 
linked to IGF-1Ea expression. To prove that the transduced cells produced IGF-1Ea that 
was able to confer an effect, a functional assay should be considered in future. The 
functional assay could analyze expression of downstream molecules of IGF-1Ea signalling 
such as Akt, PDK1 or MAPkinases, following treatment of the untransduced cells with 
conditioned media from IGF-1Ea transduced cells.   
 
In general, timing and method of delivery still are challenges for cell therapy studies. The 
current study utilized an intramyocardial route for cell injection. Intramyocardial route, 
although has high efficiency of cell delivery compared to other available methods, 
encounters instant wash-out of cells as the heart is continuously active while 
transplantation is being performed. Therefore, future cell transplantation could utilize 
transiently unloaded hearts for cell transplantation. Clinically it is relevant and feasible to 
transiently relax the heart with LVAD device until the transplanted cells have fully 
engrafted. In addition, cell transplanted acutely after induction of injury might not survive 
the unfavourable environment therefore future studies could avoid the hostile initial 
inflammatory phase by using a later time-point for transplantation. However, the decision 
on the timing of cell transplantation will depend on the objective of the study. The 
objective of the current study was to deliver survival factor IGF-1Ea to confer better 
survival of the transplanted and the native at-risk cells therefore it was vital to deliver the 
gene earlier on in the event of injury induction to protect the surviving cells.  
 
For improving cell-engraftment, a tissue engineering approach combining different cell 
types or cell sheets seeded on scaffolds (3D tissue patch) might be better than 
transplanting single cells, to provide cell-cell contact and adherence to the transplanted 
cells to prevent easy wash-out upon their transplantation. The 3D tissue transplantation 
approach can potentially improve integration of the transplanted cells to the native tissue, 
as well as improve cell engraftment and quantification assessments that follow 
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transplantation. In addition, cell therapy studies to-date have shown improvement or 
preservation of function following cell transplantation without being able to relate the 
effects on function to the amount of cell engraftment.  Although the present study did not 
observe any effect on function following cell transplantation, it would be vital in our 
future studies to include strategies which will be able to demonstrate this clearly. The 
strategy could either be surgical removal of the transplanted grafts or in vivo destruction of 
the transplanted cells by activating suicidal genes, consequently leading to loss of 
observed improvement or maintenance of function.  
 
5.3 CONCLUDING REMARKS 
 
This study was able to generate pluripotent cells over-expressing IGF-1Ea that conferred 
greater survival to hypoxia induced injury than the control cells. The engineered cells 
maintained their undifferentiated state and very efficient differentiation capacity towards 
ventricular cardiac myocytes lineage, generating large quantities of cells optimal for the 
cell transplantation study. In addition, the cells generated cardiomyocytes that were 
functionally active and exhibited a mature phenotype.  
 
Taken together, the engineered cells displayed some of the major qualities that cells for 
transplantation studies must posses, making them suitable candidate for proof of principle, 
cell therapy approach.  However, in future one should use safer cells to be able to securely 
translate the findings to clinical research. Upon allogeneic transplantation into wild type 
murine infarcted hearts, there was a trend for maintenance of function at short-term. 
Paracrine factor analyses revealed only a tendency for their enhanced expression, which 
could only be linked to injury and not cell transplantation. The reasons for tendency in 
maintenance of function at short-term could be due to cell engraftment and/or involvement 
of other paracrine factors than the ones examined. At long-term however, the tendency for 
maintenance of function was lost to the level of the control hearts. Cell tracing assessment 
revealed engraftment of the transplanted cells, although the cells failed to couple with the 
recipient tissue. Scar size and capillary density analyses revealed no significant difference 
between the cells treated hearts compared to the saline only treated hearts, corroborating 
with the functional data. Interestingly, IGF-1Ea-cell transplantation led to reduced LV 
remodelling of the recipient tissue, the mechanism for which is under investigation. The 
modulation of hypertrophic response however was not sufficient to confer lasting 
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maintenance of function to the injured hearts. This study nevertheless demonstrated a 
novel pathway via injection of IGF-1Ea over-expressing cells that has potential to 
maintain cardiac tissue after injury. The proposed signaling mechanism could potentially 
confer improvement of the passive function but for regeneration of the active function, 
efficient homing and integration of new contractile muscle mass is necessary.   
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